DEVELOPING FAST AND EFFICIENT MOLECULAR DIAGNOSTIC TOOLS FOR HUMAN INVASIVE CANDIDIASIS by Jainlabdin, M.Hanif
 1 
DEVELOPING FAST AND EFFICIENT MOLECULAR 













Thesis submitted for the degree of Doctor of Philosophy  
School of Biological Sciences 






DECLARATION OF AUTHORSHIP 
 
 
I, Mohd Hanif bin Jainlabdin, hereby declare that the work carried out and presented 











I would like to express my gratitude to my supervisor, Dr Jorge Tovar-Torres for the 
continuous support of my PhD research, for his patience, motivation, and immense 
knowledge. His expertise was invaluable in the formulating of the research topic and 
methodology in particular. Without his guidance and persistent help, this thesis would 
not have been possible. 
I would like to thank my advisors, Professor Simon Cutting and Dr Shobana 
Dissanayeke for their encouragement and, insightful comments. 
My sincere thanks also go to Dr Ambalika Batra, and Dr Christopher Pull for 
their wonderful collaboration and guidance in a statistical analysis of data. 
I thank my fellow lab mates in the School of Biological Sciences, Ucheoma 
Ugoji, Noor Sharif, Ravinder Bhardwaj, James March, Alaa Hussien-Ali, Ilda Hassan 
and the former project students, Atia Jakfar and, Amrita Chudasama who were of great 
support in deliberating over our problems and findings, as well as providing happy 
distraction to rest my mind outside of my research. 
A special thanks to my family. My wife, Diana has been incredibly supportive 
of me throughout this entire process and has made countless sacrifices to help me get 
to this point. My joyful daughters, Chqyra and Chqish, their cooperation, and 
motivation has given me the strength to continue the work until completion. I owe a 
special thanks to my mother-in-law, father-in-law, and my mother, for all of the 
sacrifices that they have made on my behalf. 
Last, but not least, I am much indebted to my father, the late Mr Jainlabdin 





Infection with yeasts of the genus Candida can cause invasive human candidiasis in 
hospitalised immunosuppressed patients. Mortality rates are high due to the lack of 
specific clinical signs of infection and of reliable diagnostic tools. Early diagnosis 
could facilitate implementation of accurate treatment and save lives but currently used 
diagnostic methods based on microbial culture and taxonomic identification are time-
consuming, cumbersome and non-specific. To address this problem, this research 
explores the potential of two different biomarker detection platforms as simple nucleic 
acid biosensors for the diagnosis of invasive candidiasis. These include Multiplex 
Probe Amplification (MPA) and Multi-component Nucleic Acid Enzymes 
(MNAzymes). In all cases assay specificity is conferred by diagnostic probes and 
amplification primers designed from the internal transcribed spacer (ITS) and D1/D2 
domains of the ribosomal DNA locus. A single-tube MPA assay was developed which 
relies on multiple-biomarker probe pairs with unique melting temperature profiles. 
Specific probe hydrolysis during amplification leads to measurable change(s) in post-
amplification melting profiles compared with the negative control. Nine Candida 
species associated with invasive candidiasis were targeted by the MPA-Candida 
assay, including antifungal-resistant C. auris, C. glabrata and C. krusei. A unique 
internal control certifies assay functionality and avoids false-negative results. The 
MPA-Candida assay can also be coupled with an independent pan-fungal assay, 
exhibiting detection limits of 10-100 genomic copies. In vitro characterisation of the 
assay and its evaluation against a standardised Candida panel and a commercially 
available Candida diagnostic kit are reported. The MPA-Candida assay was further 
optimised to incorporate a pan-fungal biomarker for a single-tube reaction in either 
two or three fluorescence detection channels. Finally, the engineering and 
characterisation of an isothermal MNAzyme assay for Candida diagnosis was also 
investigated. Here, homology-dependent self-assembly of a hydrolytic MNAzyme is 
driven by a synthetic single-stranded oligonucleotide complementary to the target 
biomarker. Catalytic activity is monitored by hydrolysis of dual-labelled substrate 
probe, which is detectable in a qPCR instrument.  In conclusion, the development of 
effective diagnostic tools for invasive candidiasis could save thousands of lives and 
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CHAPTER 1: Introduction 
 
1.1 Invasive fungal infections (IFIs)  
IFIs are serious infections caused by various fungal species, often life threatening to 
patients with impaired immune systems. Filamentous fungi are normally ubiquitous in 
the environment and yeasts exist as part of human normal micro flora. Whilst almost 
any fungus has the potential to cause invasive disease, Candida, Pneumocystis, 
Aspergillus and Cryptococcus are the most significant genera causing death in humans. 
The latest estimates on the global burden of IFIs show 700,000 cases of invasive 
candidiasis, 500,000 cases of Pneumocystis jirovecii pneumonia, 250,000 cases of 
invasive aspergillosis and, 223,100 cases of cryptococcal meningitis complicating 
Human Immunodeficiency Virus infection and Acquired Immune Deficiency 
Syndrome (HIV/AIDS) (Bongomin et al., 2017). Although the incidence related to 
superficial infections are much higher, invasive infections result in higher morbidity 
and mortality rates among hospitalised patients (Webb et al., 2018; Brown et al., 
2012). The trends of IFIs in the public health are expected to increase largely because 
of the expanding susceptible host and the use of immune suppressive agents that 
predispose the patients to the fungal infections (Casadevall, 2018). Concerted actions 
from public awareness, effective hospital infection controls and surveillance 
programmes are important to curb the problem.    
 Several reasons have been proposed for the increase in fungal infections, 
including the use of immunosuppressive agents and chemotherapy for cancer 
treatments, broad-spectrum antibiotics, prosthetic devices and grafts, and more 
aggressive surgery. The Candida spp., Cryptococcus spp., Aspergillus spp. and other 
emerging pathogens, such as the Fusarium spp. and Zygomycetes are largely 
opportunists, causing infection when host the defence mechanisms are breached. 
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Moreover, the infections related to the endemic dimorphic fungi, Histoplasma 
capsulatum, Blastomyces dermatitidis, Coccidioides immitis, are opportunistic in 
nature and highly prevalent in immunocompromised individuals, such as HIV/AIDS 
patients, transplant recipients or those taking steroids (Nosanchuk, 2016). Pulmonary 
involvement may prevail during onset of infection but clinical signs and symptoms 
such as fever, cough, chest pain and respiratory failure are non-specific and may be the 
sole manifestation (Person, Kontoyiannis & Alexander, 2011). The human innate and 
adaptive immune responses are important to control invasive fungal infections. The 
host cells express germ-line pattern recognition receptors (PRRs) present in 
monocytes, macrophages, dendritic cells, B-cells, T-cells and endothelial cells, which 
are responsible in recognising fungal pathogen-associated molecular patterns 
(PAMPs) (Blanco & Garcia, 2008). Impaired immune functions especially among 
cancer patients or those receiving haematopoietic stem cell transplantation (HSCT) 
were reported with high mortality rates, of which more than 50% were associated with 
IFIs (Ma et al., 2018). Furthermore, mortality rates in neutropenic patients with 
candidiasis are approximately 50% and may approach 100% for those with invasive 
aspergillosis, fusariosis, or trichosporonosis (Odabasi et al., 2004). These statistics 
have drawn special attention to fungal infections leading to better management of these 
infections. 
 Current epidemiological trends recognise Candida species as the most common 
fungal pathogen isolated from the blood of immunocompromised patients and an 
important cause of nosocomial infections (Wisplinghoff et al., 2014).  Despite the 
availability of antifungal drugs, Candida species infections are reported with mortality 
rates as high as 60% in candidaemia (De Rosa et al., 2015; Bassetti et al., 2018). An 
increase of up to 20% mortality rates has been demonstrated in invasive candidiasis 
for every 12 hours delay of initiation of an effective antifungal therapy (Morell et al. 
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2005). Late or no treatment of invasive candidiasis are independent predictors of death 
(Denning 2003). Therefore, improvements from the current state of diagnosis which is 
based on the microbiological cultures and an effective administration of antifungal 
therapy are pivotal for a better management of Candida infections.  
 
 
1.2 Human pathogenic Candida species 
Yeast of the genus Candida is a normal commensal of the human skin, gastrointestinal 
and genitourinary tracts but, the infections on the mucosal surfaces caused by this 
species are extremely frequent. Although many Candida species exist, only a small 
number are pathogenic to humans. Up to 90% of all Candida infections are caused by 
C. albicans, C. glabrata, C. parapsilosis, C. tropicalis and C. krusei (Guinea, 2014; 
Ng et al., 2015). Less frequent pathogenic Candida species include C. dubliniensis, C. 
guilliermondii, C. lusitaniae, C. rugosa, C. orthopsilosis and C. metapsilosis, and 
emerging of rare species have been reported as infectious agent (Turner & Butler, 
2014).  A newly emerging C. auris, multidrug-resistant yeast, has caused nosocomial 
outbreaks in the United Kingdom (UK) and multiple countries across five continents 
(Rhodes et al., 2018). In the UK, there was an estimated 6,500 cases of invasive 
candidiasis with one third of the manifestations in the bloodstream infections (Public 
Health England, 2017).  
C. albicans remains the human major fungal pathogen and the most common 
cause of systemic fungal infections among immunocompromised patients (Guinea, 
2014). C. albicans is usually susceptible to azole antifungals, however, overuse of the 
drugs in therapy and prophylaxis has led to a rise in non-albicans species (Ruhnke, 
2014). In many hospitals, C. glabrata is the second most cause of candidaemia after 
C. albicans (Colomba et al., 2014; Pfaller & Castanheira, 2016; Public Health 
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England, 2017). Increasing incidences related to C. glabrata is alarming as the species 
is well-known for its reduced susceptibility to antifungal drugs (azoles and 
echinocandins).  
C. krusei is another clinically significant species, although less common in 
candidaemia cases in the UK, it is intrinsically resistance to fluconazole and is highly 
prevalent among patients with recent exposure to fluconazole (Pfaller et al. 2008).  It 
is also noted that C. krusei showed resistance to flucytosine and reduced susceptibility 
to other antifungal drugs. The Minimum Inhibitory Concentration (MIC) of C. krusei 
towards fluconazole is significantly higher (64 µg/mL) compared to C. albicans 
towards the same antifungal drug (2 µg/mL) (Badiee et al., 2017). It is therefore not 
surprising that C. krusei is associated with a higher mortality rate than C. albicans 
(Abbas et al., 2000). C. krusei is frequently recovered from patients with 
haematological malignancies complicated with neutropenia and transplant recipients.  
C. parapsilosis, is a member of the skin microbiota, often associated with 
catheter-related candidaemia and can efficiently colonise prosthetic devices. This 
species produces slime as a virulence factor enabling it to persist and survive on the  
environmental surfaces and the skin of healthcare workers (Welsh et al., 2017). Of 
note, this species is also reported at the second rank after C. albicans causing 
candidaemia in some centres in the United States of America (USA) (Wisplinghoff et 
al., 2014). It is more prevalent among early age patients, whereas the opposite is true 
for C. glabrata.  
C. tropicalis has also gained importance due to its high prevalence (41.6%) 
among patients in the intensive care unit (ICU) across hospitals in India (Chakrabarti 
et al., 2015). The number is also highly recorded in the Central and South America 
countries (Zuza-Alves, Silva-Rocha & Chaves, 2017). In the UK, C. tropicalis was 
recorded as low (3%) causing bloodstreams infections (Public Health England, 2017). 
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The risk factors include immunocompromised patients with leukaemia, receiving 
chemotherapy for cancer treatments and prolonged hospitalisation in the ICU (Leung 
et al., 2002). 
Recently, multidrug-resistant C. auris has caused outbreaks of bloodstream and 
wound infections in healthcare settings around the world (Schelenz et al., 2016; 
Rhodes et al., 2018). The species was first identified in Japan as a cause of ear infection 
in an elderly patient (Satoh et al. 2009). C. auris has been misidentified as C. 
haemulonii, a less virulent Candida species, by most commercial identification 
systems (Centres for Disease Control and Prevention, 2018). Improving the diagnosis 
of C. auris is essential to support clinical decision making, and to provide timely 
prescription of therapeutics drugs to patients (Sexton et al., 2018).  
 
 
1.3 Cell biology of yeasts and phylogenetics 
Yeasts are single-celled fungi that reproduce asexually by the process of septation and 
separation of daughter cells, either by budding (blastoconidia formation) or binary 
fission (Brooks et al., 2013). Yeasts are different from most fungi which are 
multicellular (moulds) and exist as filament-like hyphae, which can grow and form a 
mycelial map. Human fungal pathogens, including Candida species, Cryptococcus 
species and Histoplasma species produce yeast cells that propagate during infection 
through budding formation (Kauffman et al., 2003). Meanwhile, Penicillium marneffei 
yeast cells can divide by fission to form two uninucleate cells, and these cells can 
further propagate by binary fission (Vanittanakom et al., 2006). The release of yeast 
cells in the human bloodstream will allow rapid dissemination in the host and organs, 
causing systemic and deep-seated fungal infections.  
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Some of the yeasts such as H. capsulatum, B. dermatitidis and, C. immitis are 
categorised as dimorphic for their ability to form hyphae under certain environmental 
conditions. Notably, C. albicans is called a polymorphic fungus, as it can form several 
morphologies from the budding yeast cells, pseudohyphae and hyphae (Gow & Yadav, 
2017). The term pseudohyphae describes an elongated budding yeast cell that remains 
attached after cytokinesis which forms branches of yeast cells with a constriction 
between the cells (da Silva Dantas et al., 2016). Due to its medical importance, C. 
albicans is the most studied yeast within its genus. The cell wall of C. albicans plays 
pivotal roles in pathogenesis; as the first structure that comes into contact and 
maintains its adherence to the host cells, this is responsible for the invasion of the host 
cells and, carries important antigenic determinants of the fungus for host recognition 
(Ruiz-Herrera et al., 2006). Figure 1.1 illustrates the fungal cell wall composed of an 
inner polysaccharide surfaces of b-glucans and chitin and an outer surface of 
mannoproteins which are bound to the inner surface through the lateral chains of b-
1,6-glucan or 1,3-glucan (Gow et al., 2012). Notably, except for Cryptococcus, which 
is composed of the glucuronoxylomannan and galactoxylomannan polysaccharides 






Figure 1. 1 Schematic representation of the molecular structure of the C. 
albicans cell wall. The figure adapted from Gow et al., (2012).  
 
 
 The metabolism of C. albicans is adaptable to niche-specific conditions, 
facilitating cell growth within the host during infections (Martin et al., 2011). The 
critical characteristics of C. albicans as a pathogen are its adaptability to use a variety 
of micronutrients (da Silva Dantas et al., 2016), the active manipulation of the 
environmental pH and its adaptation to stresses (Brown et al., 2014; Hube, 2009).  
 The Candida genus is diverse, and its taxonomy classification was previously 
based on morphological features and sexual reproduction (Guarro, Gené & Stchigel, 
1999). The advancement of DNA based taxonomy has broadened the understanding of 
the relationship between the Candida species and the fungal kingdom. Systematic 
DNA sequence analysis by the recognition of fungal DNA barcoding serves to define 
fungal species relationships and their evolution (Robert et al., 2011; Schoch et al., 
2012). The genomic data ascertained the classification of the Candida species 
belonged in the phylum Ascomycota and the important order of Saccharomycetales 
(Hibbett et al., 2007). Phylogenetic analysis also demonstrated that C. glabrata 















Saccharomyces cerevisiae than to C. albicans and C. dubliniensis, C. parapsilosis, or 
C. tropicalis, which are classified in the CTG clade (CTG codon codes for serine, 
rather than leucine) (Brunke & Hube, 2013; Turner & Butler, 2014). A non-exhaustive 
list of Candida species in approximate order of phylogenetic relationship is 
demonstrated in Table 1.1. 
 
Table 1. 1 Classification of Candida pathogenic species according to 
phylogenetic analysis. The table adapted from Brunke & Hube, (2013).  
 
Candida species Teleomorphic/sexual name Ploidy 
CTG clade species 
C. albicans  Diploid 
C. dubliniensis  Diploid 
C. tropicalis  Diploid 
C. parapsilosis  Diploid 
C. orthopsilosis  Diploid 
C. metapsilosis  Diploid 
C. famata Debaryomyces hansenii Haploid 
C. lusitaniae Clavispora lusitaniae Haploid 
C. guilliermondii Meyerozyma guilliermondii; 
Pichia guilliermondii 
Haploid 
WCD clade species 
C. krusei Issatchenkia orientalis; Pichia 
kudriavzevii 
Haploid 
C. glabrata  Haploid 
C. kefyr Kluyveromyces marxianus Haploid 
C. norvegensis Pichia norvegensis Haploid 
C. inconspicua Pichia cactophila Haploid 
C. lypolytica Yarrowia lipolytica Haploid 
*CTG clade, the CTG codon exchange from leucine to serine; WCD, the species that have 
undergone whole-genome duplication. Haploid represents isolates exist in stable haploids; 
diploids may also be formed.  
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1.4 Traditional diagnostic methods for fungal infections 
 
1.4.1 Blood cultures and histopathology  
Blood culture is considered the “gold standard” for the diagnosis of invasive 
candidiasis, particularly when candidaemia is suspected (De Pauw et al., 2008). 
Positive culture results can yield a specific aetiological agent and allows for 
susceptibility testing (Kozel & Wickes, 2014). However, autopsy results suggest that 
blood cultures are 50% less sensitive for cases with proven invasive candidiasis 
(Clancy & Nguyen, 2013). Therefore, negative blood cultures do not rule out invasive 
candidiasis. A more extended time period for cultures positivity which typically can 
take 24 to 72 hours further complicated the use of blood culture for early diagnosis of 
invasive candidiasis (Pfaller & Castanheira, 2016). Fully automated blood culture 
systems such as the BACTEC® (Becton–Dickinson Diagnostic Systems, USA) and the 
BacT/Alert® (BioMérieux, France) are routinely performed in healthcare facilities 
(Pryce et al., 2006). The alert sign from the blood culture system for the positive results 
signals the subculture of the broth onto the solid mycological media for further 
identification (Horvath et al., 2004). The isolation and identification of the Candida 
species can be performed in parallel on chromogenic media. The principle for the use 
of the media is the formation of different coloured colonies with varied morphology 
which result from the cleavage of chromogenic substrates by species-specific enzymes 
(Alam et al., 2014). The CHROMagar Candida is one of the chromogenic agars that 
are commercially available and could provide faster identification of major Candida 
species (Nadeem, Hakim & Kazmi, 2010).  
 Positive blood cultures for invasive aspergillosis is rare and hence have a little 
value as a diagnostic tool, even in cases of widely disseminated disease (Barton, 2013). 
A positive culture result may represent environmental contamination or colonisation, 
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especially when the samples are from a non-sterile site therefore; overall interpretation 
is necessary by considering the patient’s risk factors (Ostrosky-Zeichner, 2012). 
Interestingly, the study conducted by Kontoyiannis et al., (2000), to differentiate 
between true bloodstream aspergillosis and a contamination issue in their institution, 
found that the false-positive results for the Aspergillus species do occur due to culture 
media contamination. However, it is also important to recognise that positive culture 
results in a high-risk patient may suggest the presence of infection (Kauffman et al., 
2011). Aspergillus species also are slow-growing fungi and can take several days to 
weeks to sporulate on an appropriate selective media (Borman & Johnson, 2014). Also, 
cultures and microscopic morphology lack specificity and identification of the species, 
is laborious to perform and require specialised expertise (Reyes-Montes et al., 2018). 
Histopathology of the clinical specimens has the advantage of detecting fungal 
elements from the targeted biopsies including the host response or tissue necrosis 
(Arvanitis et al., 2014). However, histopathologic analysis is not always suitable for 
all patient groups, for example, patients with severe thrombocytopenia tend to have a 
high possibility of bleeding complications thus, preventing the use of biopsy or other 
invasive techniques (Oz & Kiraz, 2011).  
 
1.4.2 Candida albicans Germ Tube Antibody (CAGTA) and antibody (anti-
mannan), antigen (mannan) detection  
The CAGTA test is based on the detection of specific IgG antibodies against the 
antigens located on the surfaces of the C. albicans germ tubes by indirect 
immunofluorescence (Martín-Mazuelos et al., 2017). The test has reported a sensitivity 
of 91.3%, and a specificity of 68.1% for the diagnosis of invasive candidiasis among 
critically-ill patients (Trovato et al., 2019). The test sensitivity can be lower for 
detection of non-albicans Candida (Clancy & Nguyen, 2018a). The test has shown 
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clinical utility for reducing the mortality rates in ICU patients with positive CAGTA 
assay that allowed appropriate antifungal treatment (Zaragoza et al., 2009). The 
sensitivity of CAGTA assay is not affected by the prior intake of antifungal drugs or 
Candida colonisation, demonstrating it as a useful serological biomarker for diagnosis 
of the invasive candidiasis in ICU settings (Bassetti et al., 2018). The combination of 
the CAGTA and b-D-glucan tests as a diagnostic tool has shown a higher sensitivity 
of 97% in a population studied (Martínez-Jiménez et al., 2015).  
 Other serological biomarkers available for diagnosis of the invasive candidiasis 
are the mannan antigen and anti-mannan antibody detections (Duettmann et al., 2016). 
Optimal result can be achieved from the combination of these two biomarkers. The 
combination of the mannan and anti-mannan antibody detections has a sensitivity of 
83% and a specificity of 86% in patients with Candida species infections (Clancy & 
Nguyen, 2018b). The high Negative Predictive Values (NPV) of the test is useful to 
guide clinical decisions regarding the need for antifungal therapy in 
immunocompromised patients (Ellis et al., 2009). Other than Candida immunogenic 
detection, the increased level of the metabolic products from the Candida species such 
as enolase or D-arabinitol/creatine ratio has been demonstrated in patients with 
invasive candidiasis (Ostrosky-Zeichner, 2012). D-arabinitol is produced by most of 
the Candida species with exceptions for C. krusei and C. glabrata. However, an 
elevated D-arabinitol/creatine ratio level is observed in patients with renal failure. 
Fungal antigens and metabolites are usually cleared rapidly from the 
immunocompromised patient's body leading to false negative results of the antibody 





1.4.3 Galactomannan (GM) detection for Aspergillus 
GM is the main polysaccharide component of the cell wall of the Aspergillus species, 
which is released into the bloodstream during hyphae growth (Taghizadeh-Armaki et 
al., 2017). The antigen GM is detectable from serum, bronchoalveolar lavage (BAL) 
and cerebrospinal fluid (CSF) and can be considered specific for the diagnosis of 
invasive aspergillosis (Eigl et al., 2017). However, other fungal species, Penicillium 
spp., Fusarium spp. may also contain a smaller amount of GM and can lead to a false-
positive test to invasive aspergillosis (Barton, 2013). The sandwich enzyme-linked 
immunosorbent assay (ELISA) PlateliaÒ Aspergillus (Bio-Rad, USA) is the most 
commonly used test for GM antigen quantification and is included in the European 
Organization of Research and Treatment of Cancer/Mycoses Study Group 
(EORTC/MSG) as a mycological criterion of probable invasive aspergillosis (De Pauw 
et al., 2008). The recommended cut‐off value is an optical density index (ODI) of ≥0.5 
for a positive result in serum GM detection (Zhou et al., 2017; De Pauw et al., 2008).  
 The sensitivity and specificity of the GM assay ranges from 71-75% and 80-
89% for invasive aspergillosis and the value can vary considerably due to factors such 
as the patient population, host factors, nutrition of the patient, and most importantly it 
can be affected by prior treatment (Zhou et al., 2017; Hsu et al., 2014). The main utility 
of the GM test is in the high-risk haemato-oncological patients especially with the 
combination test with Computed Tomography (CT) imaging, in the early diagnosis of 
invasive aspergillosis (Ruhnke et al., 2018). The result agreement between the GM test 
from BAL and PCR tests have highly supported the diagnosis of pulmonary 
aspergillosis (Reinwald et al., 2012). One of the significant problems with the GM 
assay are false positive results. The use of the b-lactam antibiotics such as 
piperacillin/tazobactam (PTZ) in patients was reported for false-positive detections in 
the Platelia GM assay (Alhambra et al., 2007). It has been suggested that the GM was 
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passed to the PTZ through the production of piperacillin as a fermentation product of 
the Penicillium species that also contain GM in the cell wall (Vergidis et al., 2014). 
False-positive results are frequent in neonates and children colonised by 
Bifidobacterium spp. (Arendrup, Fisher & Zaoutis, 2009). In contrast, the sensitivity 
of the GM test is negatively affected by the prior use of azole drugs as a preventive 
treatment (Barton, 2013).  
 
1.4.4 b-D-glucan (BDG) for pan-fungal detection 
BDG is a polysaccharide component of fungal cell walls found in most fungal 
pathogens (Kolomeyer et al., 2018). Due to its universal presence in the fungal species 
but not in humans, bacteria, or viruses, BDG detection is useful for a pan-fungal 
diagnostic test (Theel & Doern, 2013). The BDG test is routine in hospitals for 
surveillance and diagnosis of invasive candidiasis, invasive aspergillosis and 
Pneumocystis pneumonia but, not for cryptococcosis and mucormycosis (Pfaller & 
Castanheira, 2016; Passos et al., 2017). Detection of the BDG is not reliable for the 
Cryptococcus spp. and the Mucor sp., as the amount of the component, is more variable 
and rarely detected by the BDG assay (Ostrosky-Zeichner, 2012).  
  The BDG assay is based on the activation of a coagulation cascade, which 
uses purified components from horseshoe crabs (Hope, Walsh & Denning, 2005). The 
assay was developed to detect glucan and measure transformation of a chromogenic 
substrate which is quantifiable by a spectrophotometer (Azoulay et al., 2016). One of 
the BDG assays, the Fungitell (Associates of Cape Code, USA) is FDA-approved 
(Food and Drug Administration) for use on serum and the test was included in the 
EORTC/MSG mycological criteria for classification of probable invasive fungal 
infection (De Pauw et al., 2008). The meta-analysis conducted by Karageorgopoulos 
et al., (2011) included 16 studies which reported that the overall sensitivity and 
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specificity of BDG assays is 76.8% and 85.3% and respectively. The test showed high 
NPV of 94% (with a 10% prevalence of IFI) and is practical to exclude the fungal 
disease from other infections (Azoulay et al., 2016). However, given the fact that the 
fungi are ubiquitous in the environment, the false positive of the test is common (Hsu 
et al., 2014). 
 
1.4.5 Antigen detection and lateral-flow assay for cryptococcosis 
Cryptococcosis is an infection caused by C. neoformans and C. gatti (Mada & Alam, 
2019). The major capsular polysaccharide of Cryptococcus spp. termed as 
glucuronoxylomannan, is released into blood and CSF during the course of 
cryptococcal meningitis (Nalintya, Kiggundu & Meya, 2017). The detection of the 
cryptococcal polysaccharide antigen in CSF or serum has been included as a standard 
method in the diagnosis of cryptococcal meningitis (De Pauw et al., 2008). Latex 
agglutination testing and enzyme immunoassay (EIA) techniques have been used 
widely for cryptococcal antigen detection, both demonstrate excellent performance, 
with 97% sensitivity for the test on CSF (Marchetti et al., 2012). A lateral-flow format 
of the immunoassay detection of cryptococcal antigen has demonstrated a performance 
comparable to those of EIA and latex agglutination on CSF and serum samples 
(Arvanitis et al., 2014). The lateral-flow assay uses gold-conjugated, monoclonal 
antibodies impregnated onto an immunochromatographic test strip to detect the GXM 
antigen for all four C. neoformans serotypes (Nalintya, Kiggundu & Meya, 2017). The 
cryptococcal antigen lateral-flow assay is rapid, highly accurate, and has the ability to 
be performed on different clinical samples including urine samples, making it very 





1.5 Molecular diagnostic methods for Candida infections 
 
1.5.1 T2 Magnetic Resonance (T2MR) 
The T2 Candida assay (T2 Biosystems, USA), a recent FDA-cleared diagnostic test 
for clinical use, has introduced a novel method for detecting Candida species directly 
from the patient’s blood sample (Clancy & Nguyen, 2018c). The technology is based 
on nuclear magnetic resonance (NMR) spectroscopy and has been widely applied in 
chemistry and radiology (Arvanitis et al., 2014). In brief, a blood sample in the EDTA 
(Ethylenediaminetetraacetic acid) collection tube is loaded into a fully automated 
instrument platform, T2DX, to provide a sample-to-answer diagnostic test. It lyses the 
yeast cells by mechanical bead-beating, amplifies the target sequence from the 
multicopy internal transcribed spacer region 2 (ITS2) of the fungal ribosomal DNA 
(rDNA) and finally detects amplified DNA using magnetic resonance technology 
(Mylonakis et al., 2015). Specifically, Candida DNA amplified in blood hybridises to 
nanoparticles coated with target-complementary oligonucleotide probes. The 
nanoparticles aggregate into clusters which alter T2 magnetic resonance (MR) signals 
producing a ‘signature’. The signature is then statistically compared to a known 
database to identify the target of interest, in this case, the Candida species. The flow 
of the T2MR is illustrated in Figure 1.2. In a preliminary study, the T2MR assay can 
identify the five major Candida species at a sensitivity of 91.1% and the limit of 
detection was found to be 1 Colony-forming Unit (CFU)/mL for C. tropicalis and C. 
krusei, 2 CFU/mL for C. albicans and C. glabrata, and 3 CFU/mL for C. parapsilosis 
in blood within 3 to 5 hours (Mylonakis et al., 2015). The median time of detection is 
4.2 hours compared to 129 hours in blood culture-based diagnostic. In addition to the 
Candida panel, T2Biosystem also released their product for the detection of multidrug-
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resistant C. auris, T2C. auris panel. The panel is currently for research use only and 
yet to be validated for clinical utility. The T2C. auris assay can detect all four known 
clades of C. auris and demonstrates a consistent limit of detection at 5 CFU/mL 




Figure 1. 2 A simplified process of T2MR. Amplification of the target sequence 
found in the blood sample. The DNA probes coupled with paramagnetic nanoparticles 
are added to the amplicon and are allowed to hybridise with the amplified sequence. 
As a result, the signal changes the nanoparticle T2 relaxation time, and the change is 
detected via magnetic resonance imaging, thus identifying the target. The diagram is 
adapted from Arvanitis et al., (2014).  
 
1.5.2 Peptide Nucleic Acid-Fluorescent In situ Hybridisation (PNA-FISH)  
FISH is a technique that uses fluorescent probes to identify target areas on the genomes 
of microbial pathogens in human samples, which can then be detected by fluorescence 
microscopy (Figure 1.3). Recently, several studies have evaluated the use of PNA 
probes in FISH assays. PNAs are synthetic nucleic acid sequences with a neutral 
polyamide backbone that exhibits more consistent and robust hybridisation 
characteristics than traditional nucleic acid probes. Yeast Traffic Light PNA-FISH 
(AdvanDx, USA), a FDA-cleared rapid diagnostic test, can identify five pathogenic 
Candida species within 90 minutes from positive blood cultures. The three-probe 
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colours coded in the assay represent the general susceptibility of the Candida species 
to the fluconazole with the green indicator for likely susceptible (C. albicans/C. 
parapsilosis), red for likely resistance (C. glabrata/C. krusei) and yellow for inducible 
resistance (C. tropicalis). In multiple studies, PNA-FISH-based assays have been 
shown to have 99% and 100% sensitivity and specificity respectively (Hall et al. 2012, 
Shepard et al. 2008). The Yeast Traffic Light PNA-FISH can save between 24 to 48 
hours of identification compared to conventional laboratory methods. This approach 
shows no fluorescence to bacteria and a limited spectrum of detection to only five 
Candida species. The PNA-FISH test successfully showed cost savings at 
approximately equivalent to £1,300 per patient as a result of the correct choice of 
antifungal in the patient with candidaemia due to C. albicans (Forest et al. 2006). In 
the same study on the patient group, fluconazole substituted caspofungin, after results 
of the PNA FISH-testing, has led to a significant decrease in antifungal costs and 
importantly, allow effective treatment to the patients.   
 
 
Figure 1. 3 FISH technique. Fluorescent probes against a specific target sequence 
are mixed with the tested sample and allowed to bind to the complementary DNA 
sequence, if present in the sample. The excess probes are then washed off, while the 
bound probes are detected via fluorescence microscopy. The diagram is adapted from 
Arvanitis et al., (2014).   
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1.5.3 Matrix-Assisted Laser Desorption-Ionisation Time of Flight Mass 
Spectrometry (MALDI-TOF MS) 
MALDI-TOF MS analysis identifies protein fingerprints of an unknown fungus 
through direct comparison of its spectral pattern with the known patterns of different 
organisms in databases (Figure 1.4). It can identify pathogenic fungi at the genus, 
species and even to strain level. FDA-approved MALDI-TOF systems, from the 
Bruker Maldi Biotyper (Bruker Daltonic, Germany) are able to identify yeasts and 
moulds in the clinical diagnostic environment (Sanguinetti & Posteraro, 2017; Aslani 
et al., 2018). Proteomic analysis by MALDI-TOF MS can accelerate species-level 
identification of yeasts directly from blood cultures, with a sensitivity of 95.9% for C. 
albicans and 86.5% for non-albicans Candida species, C. guilliermondii being the 
species most frequently missed (Spanu et al., 2012). This species is also found to be 
misidentified in other studies including the one tested in the Vitek MS system (Cheng 
et al., 2016; Dhiman et al., 2011). The C. guilliermondii complex is a phenotypically 
indistinguishable yeast species (Cheng et al., 2016). Updated mass spectral profiles are 
crucial to improving the identification accuracy of emerging species. Misidentification 
of multidrug-resistant C. auris as  C. haemulonii was previously reported using an 
outdated database (Wattal et al., 2017). Currently, Bruker Biotyper with Version Claim 
4 System and Vitek with Saramis Version 4.14, are updated databases that should be 
able to accurately identify C. auris, though misidentifications of strains from a few 
clades have been reported (Centers for Disease Control and Prevention, 2018). Despite 
advances and acceptance into routine testing in microbiology laboratories, this method 
does not identify polymycosis, and sample preparation requires time and expertise 





Figure 1. 4 General principles of MALDI-TOF MS. Firstly, the sample is 
added into a well that contains matrix material which has the ability to absorb 
ultraviolet (UV) light and transform it into heat. Secondly, a laser beam is targeted to 
the mix and absorbed by the matrix, and part of the analyte-matrix mix is vaporised 
and ionised, creating a cloud of ionised protein and matrix. Next, this cloud is subjected 
to an electric field, which leads the particles to accelerate towards a detector. The mass 
and charge of each particle determine the time needed to reach the detector. This allows 
the mass spectrometer to determine the characteristics of the particles within the tested 
sample. Finally, the produced spectral pattern can be compared against a standard 
database which allows for the identification of the microorganisms in the samples. The 
diagram is adapted from Arvanitis et al., (2014).  
 
 
1.5.4 Novel nucleic acid detections platforms 
 
1.5.4.1  Multiplex Probe Amplification (MPA) 
MPA is a novel method of detecting multiple targets in the real-time PCR platform. 
Up to six probes with a unique melting temperature labelled with the same fluorescence 
dye can be detected in a single channel. Each probe for every target was designed with 
two oligonucleotides; a dual-labelled target-hybridising oligonucleotide (THO) and 
partially-complementary oligonucleotide (PCO) (Figure 1.5, panel A). The technology 
allows utilisation of the unbound THO after amplification to hybridise to its PCO. The 
PCO is composed of 17% to 23% of nucleotide mismatch against the THO sequence 
and has a slightly lower annealing temperature compared to the full complementary 
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target sequence. In the presence of the DNA target sequence, the dual-labelled 
oligonucleotide preferentially anneals to the fully complementary target sequence at a 
higher temperature and is hydrolysed during the extension steps in the PCR. In the 
absence of the target DNA, the intact THO is bound to its PCO and dissociates during 
the melt curve analysis. The probe fluoresces the most when the THO is hybridised to 
the PCO and reduces as the temperature is raised (Figure 1.5, panel B). The highest 
rate of fluorescence change is seen in the melting curve analysis when 50% of the THO 
dissociated from the PCO at the specific melting temperature (Figure 1.5, panel C) (Fu, 
Miles & Alphey, 2012). 
 
    
 
   
 
Figure 1. 5 The MPA nucleic acid probe and its melting profile. Panel A) The 
probe consists of a THO labelled with a fluorophore (F) at the 5’end and quencher (Q) 
at the 3’end, and attached with a PCO. Panel B) The melting curve shows decreased 
fluorescence emission with increasing temperature. Panel C) the negative derivative 
plot of the emission reading versus temperature reveals a positive value of the melting 
peak.  
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1.5.4.2  Multi-component Nucleic Acid Enzymes (MNAzymes) 
Ribozymes (ribonucleic acid or RNA enzymes) are catalytic molecules found in nature 
which are hypothesised to be fossil molecules in a prebiotic ‘RNA world’ (Silverman, 
2008). Representative ribozymes that exist in nature such as hammerhead and hairpin 
are capable of catalysing the phosphodiester cleavage of RNA sequences (Feldman & 
Sen, 2001). Conversely, Deoxyribozymes or DNAzymes are artificial molecules and 
not found in nature (Zhou, Ding & Liu, 2017). The development of catalytic DNA 
molecules through in vitro selection and evolution procedures has introduced a new 
versatile platform for the design of a variety of therapeutic tools (Fiammengo & 
Jäschke, 2005). Sharing the advantages of biocompatibility and simplicity of structural 
prediction and modification with ribozymes, DNAzymes are much more stable and 
cost-effective than RNA counterparts (Gerasimova & Kolpashchikov, 2010). 
DNAzymes have an excellent potential for sensing a variety of analytes mainly due to 
the possibility of catalytic signal amplification. RNA-cleaving DNAzymes are 
particularly useful because DNAzymes interact with their RNA substrates through 
Watson–Crick base pairing, and it can be tailored to recognise any RNA sequence 
(Feldman & Sen, 2001). Two general RNA-cleaving DNAzymes that have been 
extensively studied are the 10–23 and 8–17 DNAzymes (Santoro & Joyce, 1997) 










        
Figure 1. 6 Composition of the 10–23 and 8–17 Deoxyribozymes or DNAzymes.  
The DNAzyme (bottom strand) is capable of cleaving single-stranded RNA (top 
strand) at the specific site and forms a product with 2’,3’-cyclic phosphate and 5’ 
hydroxyl RNA termini. R = Adenine or Guanine; Y = Uracil or Cytosine. This figure 
is adapted from Santoro & Joyce, (1997).  
 
Taking advantage of deoxyribozymes, Mokany et al., 2010 split the conserved 
catalytic core domains of 10–23 and 8–17 to form MNAzymes. MNAzymes provide 
tremendous flexibility in terms of tailoring the nucleic acid input to work with 
developed universal partial enzymes to produce readout fluorescence signals (output). 
The partial enzymes (Partzymes) are composed of a target-binding domain, a partial 
catalytic core derived from DNAzymes and a probe-binding domain (Figure 1.7) 
(Mokany et al., 2010). The Input sequence, also referred to as the Assembly Facilitator 
(AF), is a specific sequence of 40- to 44-nucleotide bases that is tailored to complement 
the target-binding domains. The AF sequences that bind to the target-binding domains 
allow partial catalytic cores to combine to form a complete catalytic core. The active 
core can then bind to universal reporter probes at probe-binding domains and cleave 
them in between the fluorophore and quencher moieties. The loss of proximity between 
the quencher and reporter cause the release of a fluorescent signal that can be 
monitored by a spectrofluorometric in real-time. 









Figure 1. 7 A schematic representation of the association and subsequent 
cleavage activity of the MNAzyme. Partzyme A and B combine in the presence of 
the AF, hydrolysing the RNA substrate, separating the fluorophore (F) from the 
quencher (Q) to allow emissions of the fluorescence signal. 
 
Currently, eight different universal probes have been tested with MNAzymes, 
and each probe could be labelled with different fluorophores to give distinctive signals 
(Bone et al., 2014).   Furthermore, two different types of MNAzymes that are derived 
from 10-23 and 8-17 DNAzymes indicates that this technology has the potential for 
multiplexing, therefore, increasing its versatility to be used in the field of molecular 
diagnosis. However, MNAzymes derived from the 10-23 nucleic acid enzyme have 
shown higher enzymatic activity and stable probe hybridisation than those derived 
from 8-17 nucleic acids (Mokany et al., 2010).  
Furthermore, to further increase the versatility of MNAzymes, the molecular 
switches and cascades were developed by introducing the Assembly Facilitator 
Components (AFc) and Assembly Inhibitor (AI) (Mokany et al., 2010). This technique 
is capable of performing switch functions from an ‘on’ state (active MNAzyme) to an 
‘off’ (inactive MNAzyme) state of the enzyme by relying on the presence of multiple 
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AFc and an AI. Moreover, this technique can open the possibility of incorporating up 
to four different substrates, with the ability to label each different substrate with 
different dyes for multiple detections. Therefore, the detections are performed in 
stages, starting from the cleavage by an ‘initiating MNAzyme’, to controlling the 
formation of the next stages of MNAzymes or also known as ‘cascading MNAzymes’. 
Thus, the whole system will produce four different fluorescent signals indicating the 
stages of cleavage and cascade by the enzymes and their cleavage products (Mokany 
et al., 2010). An MNAzyme cascade is a promising technique offering greater 
sensitivity through the application of a fluorescent dye, which could combine and 
amplify the detection signals in an isothermal temperature.  
 
 
1.6 Molecular diagnostic tools for fungal infections 
 
1.6.1 PCR-based diagnostic assays 
The purpose of this sub-section is to provide the reader with an overview on the 
evolution of PCR-based methods in human fungal pathogens diagnostic assays. PCR 
is a method used for the enzymatic exponential amplification of a specific target region 
using short primers, leading to detectable amounts of amplified DNA from one or a 
few original sequences. PCR-based methods are the most common molecular-based 
approaches in many fields and the core method in fungal molecular diagnostics 
(Wickes & Wiederhold, 2018). Various methods of PCR exist for qualitative and/or 
quantitative detection and identification of fungi. Conventional PCR can include 
nested and multiplex PCR which are very simple to design, but their sensitivity is 
directly related to the ability to visualise the fragments and their specificity depends 
on the recognition of the amplicon size for a target species as the final readout 
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(Kauffman et al., 2011). In contrast to conventional PCR, real-time PCR has shown 
promising results. The major advantages of real-time PCR include a rapid time to 
results for some targets and the flexibility of the platform (Bustin, 2005). This approach 
employs a closed system that provides simultaneous amplification and detection, and 
limits the risk of assay contamination. Real-time PCR is often fluorescence-based and 
allows for quantification.  
Conventional PCR is not quantitative but is qualitative and has been used to 
detect, monitor and identify fungi either permitting species-specific, genus-specific, or 
broad-range (pan-fungal) detection. It relies on specific primer sequences to generate 
a DNA product that is visualised on an agarose gel or after capillary electrophoresis. 
The amplified products of the Candida species from conventional PCR techniques can 
be further discriminatory to the species-level by using restriction enzymes to digest the 
PCR products, which are resolved on a gel and visualised as the final step in the assay 
(Vijayakumar, Giri & Kindo, 2012). The Restriction Fragment Length Polymorphism 
(RFLP) method has been used extensively as markers on genetic maps and fungal 
epidemiology (Alam et al., 2014). The presence or absence of a fragment and their 
various sizes and patterns can be used as a mean of identification. 
Associated technologies include methods that increase sensitivity and are more 
discriminative such as nested and multiplex PCR. Two-step nested PCR in which a 
second round of PCR using a separate primer set internal to the first-round increases 
amplification of a specific region in the first PCR amplified target gene. This is not 
only more specific but is also much more sensitive allowing the detection of the target 
DNA several fold lower than conventional PCR (Ahmad et al., 2002). Another robust 
PCR method used in molecular fungal diagnostics is multiplex PCR. Multiplex PCR 
can detect multiple targets sequences within the genome of the fungi and also can be 
used to identify several fungal genera at once in the same sample. The technique is 
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fairly simple and is based on the use of primers specifically designed to amplify a 
region that is conserved among different fungal genera.  Detection of several different 
fungal genera in the same PCR reaction can be achieved if the highly specific primers 
are designed to anneal at the same temperature and the PCR products are designed to 
be of different sizes to allow discrimination. More recently, Jainlabdin et al., 2018 
have described a low-cost yet reliable method in which an optimised set of primers for 
the simultaneous detection of pan-fungal and three major pathogenic fungal genera 
was applied (Candida spp., Aspergillus spp. and Fusarium sp.) as well as resistant 
pattern species through recognition of signature amplicon sizes. Nevertheless, all 
electrophoresis-based PCR assays have inherent disadvantages. A primary factor that 
hinders it as an ideal fungal diagnostic test lies in the end-point detection that does not 
correlate with the starting amount of the targets that have been amplified (Nurmi et al., 
2000; Mackay, 2004). Therefore, the finding may be biased and not able to quantify 
the fungal burden within the human body.  
The solution to the above problem is given by the development of real-time 
PCR methods. Real-time PCR assays are able to quantify the amount of amplified 
DNA as it occurs (Walsh et al., 2011). As a result, real-time PCR techniques have 
largely replaced conventional PCR methods in clinical laboratories (Mackay, 2004). 
Real-time PCR uses fluorescent dyes to enhance specificity through either a non-
specific double-stranded DNA binding dye or a specific fluorescently labelled probe 
directed to a target sequence lying within the amplicon. A commonly used fluorescent 
DNA binding dye, SYBR Green dye chemistry, binds to all double-stranded DNA by 
intercalating between the bases (Fraga, Meulia & Fenster, 2014). There are various 
chemistries for probe labelling and fluorescent detection available such as TaqManÒ 
hydrolysis probe (also known as fluorogenic 5´ nuclease chemistry), hybridisation 
probe and Molecular Beacons, as well as numerous thermocycler platforms, from the 
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high performing, LightCycler 480 (Roche Diagnostics) to the simpler instruments such 
as 2-Plex HRM Rotor-Gene Q (Qiagen, Germany), which, depend on the levels of 
throughput and combination of the detection channel (Froehlich, Sagner & Tellmann, 
2009). The TaqMan probe consists of a 5’ end reporter dye coupled with a 3’ end 
quencher dye on the sequence-specific oligonucleotide probe that hybridises to the 
complementary sequence within the target PCR amplicon. The probe is cleaved by the 
5’ endonuclease activity of Taq polymerase during the extension stages, thus releasing 
the fluorescent emission only when the probe sequence is hybridised to a 
complementary target. The hybridisation probe assays rely on the interaction of the 
two probes (known as donor and acceptor) hybridised adjacently to the target sequence 
and emits fluorescence signal when the donor (dye labelled at 3’ end) and acceptor 
(dye labelled at 5’ end) probes are in the close proximity. The instrument’s 
fluorescence detector measures the emission from the excited acceptor probe. Finally, 
the Molecular Beacons are single-stranded hairpin-shaped oligonucleotide probes, 
which unfold and release fluorescence when bound to the complementary target. 
The identification methods of the real-time PCR assay can be more complex 
and far more useful than conventional PCR assay. The higher the initial copy number 
of target DNA molecules in the reaction, the faster an exponential increase of 
fluorescence is observed during the PCR cycles.  A significant fluorescence signal 
increase can be determined at the threshold cycle (Ct), at which the amplification plot 
crosses the threshold line. In contrast, an endpoint PCR assay measures the amount of 
accumulated PCR product from the plateau phase (level-off) in the fixed PCR 
cycles. Target DNA can then be quantified by construction of a calibration curve that 
corelates Ct to a known number of DNA copies. Secondly, numbers of fungal detection 
tests are based on the melting curve analysis of an amplified product or through 
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evaluation of the design of probes that bind to amplified fragments and have different 
melting temperatures, so they can be detected by melting curve analysis.   
 
1.6.2 Use of DNA biomarkers in the taxonomic identification of fungi 
The advancement of phylogeny research in fungi provides access to fungal genome 
sequences on the reference sequence databases. In general, the DNA biomarkers 
demand two essential characteristics which are high taxonomic coverage and 
specificity to the target group (Hebert et al., 2003). Studies have analysed numerous 
fungal biomarkers including single copy genes, such as translation elongation factor 
(TEF-1a) and b-tubulin genes and a gene encoding mini-chromosome maintenance 
protein (MCM7), but scientific consensus has recognised the sequences within the 
multicopy rDNA gene complex as the most useful fungal biomarkers (Schoch et al., 
2012; Xu, 2016). The rDNA genes are organised in repeats of 50 to 100 copies in a 
haploid genome, and these multicopy genes are amplified with better sensitivity than 
a single-copy gene (Wickes & Wiederhold, 2018). The fungal rDNA gene complex 
that consists of the 18S, 28S and 5.8S and the intervening internal transcribed spacers 





   
 
 
Figure 1. 8 Structural organisation of the fungal rDNA gene complex. The 18S, 
5.8S and 28S rDNA genes are flanked by the ITS1 and ITS2. The 28S and 5S rDNA 
genes are flanked by the intergenic spacer (IGS1) meanwhile, IGS2 separates the 
repeat units. The conserved regions exist at the beginning and at the end (marked with 




        28S rDNA 
5S 
rDNA 
Major rDNA transcript (1 rDNA repeat unit) 
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two bands) within the D1/D2 region (~600 base pair) of the 28S (large ribosomal 
subunit) gene.  
 
 
Several loci within the rDNA genes and ITS regions have been employed as an 
ideal target sequence in various molecular detection assays (Arvanitis et al., 2014). 
The ITS regions are good molecular targets for species level identification (Landlinger 
et al., 2009) and extensively used as a universal DNA barcode in fungal taxonomy 
studies (Sulaiman et al., 2014). Both, the rDNA and ITS regions contain the 
aforementioned criteria for the DNA biomarkers; highly conserved and variable 
regions, facilitating the design of the PCR primers within the conserved genes to 
amplify DNA from a large number of fungal species and identification of the target 
probe within the hypervariable sequence to define a particular genus or species. 
Although most of the universal primers used to amplify fungal ITS biomarkers are 
ITS1, ITS2, ITS3 and ITS4, primers SR6R, V9D, V9G, LS266, LR1, IT2 and ITS1F 
on the large subunit (LSU) rDNA are also recommended to avoid cross reactivity with 
human DNA, especially when amplification takes place directly from clinical 
specimens (Irinyi et al., 2016; Leslie et al., 2012). Within the ITS, the ITS2 region has 
become the genetic marker in fungal identification and molecular taxonomy because 
of the availability of universal primers to amplify the region in most of the fungal taxa, 
and the high discrimination power to distinguish even closely related fungal species 
(Irinyi et al., 2016; Valero et al., 2016; Zeller et al., 2017). In addition, other useful 
multicopy genes include cytochrome P450 lanosterol C-14a-demethylase, alkaline 
proteinase and, mitochondrial cytochrome (mtCytB). Non-exhaustive PCR-based 
assays with the choice of target genes for Candida species as well as other targets 
species are listed in Table 1.2.  
 
 58 
Table 1. 2 PCR assays and target genes for fungal species detection.  
 




ITS1 for C. albicans, C. tropicalis,  
C. glabrata, C. krusei, C. parapsilosis 




MycoReal Candida  
(Ingenetix), RuO 
ITS2 for C. albicans, C. glabrata, 
C. dubliniensis, C. krusei, C. tropicalis, 




Genesig Candida kits 
(PrimerDesign), RuO 
ITS2 for C. albicans, C. glabrata,  
C. dubliniensis, C. tropicalis,  




C. albicans, C. glabrata, C. krusei,  









Candida species (C. albicans,  
C. tropicalis, C. dubliniensis,  




RPR1 gene for Candida species;  
Hwp1 gene for C. albicans;  
M antigen for Histoplasma capsulatum;  
TEF1a for Cryptococcus neoformans;  
WI-1 adhesion gene for Blastomyces 
dermatitidis  
Multiplex PCR 
coupled with bead 
probe fluid array  
 
Seeplex STI Master 
Panel 3 PCR system 
(Seegene) 
C. albicans, C. glabrata, C. dubliniensis, 
C. krusei, C. tropicalis, C. parapsilosis 
PCR and 
electrophoresis 
Lau et al., 2010 ITS1, IT2, TEF-1a  and b-tubulin genes 
for Candida species  
Amplification curve 
Tirodker et al., 2003 ITS1 for C. albicans, C. glabrata,  
C. tropicalis, C. parapsilosis 
PCR and gel 
electrophoresis 
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Moreira-Oliveira et al., 
2005 
5.8S for Candida species PCR and sequencing  
Trovato et al., 2012 ITS1, 18S and 28S rDNA for Candida 
species 
PCR and gel 
electrophoresis 
Ahmad et al., 2002 ITS2 for C. albicans, C. glabrata, C. 
tropicalis, C. parapsilosis 
PCR and gel 
electrophoresis 
Jainlabdin et al., 2018 ITS1 and ITS2 for pan-fungal, ITS2 for 
pan-Candida species, C. krusei,  
C. glabrata and Aspergillus terreus 
PCR and gel 
electrophoresis 
ITS, Internal Transcribed Spacer; rDNA, ribosomal deoxyribonucleic acid; LSU, large subunit; 
FDA, Food and Drug Administration; IVD, in vitro diagnostic device; RuO, Research Use Only; 
Hwp1, hyphal wall protein 1; RPR1, ribonuclease P RNA 
 
 
1.7 Clinical specimens and source of the fungal nucleic acid 
One of the considerations in designing a PCR assay is the choice of the starting clinical 
specimen. The methodological standardisation for an optimal sample for Candida PCR 
testing is still to be determined, for the testing on whole blood or serum/plasma 
(Wickes & Wiederhold, 2018). The specimen type and the effectiveness of the nucleic 
acid extraction procedure will affect the sensitivity of the target DNA amplification 
from the inhibitor-free DNA sample (Hsu et al., 2011; Safavieh et al., 2017).  The 
choice of blood fraction; serum/plasma determines free circulating DNA is targeted 
during extraction and, the use of whole blood should target the cell-associated DNA 
(Halliday et al., 2015). The overview of fungal DNA extraction from clinical samples 
for detection in PCR assays, is illustrated in Figure 1.9. However, with the presence of 
the complex structure of the fungal cell and the need for a rigorous cell lysis steps, the 
method of fungal DNA extraction is complicated when associated with the use of 
whole blood (Arvanitis et al., 2014). Moreover, the extraction method must 
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consistently remove the PCR inhibitors and separate the relatively abundant human 
DNA from blood samples (Wickes & Wiederhold, 2018).  
The serum is a specimen of choice because it requires less complicated DNA 
extraction and, contains fewer inhibitors than whole blood; therefore, amenable to 
standardisation (Alanio & Bretagne, 2014). A systematic comparison between the PCR 
detection of the Candida DNA isolated from plasma (75%) and serum (71%) are more 
sensitive than whole blood (54%) (Lau et al., 2010). Ideally, an automatic process of 
DNA isolation and purification is the best approach towards standardisation of the 
method and shortening the test turnaround time as well as reducing the workload 
(Sexton et al., 2018). Humans are prone to introduce processing errors by cross-
contamination between the handled samples, and manual extraction may be not ideal 







Figure 1. 9 The principles of the molecular detection of fungi and DNA 
extraction from clinical samples. The sources of fungal DNA from the whole blood 
are highlighted as red arrows and serum/plasma as a yellow arrow. Broken lines 
indicate limited evidence. CSF, cerebrospinal fluid; IPA, invasive pulmonary 
aspergillosis; ppt, precipitation; RT, real-time; SDS, sodium dodecyl sulphate; 
SERRS, surface-enhanced resonance Raman spectroscopy. The diagram is adapted 








1.8 Research aims and objectives 
This thesis aims to explore the potential of the MPA and MNAzyme biomarker 
detection platforms as simple nucleic acid biosensors for the diagnosis of invasive 
candidiasis. The research has the following work packages:  
 
i) Identification through bioinformatic sequence analysis of nucleic acid 
biomarkers with a range of specificities, including pan-fungal (detection of 
any fungi), pan-Candida (detection of all Candida species) and species-
specific biomarkers for the identification of multidrug-resistant C. auris, C. 
glabrata, and C. krusei.  
ii) Engineering and in vitro characterisation of a single-tube, dual channel 
pentaplex MPA-Candida assay.  
iii) Optimisation of the pentaplex MPA-Candida assay to incorporate a pan-
fungal biomarker and further develop it into a single-tube, single channel 
reaction.  
iv) Evaluation of three different Candida DNA isolation protocols from blood 
and serum samples for downstream processing with the MPA-Candida 
assays.  
v) Engineering and in vitro characterisation of an MNAzyme test for the 
isothermal detection of fungi.  
 
This thesis is organised in seven chapters:  
 
Chapter 1 introduces the current understanding of invasive fungal infections and some 
critical issues related to Candida infections. A brief section on the biology of the yeast 
intended to discuss the characteristics of the relevant species and their relationship at 
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the genus level. This chapter also elaborates the traditional diagnostic methods for the 
fungal infections as well as cutting-edge technologies to provide an insight into the 
molecular tools used to improve the diagnosis of invasive candidiasis. The principles 
of novel nucleic acid detection platforms, the MPA and MNAzymes, are discussed to 
provide the reader with some understanding of the potential use of the platforms in 
achieving the research objectives. The prior knowledge of the fungal DNA biomarkers 
serves as a cornerstone in the development of reliable nucleic acid biosensors for the 
diagnosis of invasive candidiasis. The possible sources of fungal DNA from human 
specimens are also reviewed with considerations of the methods of fungal DNA 
isolation that may be involved in testing biomarker detection platforms. The research 
objectives are outlined in the form of work packages to provide a systematic approach 
to achieve the research aims. Chapter 2 describes the methods used to conduct the 
research as well as the laboratory instruments and equipment. The standard analysis 
procedures and overall numerical operations employed are also detailed in Chapter 2. 
Chapter 3 provides the main findings of the thesis on the development of the MPA-
Candida assay for reliable detection of nucleic acid biomarkers of clinically relevant 
Candida species. A comprehensive description of the probe and in vitro 
characterisation of the assay are reported in this chapter. The assay’s analytical 
specificity and sensitivity are tested against a range of Candida species that are 
frequently associated with candidiasis. This chapter also discusses the validation and 
evaluation tests of the assay with a standard Candida species Evaluation Panel and a 
commercial C. auris qPCR diagnostic kit. The potential use of the MPA-Candida assay 
is highlighted here as a novel qPCR assay for the early diagnosis of invasive 
candidiasis and to assist patients and doctors to make informed decisions on outlook 
and treatment options. Chapter 4 describes experimental exploration to improve the 
state of the MPA-Candida assay, possibly from a two-tubes system into a single tube 
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assay. This chapter is presented in two sections; assay design 2 for the reaction 
optimisations in two fluorescence detection channels, and assay design 3 for the hexa-
plexing assay in three real-time PCR detection channels. Chapter 5 presents the 
effectiveness of independent DNA isolation protocols for the recovery of Candida 
DNA from mammalian blood and serum samples. Three commercial DNA isolation 
kits with a slight modification for the mechanical cell lysis step are assessed for the 
DNA yield by a real-time PCR assay and spectrophotometer. The optimum protocol 
established here is employed to process spiked serum samples of the Candida 
Evaluation Panel, of which the findings are reported in Chapter 3. Chapter 6 provides 
another main finding in the development of an isothermal MNAzymes assay for the 
detection of fungal DNA biomarkers. The results are presented from the identification 
of the pan-fungal DNA biomarker as a target sequence, reagents optimisation as well 
as specificity and sensitivity tests. The Pan-Fungal assay kinetic activity is also 
assessed to broaden the understanding of the kinetics of MNAzyme catalysis and 
compare the assay activity against the previously reported assays. Finally, Chapter 7 
summarises the main findings through an overarching discussion within the context of 
clinical diagnosis of invasive candidiasis. The strengths and limitations of the study as 






CHAPTER 2: Materials and Methods 
 
2.1 Fungal and bacterial isolates 
Strains of the Candida species, C. albicans, C. glabrata, C. tropicalis, C. dubliniensis, 
C. krusei, C. guilliermondii and C. parapsilosis were a kind gift from Professor Julian 
Naglik (King’s College London). C. auris (NCPF 8971) and C. haemulonii (NCPF 
8402) strains were purchased from Public Health England, Bristol, UK. Filamentous 
fungi species strains of Aspergillus fumigatus, Aspergillus flavus, Fusarium solani, 
Penicillium rubens and, Mucor circinelloides as well as bacterial species strains of 
Staphylococcus epidermidis, Staphylococcus aureus, Proteus mirabilis and 
Escherichia coli were obtained from the Centre for Biomedical Sciences, Royal 




2.2 Microbial growth media preparation  
 
2.2.1 Yeast extract Peptone-Dextrose (YPD) broth 
The YPD broth was prepared according to Bergman, 2001. The broth was prepared 
with the bacteriological Peptone, 20 grams; Yeast extract, 10 grams; Glucose, 20 
grams. The ingredients were dissolved completely in 1,000 mL distilled water. The 
mixture was sterilised by autoclaving at 121°C for 15 minutes. Single yeast colonies 
were inoculated in the YPD broth and incubated at 37°C in a rotary shaker (SciQuip, 




2.2.2 Sabouraud Dextrose Agar (SDA) 
A selective medium SDA (Sigma-Aldrich, UK) for yeast, filamentous fungi and 
aciduric bacteria was prepared according to the manufacturer’s instructions. Briefly, 
65 grams medium powder, composition of mycological peptone, dextrose and agar, 
was suspended in 1,000 mL of distilled water. The medium was dissolved completely 
by heating and stirring for 5 minutes on the magnetic stirrer followed by sterilisation 
by autoclaving at 121°C for 15 minutes. The prepared medium was poured aseptically 
onto a general plastic petri dish (100 mm ´ 15 mm) and stored at 4°C. Fungal isolates 
were sub-cultured onto the SDA and incubated at 37°C for yeast and 25°C for moulds 
in the incubator for 15 to 24 hours.  
 
2.2.3 Luria-Bertani (LB) medium 
The LB nutrient-rich broth (Merck, Germany) for Escherichia coli cultivation contains 
peptone, yeast extract, sodium chloride and water-soluble vitamins. The medium 
powder (25 grams) was dissolved in 1,000 mL of distilled water.  The autoclaved broth 
is clear and yellowish-brown. Bacterial isolates were cultured in LB broth at 37°C in 
a rotary shaker (SciQuip, UK) for 24 hours. The LB agar was supplemented with the 
Ampicillin 50 µg/mL (Merck, Germany) for cultivation of transformed E. coli in the 









2.3 Nucleic acid extractions 
The basic principle of nucleic acid extractions involves three common steps; cell lysis, 
removal of the cell components, contaminants and nucleic acid precipitation and the 
elution of the nucleic acids. These steps are normally applied by the commercial DNA 
extraction kits. The procedure, buffers, as well as the kit contents are summarised in 
Table 2.1.  
 
Table 2. 1 The principle of the nucleic acid extraction kits and the equipped 
buffers. 
  








Cell disruption  Cell Lysis solution Extraction Tube 
with lysis 
components1 






ZB Lysis solution 







(Isopropanol) &  






Isopropanol DNA Binding 
Buffer 
70% ethanol Wash buffers 1 
& 2 
Zymo Spin Filter-Z 





Elution buffer Zymo Spin Filter-F 
& Nuclease-free 
water 
RNase A solution  Zymo-HRC 
solution 
1 Extraction Tube is prefilled with lyophilised lysis components (lysis buffer, Lysozyme, 
Proteinase K, Carrier RNA). 
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2.3.1 Wizardâ Genomic DNA Purification Kit (Promega Corp.) 
 
2.3.1.1 Fungal DNA isolation 
One millilitre (mL) aliquots of a culture grown was centrifuged at 13,000–16,000 × g 
for 2 minutes to pellet the cells. The pelleted cells were homogenised in the mini-pestle 
BioMasherâ (Nippi Inc., Japan) (Figure 2.1) to lyse the cell wall and cell membrane. 




Figure 2. 1 A set of mini-pestle BioMasherâ-II by Nippi Inc. Japan. Coarse-
grained surfaces on the pestle tip (A) and inner tube area (B) ensure efficient grinding 
of samples. 
 
The bead-beating technique is another mechanical cell wall lysis method used 
in this study. The technique applied after the cell pellet was resuspended in 300 µL of 
lysis buffer from the Wizard® Genomic DNA Purification kit (Promega, USA). 
Following the addition of 200 mg of 500-micron glass beads (BioSpec Products, USA) 
yeast cells were homogenised with a FastPrep-24™ instrument (MP Biomedicals, 
USA) using five pulses with 60 seconds cooling intervals at 6.5 m/s speed setting. The 
A B 
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same technique was also performed in the vortex-based instrument, the Disruptor 
Genie® (Scientific Industry, USA) for 20 minutes and can be operated in 4°C cold 
room.   
Next, the cellular proteins were removed by a salt precipitation step and, the 
DNA was concentrated and desalted by isopropanol precipitation. Briefly, 100 µL of 
Protein Precipitation Solution was added and mixed by vortex at high speed for 20 
seconds. The samples were kept on ice for 5 minutes then, further with centrifugation 
at 13,000–16,000 × g (bench microcentrifuge Heraeus, Germany) for 2 minutes to 
remove the cell debris. The supernatant containing the DNA was transferred to a clean 
1.5 mL micro-centrifuge tube that has been filled with 300 µL of room temperature 
isopropanol. At this stage, some supernatant on top of the precipitated protein was left 
to avoid contaminating the DNA solution with protein. Samples were mixed by 
inversion until the thread-like strands of DNA form a visible mass. Then, the tubes 
were centrifuged at 13,000–16,000 × g for 2 minutes. The supernatant was thrown, and 
the tube was drained on clean absorbent paper.  
The DNA pellet formed was washed by gently inverting the tube several times 
with 300 µL of room temperature 70% ethanol. The samples were proceeded to 
centrifuge at 13,000–16,000 × g for 2 minutes. Then, ethanol was carefully removed 
from the tubes. Again, the tubes were drained on clean absorbent paper and allowed 
the pellet to air-dry for 10–15 minutes. 50 µL of DNA Rehydration Solution was added 
into the tubes containing DNA pellet. The DNA was resuspended in 50 µL of DNA 
nuclease-free water, a process optimised by incubating at 65°C for 1 hour. Throughout 
the period, the solution was gently mixed in the tube. The extracted genomic DNA 




2.3.1.2 Bacterial DNA isolation 
One mL aliquots of a culture grown was centrifuged at 13,000–16,000 × g for 2 
minutes to pellet the cells. The supernatant was discarded, and the bacterial cell pellet 
was resuspended in 60 µL of 10 mg/mL lysozyme and incubated at 37°C for 30 
minutes to ensure efficient cells lysis. The cell pellet was resuspended in 300 µL of 
Nucleic Lysis buffer followed by the protein precipitation and nucleic acid pellet 
purification steps as described in sub-Section 2.3.1.1.  
 
2.3.2 RTPâ Pathogen Kit (Stratec Molecular GmbH) 
A total amount of 107 yeast cells suspension was processed for DNA extraction using 
RTP® Pathogen Kit (Stratec Molecular, Germany) with slight protocol modifications 
for mechanical yeast cells lysis. The sample was mixed with Resuspension buffer and 
subjected to the Extraction tube pre-filled with lyophilised lysis components (lysis 
buffer, Lysozyme, Proteinase K, Carrier Nucleic acids) to lyse the samples, stabilise 
the nucleic acids and inactivate RNases and DNases. The sample in the extraction tube 
was incubated at 65°C under continuous shaking for 20 minutes in the thermomixer 
(Grant-bio, UK). An essential step of vigorous mechanical yeast cells lysis was 
performed by 400 mg of 500-micron glass beads (BioSpec Products, USA) in the 
Disruptor Genie® (Scientific Industry, USA) for 20 minutes operated in 4°C cold room. 
Subsequently, the lysed cells were loaded into the RTA Spin filter and centrifuged to 
remove the contaminants from the filter membrane. The nucleic acids bound to the 
filter membrane were washed with 100% ethanol in two steps, 500 µL and 700 µL 
before drying the filter with maximum speed of centrifugation for 4 minutes. The final 
volume of 50 µL of nuclease-free water or supplied elution buffer was used to elute 
the purified nucleic acids. In all cases, the Carrier RNA will account for most of the 
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eluted nucleic acids therefore, quantitative real-time PCR is recommended to quantify 
the extracted nucleic acids. 
 
2.3.3 ZymoBiomicsÔ DNA Miniprep Kit (Zymo Research Corp.) 
The yeast DNA isolation of 108 cells was performed according to the ZymoBIOMICSÔ 
DNA kit (Zymo Research, USA) standard protocol for bead beating cell lysis steps. 
The sample was added to ZR Bashing Bead lysis tube containing 100-micron and 500-
micron beads and mixed with the ZB lysis solution. The cell lysis steps were performed 
in a FastPrep-24™ instrument (MP Biomedicals, USA) using five pulses with 60 
seconds cooling intervals at 6.5 m/s speed setting. The ZR Bashing Bead lysis tube 
containing cell extracts was subjected to centrifugation at the maximum speed for 1 
minute. The supernatant was carefully transferred with no cell debris into the Zymo 
Spin Filter-F fitted in a collection tube. After a minute of the centrifugation step, the 
spin filter was discarded and the filtrate was mixed with 1,200 µL DNA Binding 
Buffer. The total mixture volume was loaded to the filter membrane in the Zymo Spin 
Filter-Z followed by centrifugation in two repeated steps. Filter bound-nucleic acids 
were washed with Buffer 1 and subsequently twice washing steps with Buffer 2 before 
placed the Zymo Spin Filter-Z into a clean 1.5 mL tube. The filter membrane was 
incubated for one minute in the 50 µL nuclease-free water followed by centrifugation 
at the maximum speed for 3 minutes. The filtered nucleic acids were added into Zymo-
Spin HRC Filter containing 600 µL Zymo-HRC Solution and centrifuged at the 
maximum speed for 3 minutes. The purified nucleic acids are now ready for 





2.3.4  Recombinant plasmid DNA isolation   
Cloned plasmid DNA was purified from bacterial cells using a QIAprep Miniprep Kit 
(Qiagen, Germany) according to the manufacturer instructions. Briefly, samples were 
subjected to alkaline lysis in buffer PB and neutralised. Cleared lysates were applied 
to QIAprep purification columns under high-salt concentration affinity binding 
conditions and eluted in 30 µL of elution buffer. In all cases, the concentration of 
purified DNA was measured using a NanoDrop™ 1000 spectrophotometer (Thermo 
Scientific, USA) and stored at 4°C until use. 
 
2.4 DNA purification  
Extracted or amplified DNA products may require purification to remove primers, 
nucleotides, salts, agarose and other impurities from the DNA sample. The volume of 
20 µL of the PCR product was subjected to QIAquick® PCR Purification Kit (Qiagen, 
Germany). Buffer PB was mixed with PCR product and observed for yellow colour 
indicating the correct pH condition. The QIAquick column was placed in the provided 
collection tube, and the sample was applied to the QIAquick column and centrifuged 
for 1 minute. The flow-through was discarded and the QIAquick column was returned 
to the same collection tubes. The buffer PE was added and centrifuged for 1 minute to 
wash the sample. Centrifugation was repeated for one minute to remove residual wash 
buffer. Next, the QIAquick column was placed in a clean 1.5 mL micro-centrifuge tube 
and 50 µL of elution buffer was added to centre of the QIAquick membrane. The 
QIAquick column in micro-centrifuge tube was spun for one minute and the flowed-





2.5 Determination of nucleic acid concentration and purity 
The concentration and purification of the genomic or purified DNA was determined 
by using a Nanodrop™ 1000 Spectrophotometer (Thermo Scientific, USA). 
Absorbance measured at 260 nm and 280 nm. As A260 of 1.0 is equal to 50 µg/mL pure 
DNA, DNA concentration can be estimated by measuring the absorbance at 260 nm, 
multiplying by the dilution factor and 50 µg/mL. The DNA purity can be estimated 
from the A260/280 ratio. A ratio of A260/280 in between 1.8 and 2.0 generally represents a 
high-quality DNA sample with minimal protein contamination. 
 
2.6 Calculation of DNA copy number 
The number of double-stranded DNA copies can be determined from the amount of 
the DNA obtained in nanogram (ng) and the length of the DNA in base pair (bp).  The 
number of molecules was calculated with this information using the following formula:  
 
Number of copies (molecules) = (DNA amount in ng) ´ 6.0221 ´1023 molecules/mole 
     (length in bp) ´660 g/mole ´ 1´109 ng/g 
 
2.7 Haemocytometer cell counting 
Cell counts were performed using a microscope (Leica DM500, Germany) and 
haemocytometer, an improved Neubauer ruling and its coverslip. Cell suspensions 
were diluted 1:10 and mixed in normal saline solution for a uniform distribution of the 
cells in the chamber represents a random sample from the total volume. Briefly, 10 µL 
of cell suspensions were loaded in between of the coverslip and haemocytometer and 
were allowed to cover the entire grid. The cells were counted systematically under an 
optical microscope at 40´ magnification. The averages were counted from the 5 
corners of the 25-square within 1-mm2 grid area.  The density of the cells/mL was 
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calculated from the averages multiplied by the dilution factor and divided by 0.000004 
mL account for the volume of the small square counted.   
 
2.8 Serial dilution preparation  
Serial dilution of the sample was prepared to create a sequence of dilutions with the 
same dilution factor in each successive step. To make a 1:10 dilution of 1,000 μL 
sample volume, the stock was mixed well and transferred 100 μL to another tube 
containing 900 μL of buffer, media or nuclease-free water. Each dilution was mixed 
well before transferring the volume to be brought up to a predetermined volume.  
 
2.9 Colony-Forming Unit (CFU) 
CFU is a term which refers to the number of cells which grow into a colony determined 
from a preparation of cell dilutions. The cells from each dilution were spread on the 
plates in duplicate. Following an overnight incubation, the averages colonies growth 
on the plates were counted. The numbers CFU per millimetre was determined 
following the calculation:  
                 CFU/mL= (number of colonies present on the plate) ´ (dilution factor)  
                                                           volume of culture plate 
 
2.10 DNA cloning 
In order to prepare cloned plasmid DNAs, first-round PCR amplicons were cloned into 
the pCR® 2.1-TOPO® vector using the TOPO® TA Cloning® system (Invitrogen, 
USA). The reaction mixture was prepared as in Table 2.2. The mixture was mixed and 
incubated for 5 minutes at room temperature. The enzyme Taq-polymerase from the 
amplification reaction has terminal transferase activity that adds a single 
deoxyadenosine (A) to the 3’ ends of PCR products (Figure 2.2). The linearised vector, 
pCR® 2.1-TOPO® has single, overhanging deoxythymidine (T) residues at the 3’ ends 
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adjoining the sequence 5’-CCCT-3’. This allows hybridisation of the (A) and (T) 
residues between vector and the PCR product. As a result, the PCR product and the 
vector can efficiently ligate by the enzyme Topoisomerase I from Vaccina virus. The 
Topoisomerase I covalently attaches to the phosphate groups at the 3’ end of the vector, 
as the vector and the PCR product are mixed, the enzyme transfers the phosphate 
linkages to the 5’ ends of the DNA fragment, thus joining the insert and the vector. 
The recombinant vector was subsequently transformed into competent TOP10 E. coli 
supplied in the cloning kit. Briefly, 2 μL of the cloning reaction into chemically 
competent E. coli cells by heat shock. One mL of S.O.C (Super Optimal broth with 
Catabolite repression) medium was added to the cells and incubated at 37°C for 1 hour 
in a rotary shaker (SciQuip, UK). Each transformation sample was spread onto a LB 
plate containing 40 μg/mL Ampicillin (Merck, Germany). The plates were prepared in 
duplicate and incubated overnight at 37°C to grow colonies. Each colony grown was 
picked and, inoculated in 5 mL LB broth containing 40 μg/mL Ampicillin. Next, 
plasmid DNA was isolated using a QIAprep Miniprep Kit (Qiagen, Germany) as 
described in Section 2.3. The resulting plasmid with insert was quantified and 
sequenced to confirm the identity of the cloned DNA.  
 
Table 2. 2 The preparation of TOPO® cloning reaction. 
 
Reagent Volume 
Fresh PCR product 3 µL 
Salt solution (NaCl, 1.2 M) 1 (final concentration, 0.2 M) 
Water 1 
TOPO® vector 1 




Figure 2. 2 The map of the pCR® 2.1-TOPO® vector as described in the 
manufacturer’s instruction manual.  
 
 
2.11 End-point PCR mixture preparation  
The master mix for end-point PCR preparation, 2 × GoTaq® Green Master Mix 
(Promega, USA) composed of GoTaq® DNA Polymerase, 400 µM 
deoxyribonucleotide triphosphate (dNTP) and 3mM Magnesium Chloride (MgCl2). 
The reaction mixture was prepared for amplification of DNA as showed in Table 2.3. 
A standard amplification condition was set in a PCR thermocycler (Techne TC-512, 
UK). The reaction started with 5 minutes of 94°C initial denaturation step, followed 
by 34 cycles at 94°C for 1.5 minutes, 55°C for 2 minutes and 72°C for 3 minutes and 
a final extension step at 72°C for 10 minutes. In a case of the annealing temperature 
optimisation, the temperature gradient performed in a range of 10°C for 2 minutes.  
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Table 2. 3 The preparation of the PCR mixtures for end-point analysis. 
 
Component Volume (μL) for 1 × 
reaction 
Final Concentration 
in 20 μL reaction 
2 × GoTaq® Green Master Mix, 
Promega 
10.0 1× 
Forward Primer 1.0 0.5 µM 
Reverse Primer 1.0 0.5 µM 
DNA 4.0 10 ng - 40 ng 
Nuclease-Free Water to 4.0 - 
 
 
2.12 Agarose gel electrophoresis for DNA band analysis 
The preparation of 1.2% agarose gel was started with mixture of 360 mg agarose 
powder (Merck, Germany) into 30 mL of electrophoresis buffer, Tris-borate-EDTA 
(TBE) (Merck, Germany). The agarose suspension was boiled in a conventional 
microwave oven (Stirflow, UK) for 1 minute at the high temperature setting and 
swirled for the homogenous agarose solution. The molten agar was let to cool before 
mixed with 3 µL SYBRÔ Safe Nucleic Acid Stain (Invitrogen, UK). The molten agar 
was poured onto the gel caster with the comb positioned at the end of the plate for the 
sample wells in the gel. The gel slab was let solidify for 20 minutes before removing 
the comb and mounting the gel in the electrophoresis tank. The electrophoresis buffer 
was added enough to cover agarose gel and the comb was removed. Next, 5 µL of 100 
bp DNA marker (Promega, USA) was loaded in a well and continued with the 2 µL to 
5 µL of PCR product mixed with 1 µL of Loading dye (Promega, USA) in each well. 
The gel tank lid was closed, and the electrical leads were attached for DNA migration 
toward the positive anode (red lead). The electrophoresis was run at 80 Volts for 60 
 78 
minutes. Then, agarose gel was observed under UV trans-illuminator for the analysis 
of fluorescently stained DNA bands. 
 
2.13 Bioinformatic analysis 
Fungal rDNA sequences were retrieved from GenBank 
(https://www.ncbi.nlm.nih.gov/genbank/) and the International Society for Human and 
Animal Mycoses (ISHAM) ITS database (http://its.mycologylab.org/) and aligned 
using CLUSTALW2 or CLUSTAL Omega (EMBL-EBI; 
https://www.ebi.ac.uk/Tools/msa/clustalo). Sequences were manipulated and analysed 
using the BioEditÓ Sequence Alignment Editor Version 7.2.3 (Hall, 1999). 
 
2.14 MPA-Candida Assay 
 
2.14.1 Primers and hydrolysis probe design  
Primers and probes were designed within the rDNA region. Primers used in the MPA-
Candida assay were the universal forward primer, LR0 and specifically designed 
reverse primer, GSCand. A universal pan-fungal primer set ITS3 and LR1 was selected 
to amplify the region containing pan-fungal probe. Four dual-labelled Candida probes 
were designed to specifically target the D1/D2 of the LSU rDNA region from at least 
15 different Candida species. The pan-fungal probe was designed based on the ITS 
sequences. The MPA internal control (IC) probe consists of a unique nucleotide 
sequence cloned into the pCR™ 2.1-TOPO® vector that has no significant homology to 
any entry in the non-redundant nucleotide databases at NCBI. MPA probes were 
designed using the nucleic acid folding and hybridisation prediction software 
UNAFold (http://unafold.rna.albany.edu). All primers and probes were subjected to 
reverse Basic Local Alignment Search Tool (BLAST) in GenBank 
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(http://blast.ncbi.nlm.nih.gov) to test for cross-homology with other microorganisms. 
The MPA Candida and TaqMan® pan-fungal reaction sets are shown in Table 2.4. 
Universal 16S primer set, 516: 5’-TGCCAGCAGCCGCGGTAA-3’ and 
806R: 5’-GGACTACCAGGGTATCTAAT-3’ (Fredricks & Relman, 1998)  was 




Table 2. 4 The layout design for MPA-Candida assay and a complementary 
TaqMan® Pan-Fungal assay.  
 
Reaction type Probe target Detection 
channel 
Primer set  
MPA C. krusei (CK) FAM Forward: LR0 (Cubeta, 
1991) & Reverse: 
GSCand (designed in this 
study) 
Pan-Candida (PC) 
C. glabrata (CG) 
C. auris (CA)  HEX 
Internal Control (IC) Forward: M13 (-20) & 
Reverse: M13 (-29) 
TaqMan® Pan-fungal (PF) FAM  Forwards: ITS3 (White et 
al., 1990) & 
Reverse: LR1 (Vilgalys 
& Hester, 1990) 
IC HEX Forward: M13 (-20) & 
Reverse: M13 (-29) 





2.14.2 Real-time PCR mixture preparation 
Initially, the MPA-Candida PCR mixtures were prepared in 10× mix for a total volume 
of 180 µL as described in Table 2.5. In a 1× reaction, template DNA included 1 µL of 
IC plasmid DNA (106 copies) and 1 µL of extracted fungal DNA (1 to 105 copies) for 
20 µL final reaction volume.  Each THO was combined with the corresponding PCO 
at a ratio of 1:2. The Pan-Fungal reaction, both the pan-fungal and IC probes were 
present at a concentration of 0.4 µM (Table 2.6). 
 






for 10× mix 
Final 
Concentration 
(µM) in 20 µL 
reaction 
LightCycler 480 Probes 
Master (Roche) 
2× 100.0 1× 
Pan-Candida (PC) THO  20 2.0 0.2 
C. krusei-specific (CK) 
THO  
20 4.0 0.4  
C. glabrata specific (CG) 
THO  
20 4.0 0.4 
C. auris-specific (CA) 
THO  
20 4.0 0.4 
IC THO  20 4.0 0.4 
PC PCO 40 2.0 0.4 
CK PCO 40 4.0 0.8 
CG PCO  40 4.0 0.8 
CA PCO 40 4.0 0.8 
IC PCO 40 4.0 0.8 
LR-0, Forward primer (F) 40 3.0 0.6 
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GSCand, Reverse primer 
(R) 
40 3.0 0.6 
M13, F 40 3.0 0.6 
M13, R 40 3.0 0.6 
Nuclease-free water N.A. 32.0 N.A. 
 
 






for 10× mix 
Final 
Concentration 





2× 100.0 1× 
Pan-fungal THO 20 4.0 0.4 
IC THO 20 4.0 0.4 
ITS3, F 40 3.0 0.6 
LR1, R  40 3.0 0.6 
M13, F 40 3.0 0.6 
M13, R 40 3.0 0.6 
Nuclease-free water N.A. 60.0 N.A. 
 
 
The specificity of the pan-fungal probe was evaluated from the amplification 
curve whereas those of Candida MPA probes were evaluated from their melt curve 
profiles. The amplification curve Ct value of the Pan-Fungal assay was standardised 
by an automatic threshold setting whereas for MPA-Candida reaction, the threshold 
line was set at 5 in Fit Points analysis method using the LightCycler 480 software 
version 1.5 (Roche Diagnostics, Germany). The amplification assay was carried out in 
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a LightCycler 480 Instrument II Real-time PCR unit (Roche Diagnostics, Germany) 
using a 384-well plate format. Real-time PCR conditions were as follows: an initial 
step of 9 minutes 30 seconds at 95°C, followed by 50 cycles at 95°C for 20 s, 62°C for 
30 seconds, and 72°C for 1 minute and temperature maintained at 95°C for 10 seconds 
before melting curve profiling increases from 20°C to 80°C. Two detection channels, 
FAM (465 nm/510 nm) and HEX (533 nm/580 nm) were activated for fluorescence 
measurements during the read steps at 72°C for each experiment. 
 
2.14.3 Pan-Fungal PCR assay standard curve 
Standard curve functions to assess unknown target copy number was developed from 
TaqMan® pan-fungal PCR assay. Recombinant plasmid DNAs of C. albicans, C. 
dubliniensis, C. krusei, C. glabrata, C. auris, C. parapsilosis, C. tropicalis, C. 
guilliermondii were serially diluted for detection from 106 to 102 copies per reaction. 
Regression lines were obtained by plotting the logarithm of the initial plasmid copy 
number versus the corresponding Ct and used to determine the sensitivity and 
efficiency of the assay. Amplification efficiency was calculated by E = 10 –1/b – 1, 
where b is the gradient of the linear regression equation.  
 
2.14.4 Determination of PCR assay reproducibility 
Intra- and inter-assay reproducibility was assessed by two independent experiments of 
eight Candida species plasmid DNAs. The coefficient of variation (CV) calculated for 
Ct data was used as an indicator of relative precision and reproducibility. CV was 
determined by dividing the standard deviation (SD) by the arithmetic mean of the 




2.14.5 Assay evaluation and validation tests 
 
2.14.5.1 Candida sp. Evaluation Panel 01 (Qnostics, UK) 
A commercial Candida sp. Evaluation Panel 01 (Qnostics, UK) was used to evaluate 
the overall performance from the DNA extraction phase through amplification for 
detection of Candida species DNA. The panel is for research use only and 
manufactured to the ISO (International Organisation for Standardisation) standard 
compliant systems. The panel consists of six 500 µL serum samples spiked with 
blastoconidia of C. albicans (S01 &S02), C. glabrata (S03 &S04) and C. krusei (S05 
&S06) at high and medium concentrations respectively. For each species, the medium 
is one log lower concentration than the high sample. One serum sample (S07) has no 
cell as for the panel’s negative control. Qnostics’ Candida sp. The seven vials of the 
panel were processed as described in the nucleic acid extraction section using the RTP 
Pathogen Kit (Stratec, Germany). DNA recovered from each sample was tested in 
duplicate with 7 µL for each reaction of MPA-Candida and Pan-Fungal assays. The 
amplification cycle values obtained from both assays were cross-checked against 











Table 2. 7 Qnostics’ Candida species panel components and characteristics.  
 
Sample Code Sample Description Ct values* 
S01 C. albicans 24.5 
S02 C. albicans 27.2 
S03 C. glabrata 30.4 
S04 C. glabrata 31.9 
S05 C. krusei 29.0 
S06 C. krusei 31.3 
S07 Negative Negative 
* The Ct value provided is specific to Qnostics’ reference assay  
 
 
2.14.5.2 Candida auris kit Genesig® Standard Real-time PCR kit 
(Primerdesign™ Ltd, UK) 
The MPA-Candida for Candida auris-specific detection was validated against simplex 
C. auris Genesig® Standard Real-time PCR kit (Primerdesign™ Ltd, UK). The C. auris 
Genesig® Real-time PCR kit exploiting the TaqMan® principle for the probe targeting 
ITS2 region of the rDNA. Both assays were tested to determine the sensitivity of the 
dilution detection from the serially diluted genomic DNA from 105 to 101 copies in the 





2.15 MNAzymes Pan-Fungal Assay  
 
2.15.1 Basic components of MNAzymes assay for fungal detection 
MNAzymes composed of two partial-enzymes (Partzymes A and B), which each 
contains i) a target binding sensor arm, ii) a partial catalytic core, and iii) a substrate-
binding arm (Figure 2.3). Target binding sensor arms must have a complementary 
sequence with the input sequence (Assembly Facilitator) so that the target sequence 
can be detected. Furthermore, substrate arms had a complementary sequence with the 
substrate for it to hybridise and cleave due to enzyme catalytic activity. Each of 
partzyme was designed in 5’end to 3’end direction, with Partzyme A starting with 
sensor binding arm at 5’end and substrate binding arm at 3’end. Conversely, Partzyme 
B started with substrate arm at 5’end and sensor arm at 3’end. Both Partzymes’ 
oligonucleotide was phosphorylated to prevent the sequence from being consumed 
during PCR extension process. 
 Catalytic activity of MNAzymes were monitored by cleavage of substrate that 
hybridised with the enzyme on the substrate arms. Substrate used in this study was 
Substrate 3 (Sub3) that was labelled with JOE, (2,7- dimethoxy-4,5-dichloro-6-
carboxyfluorescein) at 5’end and the quencher Black Hole Quencher1 (BHQ-1) at 
3’end. The sequence of substrate composed of deoxyribonucleotides and at least two 
ribonucleotides (Guanine and Uracil) were present in the middle of the sequence of the 
substrate’s cleavage site. The list of substrates (Mokany et al., 2010, 2013) that could 




Figure 2. 3 Illustration of the MNAzyme components. Partzyme A is marked 
with blue colour and Partzyme B is marked with green colour. Both Partzymes bind 
adjacently to the AF sequence at their respective sensor-binding arms and hybridise 
with the substrate at substrate binding-arms. The Partzymes A and B are 
phosphorylated (P) at 3’end. The nucleic acid substrate is labelled with fluorophore 






Table 2. 8 List of optimised nucleic acids substrate sequences (probe). Each 
substrate sequence can be labelled with fluorophore and quencher for detection in a 
real-time PCR instrument. 
 












2.15.2 Optimisations of the MNAzyme Pan-Fungal assay for isothermal detection  
Each tube of MNAzyme reaction contained Partzyme A, Partzyme B, Substrate, AF, 
GeneAmp® PCR Buffer II (100 mM Tris hydrochloride, Tris-HCl; pH 8.3; 500 mM 
Potassium Chloride, KCl) (Applied Biosystems, USA) and 50 mM MgCl2 (Invitrogen, 
USA) otherwise stated with the final concentration prepared as in Table 2.9. 
Oligonucleotide sequences for Partzymes, and synthetic AF were purified in a standard 
desalting and, High Performance Liquid Chromatography (HPLC) purifications for 







Table 2. 9 Composition of the reaction mixtures for isothermal detection 
method of the MNAzyme reaction.  
 
Component Final Concentration in  
25 µL Reaction   
Partzyme A 0.05 µM 
Partzyme B 0.05 µM 
Universal MNAzyme substrate 0.2 µM 
AF 0.2 µM 
GeneAmp® 10´ PCR Buffer II  1 ´ 
MgCl2, 1 M solution 10 mM / 50 mM 
Nuclease-Free water (Promega, USA) - 
 
 
Designing the MNAzyme for fungal detection was performed by designing the 
sensor-binding sequences for each Partzyme to be complementary to a specific fungal 
DNA biomarker. The rate of catalytic activity of MNAzymes was subjected to the 
temperature, length of the substrate binding arms, the constituents and concentration 
of buffer (Mokany et al., 2010). Therefore, in this study several parameters have been 
recognised for optimisations to achieve optimum and significant enzyme activity.  
Firstly, the isothermal temperature at which the MNAzyme worked optimally 
was determined. A range of isothermal temperatures (30°C, 35°C, 40°C, 45°C, 50°C, 
52°C, 55°C, 57°C, 59°C and 64°C) were tested in standard MNAzyme reactions.  
MNAzyme temperature optimisation reactions were prepared with the synthetic AF 
for fungal biomarker (AF ITS4LR1) included and each temperature was performed in 
triplicate as described in Table 2.9.  The analyser used in this study was 2-Plex Rotor-
Q Gene (Qiagen, Germany), and this instrument was used throughout the study. The 
data for the change in fluorescence over time, indicative of cleavage of the substrate 
over time, obtained was subjected to Prism 7 Software (GraphPad Software Inc.) to 
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measure Observed rate constant (Kobs) of the substrate Sub3-JB in MNAzyme Pan-
Fungal assay.  
Secondly, the concentrations of Partzymes in MNAzyme Pan-Fungal assay 
were optimised to reduce the signal obtained from 0.2 µM of Partzymes, as this 
concentration was used in the previous report. Partzyme A and Partzyme B 
concentrations were reduced from 0.2 µM to 0.1 µM, 0.05 µM, 0.01 µM and 0.005 
µM.  
Finally, co-factor MgCl2 concentration was optimised for the highest and the 
most stable signal for hybridisation and cleavage of substrate that subjected to the 
complementary substrate-binding arms. Stock solution of 25 mM MgCl2 (Applied 
Biosystems, USA) was used to test the final concentrations at 6 mM, 8 mM, 10 mM 
and 12 mM whereas, 1M stock solution of MgCl2 (Invitrogen, USA) was used to test 
for higher final concentrations at 25 mM and 50 mM MgCl2.  Reactions without MgCl2 
and AF were also prepared as negative controls.  
 
2.15.3 Specificity tests of MNAzyme Assay for fungal detection.  
Specificity tests are important to determine the assay’s capability to accurately detect 
AF sequences in the study. The AF used to test for specificity of the pan-fungal assay 
was named as AF-ITS4LR1. The tests were performed in three independent 
experiments and was prepared in triplicate. Fluorescence signals were detected and 
recorded in a real-time PCR instrument, Rotor-Q-gene (Qiagen, Germany).  
Experiments were performed in 0.2 µM of substrate (Sub3-JB) and 1´ buffer 
solution with or without AF for fungal target sequence (AF-ITS4LR1) for positive and 
negative controls. The experiments were performed to test six different controls with 
mutated sequence of the Partzymes, mutated sequence of the AF (AF-ITS4LR1mut) 
and a different AF (AF-RO5) in the MNAzyme Pan-Fungal assay. The assay also was 
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tested in the reaction without one of the Partzymes. Nuclease-free water was added in 
every tube to make up a final reaction volume of 25 µL. Experiments were monitored 
in the real-time PCR machine at 72-second intervals for 120 minutes and signals 
observed were compared with the positive and negative controls. The set of the 
sequences used in this experiment and each sequence was synthesised by Sigma-
Aldrich, UK (Table 2.10).  
 
Table 2. 10 List of sequences used in the specificity test of the MNAzyme assay 
for fungal detection.  
 

































Different AF AF-RO5 GAAGGTGTAATCCGTCTCCACACAGACAAG
GCCAGGACTCGTTTG 
* Nucleotides underlined are partial catalytic core sequences; those outlined in italic are the substrate-
binding arm. RNA nucleotides (-g and -u) represents Guanine and Uracil in substrate sequence. The 
“-P” at the end of partzyme sequence indicates that the oligonucleotide was 3’ phosphorylated. JOEÔ 
and BHQ1 indicate the dye and quencher labelled on the sequence at the 5’ and 3’ end. Italics and 
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2.15.4 Limit of detection of an Assembly Facilitator 
MNAzyme sensitivity tests was performed to determine the assay’s limit of detection. 
The test was performed in three independent experiments in triplicate. The assay’s 
limit of detection was evaluated by reducing the concentration of the synthetic target 
sequence AF-ITS4LR1 under optimum conditions of the MNAzyme. The pan-fungal 
AF (AF-ITS4LR1) was diluted in MNAzyme assay at various concentrations (0.2 µM, 
0.1 µM, 0.75 µM, 0.025 µM, 0.01 µM, 0.0075 µM, 0.0025 µM, 0.001 µM and 0.0005 
µM). Each reaction tube contained 10 mM MgCl2, 1´ buffer solution, 0.2 µM substrate 
(Sub3-JB), 0.05 µM Partzyme A (ITS4LR1A/3-P) and Partzyme B (ITS4LR1B/3-P) 
and with or without AF (AF-ITS4LR1) in 25 µL reaction volume. Fluorescence signals 
were detected and recorded at 36-second intervals for an hour by real-time PCR 
machine, Rotor-Q-gene (Qiagen, Germany). 
  
2.15.5 Detection of purified C. albicans DNA in the MNAzyme Pan-Fungal assay 
In this experiment, the AF was C. albicans amplicon instead of the synthetic sequence, 
to be detected in MNAzyme assay. The experiment was performed to test the concept 
that MNAzymes must be able to become activated by any biological nucleic acid as 
well as synthetic nucleic acid sequences to produce an amplified output (Mokany et 
al., 2013).  
A primer set was designed (Table 2.11) to amplify the pan-fungal biomarker 
within C. albicans genome which contained the site for sensor arms hybridisation. 
Forward and reverse primers (pITS4LR1-F & pITS4LR1-R) were designed to amplify 
the sequence of interest (ITS4-LR1) with 84 bp amplicon size by using the strategy of 
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overlapping the forward primer with the 5’end of partzyme’s sensor arm. A standard 
PCR assay was prepared as described in Table 2.3 with 0.5 µM final concentration of 
primers. The PCR product was purified using QIAquick® PCR Purification Kit 
(Qiagen, Germany) as described in Section 2.4.  Before the purified C. albicans could 
be used for detection in MNAzyme assay, DNA sample was incubated in 95°C for 2 
minutes to denature the double-stranded DNA. Afterwards, the sample was kept on ice 
until subjected into the MNAzyme reaction mixtures. In  summary, the steps of the C. 
albicans amplicon detections in the MNAzyme Pan-Fungal assay is described in 
Figure 2.4. 
 
Table 2. 11 The primer sequences used to amplify the sequence of interest for 
detection of the fungal kingdom.  
 
Type Name Sequence (5’à3’) 
Forward primer pITS4LR1-F TACCCGCTGAACTTAAGC 













C. albicans from 
YPD broth 
DNA isolation








2.15.6 Kinetics of MNAzyme catalysis  
Kinetic analysis of MNAzyme assay was initiated by converting the fluorescence data, 
in arbitrary units (a.u.) into reaction velocities. To do so, a standard curve of initial 
fluorescence signal emitted from fully cleaved substrate was established from a range 
of concentrations (1 µM, 0.5 µM, 0.25 µM, 0.125 µM, 0.0625 µM, 0.00311 µM). A 
fully cleaved or processed substrate (Sub3-JB ½) is half the sequence of the original 
substrate that has a fluorophore attached to the 5’ end and this sequence was 
synthesised by Sigma-Aldrich, UK (Table 2.12). Fluorescence data obtained from a 
processed substrate in the buffer was subtracted from data of the substrate in water to 
eliminate the differences background signals. Two independent experiments were 
performed, with each reaction done in triplicate and monitored in real time at 36-
second intervals for 30 minutes at 52°C. The value of fluorescence a.u. obtained at the 
initial point of every substrate’s concentration was subjected to the Microsoft Excel 
program (Version 16) to form a linear graph with equation and R-squared properties.  
 
Table 2. 12 Sequences of substrate used in the study to determine the kinetic 
activity values of developed MNAzyme assay.  
 






Sub3-JB ½ JOEÔ-CAGCACAACC 
 
 
 To determine the enzymatic activity of MNAzymes Pan-Fungal assay, the 
isothermal direct detection method was used. Three independent experiments were 
performed, with each reaction done in triplicate with a modification of 50 mM MgCl2 
and various concentrations of substrate (either 1.00 µM, 0.75 µM, 0.50 µM, 0.25 µM, 
0.20 µM, 0.15 µM, or 0.10 µM of Sub3-JB) in the reaction mixtures. Fluorescence 
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versus time data was recorded in 18 second-intervals for 30 minutes. Averages from 
an initial value of fluorescence (a.u.) were calculated for every substrate concentration 
and values were subjected to the linear equation established (Y= mX + c) as a Y value. 
Gradient values obtained were fitted in Michaelis-Menten equation (using Prism 
version 7, GraphPad Software Inc.) to derive the enzymatic parameters; maximum 
velocity (Vmax) and Michaelis-Menten constant (Km).  In addition, catalytic constant 
(Kcat) was fitted by setting the concentration of enzyme sites, Et to a constant value in 
the model equation in Prism, GraphPad Software Inc. Kcat is the turnover number of 
substrate molecule each enzyme site converts to product per unit time. It is defined to 
equal Vmax/Et. Enzymatic values for the MNAzyme Pan-Fungal assay were compared 
with MNAzyme assay that previously developed by Mokany, Bone, Young, et al., 
(2010). As the substrate used in the study was different, Kcat/ Km was calculated to 
provide   direct comparison of the effectiveness of an enzyme toward different 
substrates. Furthermore, the observed rate constant, (Kobs) was determined for the 




CHAPTER 3: Development of a Novel MPA assay for Specific and Sensitive 




Recent advances in real-time PCR are promising for the rapid and accurate detection 
of fungal pathogens from clinical samples. An FDA-approved multiplex qPCR kit, 
SeptiFast (Roche, Germany) can identify bacterial and fungal species from its unique 
characteristic of the hybridisation probe melting curves (Straub et al., 2017; Wickes & 
Wiederhold, 2018). The kit detection of the fungal pathogen from blood samples is 
reported to have high specificity (91%), but low sensitivity (61%) (Chang et al., 2013). 
In the case of fungal detection, the kit can only detect five Candida species (C. 
albicans, C. parapsilosis, C. glabrata, C. tropicalis, C. krusei) and, A. fumigatus and 
requires four detection channels in a qPCR instrument.  In this study, we employed 
MPA nucleic acid detection platform that offers enhanced multiplexing capacity of 
two qPCR detection channels for detection of nine clinically relevant Candida species 
including discrimination of antifungal-resistant C. auris, C. glabrata and C. krusei.  
MPA is an innovative and patented probe-based PCR technology of the UK 
biotechnology company, Genefirst Ltd.  The technology relies on a novel characteristic 
of multiple-biomarker probe pairs that confer a unique melting temperature profile. 
Engineering of a PCO sequence with a few mismatches against the hydrolysis probe 
(THO) provide a functional melting profile in post-amplification analysis (Fu, Miles 
& Alphey, 2012). Here, as a proof of concept study, a dual channel, pentaplex MPA-
Candida assay was developed to detect five target-hybridising oligonucleotide and 
partially-complementary oligonucleotide pairs (THO:PCO) – four Candida target 
probes and one IC probe. Candida DNA biomarkers were designed from the conserved 
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region of the D1/D2 domains of the rDNA locus. A novel IC probe was designed with 
non-homologous characteristics with any sequence in the GenBank database as 
identified using the BLAST.  Pan-Candida, C. krusei-, C. glabrata-, C. auris-specific 
and IC target probes were paired with their PCO sequence and demonstrated an 
independent melting temperature across FAM and HEX detection channels. The 
detection of Candida species can also be tested in parallel with a pan-fungal reaction 
to provide a screening tool for fungal species and quantitative estimation of the fungal 
target copy present in the sample.  
In this chapter, the in vitro characterisation of one of three alternative MPA-
Candida assay designs is reported. The theoretical development of the two other 
designs is reported in Chapter 4. The work aimed to develop high throughput and easy-
to-use test which is compatible with most commercial qPCR instruments. The MPA-
Candida assay was used for the detection of the nine Candida species most commonly 
associated with candidiasis (C. albicans, C. dubliniensis, C. tropicalis, C. parapsilosis, 
C. guilliermondii, C. haemulonii, C. krusei, C. glabrata and C. auris) with high 
sensitivity and specificity. These species were tested over a range of genomic (100 to 
105) and plasmid (102 to 106) DNA copies. The assays’ analytical specificity and 
sensitivity were determined and evaluated against a commercial Candida panel 
(Candida Evaluation Panel, Qnostics Ltd) and a singleplex C. auris qPCR diagnostic 
kit (Genesig Standard Kit, Primerdesign Ltd). The in vitro results described here 
highlight the potential use of our MPA-Candida assay in clinical diagnosis of invasive 






3.2 Experimental Results 
 
3.2.1 Target sequences identification and characterisation 
Short biomarker nucleotide sequences that could reliably differentiate fungi from 
bacteria (pan-fungal biomarker), the genus Candida from any other fungi (pan-
Candida biomarker) and discern C. auris, C. glabrata and C. krusei from all other 
Candida species in a highly specific manner were sought within the rDNA locus 
(Halliday et al., 2015; Schoch et al., 2012; Irinyi et al., 2016), as described in Materials 
and Methods. The pan-fungal probe lies within the ITS2 region (Figure 3.1). A reverse 
BLAST search was performed to demonstrate its specificity. The probe had 100% 
sequence similarity with 100% query cover for all 100 fungal species tested (Table 
3.1). An optimised universal primer set ITS3 and LR1 was used to amplify the pan-
fungal target region (Table 3.2). Amplicon sizes ranging from 279 bp (Candida auris) 
to 451 bp (Absidia corymbifera) were obtained (Figure 3.2).  
 Genus-specific (pan-Candida) and species-specific Candida biomarkers lie 
within the D1/D2 region of the LSU rDNA gene (Figure 3.1). A reverse BLAST search 
was performed to check the specificity of these biomarkers. C. krusei, C. glabrata and 
C. auris-specific probes had 100% sequence similarity with 100% query cover to their 
respective Candida strains. The pan-Candida probe had 100% similarity with all 
Candida species tested. A similarity to some other yeast species rarely associated with 
human infection was also observed (Table 3.1). All selected biomarker sequences 
showed no strain-to-strain variability in the multiple sequence alignments analysis. A 
forward pair for pan-Candida target region was employed from the fungal universal 
primer LR0, and the reverse primer named as GSCand, was designed specifically in 
this study (Table 3.2). The primer set generated a 381 bp amplicon for most of the 
Candida species and has slightly smaller size (370 bp) for C. krusei, C. auris and C. 
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guilliermondii (Figure 3.3). Importantly, a single set of pan-Candida primers was 
designed to include all Candida probes binding sites for MPA-Candida assay. The list 
of the PCR primer sets, and the characteristics of the sequences are summarised in 




Figure 3. 1 Schematic drawing of the relative position of the primers and 
probes binding sites along the fungal ribosomal genes. The pan-fungal primer set 
(ITS3 and LR1) and pan-Candida primer set (LR0 and GSCand) are shown as arrows; 
dual-labelled probes labelled with FAM are shown as green dots for pan-fungal (PF), 
C. krusei (CK), C. glabrata (CG), pan-Candida (PC) and HEX labelled probe as 
orange dot for C. auris (CA). The quencher for the probes is shown as black dots. The 
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No. with 100% 
sequence similarity to 
probe/total no. in 
GenBank database 
Other species with 100% 
sequence similarity 
Pan-fungal (PF) 100/100 fungi strains None 











100/100 C. krusei strains None 
C. glabrata-specific 
(CG) 
100/100 C. glabrata 
strains 
None 










Table 3. 2 List of primer sets for amplification of pan-fungal and pan-Candida 
target regions.  
 
Primer set Sequence (5’à3’) Tm (°C) GC% 
Pan-fungal: 
ITS3-F GCATCGATGAAGAACGCA 48.0 50 
LR1-R GTTGGTTTCTTTTCCTCCG 48.9 47 
Pan-Candida:    
LR0-F ACCCGCTGAACTTAAGCATA 49.7 45 
GSCand-R CTGTTTCACTCTCTTTTCAAAGT 49.9 35 
 102 
 
Figure 3. 2 Multiple-sequence alignment of the fungal ITS2 region. Target sequences corresponding to the pan-fungal probe are highlighted in 





Figure 3. 3 Multiple-sequence alignment of the Candida species LSU rDNA gene. Target sequences corresponding to the Candida-specific 
probe is highlighted in yellow and species-specific probes are highlighted with different colours, and the primer set in red. 
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3.2.2 Cloning of DNA target sequences 
The target sequences of C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, C. 
krusei, C. guilliermondii, C. dubliniensis, C. haemulonii and C. auris were cloned into 
a plasmid vector pCR 2.1-TOPO. Initially, the Candida species DNA were amplified 
using the pan-fungal and pan-Candida primer sets in a conventional PCR method and 
analysed the product’s band size (Figures 3.4 and 3.5). The purified pan-fungal target 
sequence including primer binding sites confirmed the amplicon size from the 
sequencing results. Moreover, the nine Candida species DNA with pan-Candida target 
sequences were also cloned into the pCR 2.1-TOPO vector. The target included primer 
sequence sites LR0 and GSCand binding site and confirmed the products through the 
sequencing results. The total sizes of plasmid vector pCR 2.1-TOPO with the pan-
fungal and pan-Candida DNA fragments measured in a range of 4210 bp to 4360 bp 
and 4299 to 4307, respectively (Table 3.3). 
 
            
            
Figure 3. 4 Gel electrophoresis of PCR product using a pan-fungal primer set. 
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dubliniensis; lane 4: C. tropicalis; lane 5: C. guilliermondii.  Panel B) M: 100 bp 
marker; lane 1: C. albicans; lane 2: C. haemulonii; lane 3: C. auris; lane 4: C. krusei; 
NC: Negative Control.    
 
 
               
                         
Figure 3. 5 Gel electrophoresis of PCR product using a pan-Candida primer 
set. Panel A) M: 100 bp marker; lanes 1 and 2: C. albicans; lanes 3 and 4: C. krusei; 
NC: Negative Control. Panel B) M: 100 bp marker; lane 1: C. glabrata; lane 2: C. 
parapsilosis; lane 3: C. tropicalis; lane 4: C. dubliniensis; NC: Negative Control; M: 
100 bp marker. Panel C) M: 100 bp marker; lane 1: C. auris; lane 2: C. haemulonii; 
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Table 3. 3 The pan-fungal and pan-Candida amplicons and cloned plasmid 
DNA sizes.  
 
Target species Amplicon size 
(bp) 
Size (bp) from the 
sequencing 
primer set (M13F 
& R) 
Total size plasmid 
DNA (amplicon + 
3931 bp) 
Pan-fungal  
C. albicans 350 549 4281 
C. parapsilosis 323 522 4254 
C. tropicalis 340 539 4271 
C. dubliniensis 355 554 4286 
C. haemulonii 350 549 4281 
C. glabrata 429 628 4360 
C. guilliermondii 391 590 4322 
C. auris 279 478 4210 
C. krusei 359 558 4290 
Pan-Candida  
C. albicans 376 575 4307 
C. parapsilosis 376 575 4307 
C. tropicalis 376 575 4307 
C. dubliniensis 376 575 4307 
C. haemulonii 376 575 4307 
C. glabrata 375 574 4306 
C. guilliermondii 375 574 4306 
C. auris 373 573 4304 
C. krusei 368 567 4299 
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3.2.3 Engineering of a Novel IC MPA probe 
A novel IC probe was obtained by recircularisation of the plasmid pCR™ 2.1-TOPO® 
vector which resulted in a random eight base pairs insertion. As a result, the IC dual-
labelled probe was designed to contain eight nucleotide bases along with the bases 
already existing in the plasmid (Figure 3.6) and made up the total size of 3939 bp. A 
BLAST search of the IC probe sequence revealed no 100% identity to sequences on 
the database (Table 3.4). The universal M13 primer set was used in every reaction of 






Figure 3. 6 The nucleotide sequence of the IC probe and primer set. The 
alignment of cloned plasmid pCR™ 2.1-TOPO® vector sequence focusing on the eight 
nucleotide bases insert (marked with red bar) within the IC probe sequence (marked 
with green bar). The total size of the DNA fragment from the primer sites (M13F and 









IC probe M13 R 
M13 F (-20) 
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Table 3. 4 The result of BLAST search of the IC probe sequence for a non-
homologous characteristic.  
 
Description  Query cover 
(%) 




Acremonium sp. (in: Hypocreales) isolate  21/26 (80) 
Uncultured bacterium clone 16S ribosomal RNA gene, partial 
sequence 
20/26 (76) 
Flagellophora apelti partial 28S rRNA gene, isolate 1 
 
19/26 (73) 
Lactobacillus jensenii strain SNUV360, complete genome 
 
19/26 (73) 
Salinimonas sp. HMF8227 chromosome, complete genome 
 
19/26 (73) 
Crassostrea gigas tbetaRI gene for TGF-beta Type I receptor 18/26 (69) 
Uncultured bacterium clone 4-L 16S ribosomal RNA gene 18/26 (69) 
Bactris pliniana phosphoribulokinase-like protein 2 gene 18/26 (69) 
Spirometra erinaceieuropaei genome assembly 18/26 (69) 





3.2.4 Design of MPA probes and in silico melting curve analysis testing  
MPA probes consist of two partly complementary oligonucleotides, the dual-labelled 
THO and a corresponding PCO. Each THO is fully complementary to the identified 
biomarker target sequences meanwhile, the PCO was engineered with four to six 
nucleotide mismatches against the THO sequence (Table 3.5). The initial 
characterisation of all six MPA probes (THOs plus their corresponding PCO 
sequences) using UNAFold software (http://unafold.rna.albany.edu/) allowed 
confirmation of their theoretical melting profiles (Figure 3.7). The software predicts 
overlapping melting temperatures between C. krusei-specific and the IC probes as well 
as between C. auris- and C. glabrata-specific probes. However, their independent 
analysis is not affected under experimental conditions as each overlapping probe is 
labelled with a different fluorophore. For example, the pan-Candida, C. krusei-specific 
and C. glabrata-specific probes were labelled with FAM whereas the C. auris-specific 
and the IC probes were labelled with HEX. The results from the in silico analysis 
helped to assign an appropriate reporter dye to the THO probe. The probes are 
distinguishable based on its unique melting temperature that were detected in FAM 
and HEX detection channel in a real-time PCR instrument. Homodimer prediction of 
the THO probe melting temperatures shown five probes overlapped at 68°C; an 
independent C. auris-specific probe, CA THO:PCO at 77°C (Figure 3.8). In silico 
analysis showed that THO and its fully complementary target sequence has a higher 





Table 3. 5 Design of the MPA probe pairs. The THO and PCO sequences for 
pan-Candida, C. krusei-specific, C. glabrata-specific and C. auris-specific targets, 































THO: CTTATCGGAATAAGGGCGAATTCTGC 6/26 (23.0%) 
PCO2: GCAtAATTaGtCaTTATTaCtATAAG-Ph 
*Lower case nucleotides in PCO sequence denote nucleotide mismatches against THO sequence; -Ph, 







Figure 3. 7 The prediction of melting temperature of THO and PCO hybrid by 
UNAFold software. MPA probe pairs for C. krusei (CK), C. glabrata (CG), pan-
Candida (PC), C. auris (CA), IC and pan-fungal (PF). The heat capacity (Cp) curve is 
the maximum amount of heat needed to change the temperature of one mole of a hybrid 
by one degree at constant pressure which defines the melting temperature.  
 
 
Figure 3. 8 Homodimer prediction of melting temperature of THO sequences 
by UNAFold software. THO melting temperature determined for C. krusei (CK), C. 
glabrata (CG), pan-Candida (PC), C. auris (CA), Internal Control (IC) and pan-fungal 
(PF). The Cp curve is the maximum amount of heat needed to change the temperature 
of one mole of a hybrid by one degree at constant pressure which defines the melting 
temperature. 
















































3.2.5 Experimental in vitro testing of THO:PCO hybrid melting temperatures 
using the LightCycler 480 qPCR machine  
 
The melting curve analysis was performed to determine the melting temperature 
between the THO and its potential PCO sequences. Each probe’s THO and a PCO was 
tested to achieve a specific melting temperature. Initial testing of the THO:PCO hybrid 
melting temperature performed in an independent melting curve analysis, without the 
amplification step. Initial analysis of each probe melting temperature is useful for the 
probes multiplexing arrangement and assay design layout. The pan-Candida probe (PC 
THO:PCO1) and C. krusei-specific probes (CK THO:PCO1) demonstrated two 
distinct melting temperature peaks (Figure 3.9). The second set of C. krusei-specific 
probe hybrid (CK THO2) was also tested for its melting temperature and the probe was 
used in the assay design optimisations (Figure 3.10). MPA probes for C. glabrata-
specific (CG), C. auris-specific (CA), pan-fungal (PF) and IC were characterised for 
their melting temperatures (Figure 3.11). The testing of the IC THO probe hybrids to 
its potential PCO1 and PCO2, produced melting temperatures at 48°C and 34°C, 
respectively. Some of the probe pairs overlapped and did not produce the predicted 
melting temperature which led to probe re-design. Two of the probes were re-designed 
for C. glabrata-specific (CG THO2:PCO1) and C. auris-specific (CA THO2:PCO1) 
and produced melting peaks at 46°C and 49°C, respectively (Figures 3.12 and 3.13). 
The THO of these probes were further tested for the functionality of the detection in 
the PCR and is reported in next sub-section. A new THO:PCO hybrid for the pan-
fungal was also re-designed and generated melting temperature at 38.92°C (Figure 
3.14). The summary of the probes melting temperature and the selected probe pairs for 




Figure 3. 9 The melt curves analysis of C. krusei-specific and pan-Candida 
probes. C. krusei-specific probe, CK THO:PCO1 at 31.7°C and pan-Candida probe, 
PC THO:PCO1 indicated at 41.04°C. Each probe was tested in a separate reaction with 




Figure 3. 10 The melting peaks generated from C. krusei-specific probe against 
its respective PCO sequences. The CK THO2 probe its melting peaks with PCO1 at 
41°C and PCO2 at 39°C. CK: C. krusei-specific. Each THO:PCO hybrid was tested in 





















Figure 3. 11 The melt curves analysis of pan-fungal, C. auris, C. glabrata and IC 
probes, and each was tested in a separate reaction. C. auris-specific probe, CA 
THO1:PCO1 at 32.25°C; IC probes, IC THO1:PCO2 at 35.09°C and THO1:PCO1 at 
48.80°C; C. glabrata-specific probes, CG THO1:PCO2 at 35.71°C and THO1:PCO1 
at 51.38°C. The pan-fungal probe PF THO1:PCO1 showed no melting peak. The probe 
melting temperature performed in triplicates for each reaction. 
 
 
Figure 3. 12 The melt curve analysis of C. glabrata-specific probe with two 
designs of PCO sequences. Melting peaks temperature reported as means (n=9) 
between C. glabrata-specific THO (CG THO2) and PCO1 demonstrated at 46.67°C; 











































Figure 3. 13 Overlapped melting peaks at 48°C between the C. auris-specific 
probe and internal control probe. Consequently, the IC THO was paired with PCO2 
in the MPA-Candida assay. CA: C. auris-specific; IC: Internal Control. Each probe 
melting temperature was tested in a separate reaction with replicates (n=6). 
 
 
Figure 3. 14 The melt curve analysis of the pan-fungal probe with two designs 
of PCO sequences. Melting temperature reported as mean (n=3) between the pan-
fungal (PF) THO2 and PCO2 at 38.92°C; meanwhile no temperature value detected 
for the PF THO2:PCO1 hybrid.  
CA THO2:PCO1  
















PCO1: GAGAtAtCGATAGCtAAtAAGTA-Ph 41.04 




PCO1: GCGGCAtGAaTTaTAtATTG-Ph 31.70 
PCO2: GCaGCAtGAaTTaTAtATTG-Ph ND 
THO2: TTGCGGCACGAGTTGTAGATTG 
PCO1: CAATaTAtAAtTCaTGCCGCAA-Ph 41.00 




PCO1: TGGGAtTGTAaTTTGaCTATaTTCCTTG-Ph 51.38 
PCO2: TGGGAaTGTAaTTTaCaTATaTTaCTTG-Ph 35.71 
THO2: AACATAGGCAAAGTACAGTCCCA 
PCO1: TGGGAaTGTAaTTTGaCTATaTT-Ph 46.67 




PCO1: ACGAtGTaTTaTAGtAGCAG-Ph 32.25 









PCO1: CAACtAAAcAAAAGtAG-Ph 23.00 
PCO2: CAACtAAAcAAAAttAG-Ph ND 
THO2: TATGCTTAAGTTCAGCGGGTA  
PCO1: TACCCtaTtAAaTTAAaCATA-Ph ND 




PCO1: GCAgAATTaGCCaTTATTaCtATAAG-Ph 48.80 
PCO2: GCAtAATTaGtCaTTATTaCtATAAG-Ph 35.09 
* Boldface probe sequences are the selected THO and PCO in the MPA-Candida and Pan-Fungal assay; 
the number followed after THO/PCO sequences denote version of the sequence design; lower case 
nucleotides within PCO are nucleotide mismatches against THO sequence; -Ph, phosphorylated at the 













3.2.6 Experimental testing of the re-designed C. glabrata-specific and C. auris-
specific probes for detection of targets sequence in real-time PCR. 
 
The amplification of the C. glabrata plasmid DNA using the newly designed C. 
glabrata-specific probe (CG THO2) shown an amplification curve at Ct = 19.24 ± 0.68 
(Figure 3.15). The probe was further tested in the MPA reaction for its hybridisation 
with the PCO sequence. The melting temperature was determined at 46°C. Inclusion 
of the PCO1 of CG THO2 probe in the reaction with the C. glabrata plasmid DNA 
demonstrated an expected downwards shift of melting peak compared to the C. 
glabrata-specific probe no DNA control (NDC) melting profile (Figure 3.16).   
 
 
Figure 3. 15 Amplification curves detection of C. glabrata plasmid DNA. The Ct 
value at 19.24 ± SD 0.68 (n=3) using newly design C. glabrata-specific probe. The 
amplification detected by the dual-labelled probe, CG THO2 and the negative control 





Figure 3. 16 The C. glabrata-specific probe amplification and melting curves 
analysis of the MPA reaction. C. glabrata plasmid DNA at 106 copies per reaction 
and MPA probe melting peaks for detection of target sequence the reaction showed 
lowered (with blue arrow) melting peak at CG THO2:PCO1 temperature. NDC, no 
DNA control; CG, C. glabrata-specific. The experiment was performed in triplicate 
and melting temperature reported at 46 ±1°C.   
 
 
The C. auris-specific probe (CA THO1:PCO1) was tested in the reaction for 
the amplification of the C. auris plasmid DNA. As an experimental control, the pan-
Candida probe (PC THO1:PCO1) was used to amplify the same C. auris DNA 
template. Therefore, this experiment involved two NDC profiles for pan-Candida 
(40°C) and C. auris-specific (32°C). The preliminary results showed that the C. auris 
target DNA is amplified by the pan-Candida probe (PC THO1:PCO1) but not detected 
by the C. auris-specific probe, CA THO1:PCO1 (Figure 3.17). The PCR results were 
supported by the melting curves analysis as only the reaction with the pan-Candida 
probe showed a decrease in melt peak against the control. The experiment also 
performed using the probe as a standard hydrolysis probe for detection of C. auris 




plasmid DNA concluded there is no amplification by C. auris-specific probe, CA 
THO1 (Figure 3.18). The new design of the C. auris-specific MPA probe (CA THO2) 
successfully amplified the target DNA as expected in the hydrolysis probe reaction 
with the curve detected at Ct= 18 recorded for high concentration of C. auris plasmid 
DNA in the reaction (Figure 3.19). Utilisation of the C. auris-specific THO2 with 
PCO1 in a multiplex reaction of MPA-Candida showed specific detection of C. auris 




Figure 3. 17 The amplification profile and the corresponding melt curves 
analysis for C. auris plasmid DNA. The amplification signal detected in the reaction 
with pan-Candida probe (PC THO1) and melt curve showed down shift (blue arrow) 
of melting peak at pan-Candida melting peak temperature. CA: C. auris-specific. 









PC THO1: C. auris 
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Figure 3. 18 Testing the amplification of C. auris plasmid DNA by the C. auris-
specific probe.  No amplification of the C. auris plasmid DNA in the reaction with the 
C. auris-specific probe (CA THO1) (signal in the green lines) but amplification of the 
DNA detected (Ct=24) in the reaction control with the pan-Candida probe (PC THO1). 
Each reaction contained 106 copies of C. auris plasmid DNA and PCR was performed 




Figure 3. 19 The amplification curves detected by the C. auris-specific THO 
probe. The reaction contained 107 copies of the C. auris plasmid DNA and PCR was 
performed in triplicate. CA: C. auris-specific.   
  
Reaction control: 
PC THO1: C. auris 
 
CA THO2: C. auris 
C. auris 
 122 
3.2.7 Characterisation of NDC melting curves profiles for MPA-Candida assay 
MPA technology offers detection of more than one probe’s melting temperature in a 
single real-time PCR detection channel. The MPA probe is designed in such a way that 
the dual-labelled THO melting temperature is based on a unique design of its PCO 
sequence. As a result of a specific probe’s melting temperature, the THO can be 
labelled with the same reporter dye to maximise the multiplexing capacity of the assay. 
Six MPA probe pairs were optimised for their melt curve profiles and assembled into 
three alternative MPA-Candida assay designs (Table 3.7). MPA-Candida assay and 
assay designs 2 represent dual-channel 2-tube assay whereas design 3 is a triple-




Table 3. 7 The layout of Candida assay designs tested either in a single- or 




FAM HEX Cy5 
































































*MPA-Candida and design 2 were performed in two tubes qPCR reaction with two detection 
channels. The Candida qPCR assay can be coupled with the Pan-Fungal assay for 
simultaneously detection in the same reaction protocol. Assay design 3 was performed in a 
single-tube reaction using three qPCR detection channels. FAM, 465 nm/510 nm; HEX, 533 
nm/580 nm; Cy5, 618 nm/660 nm; CK, C. krusei-specific; PC, pan-Candida; CG, C. 




MPA-Candida was fully developed and experimentally tested in this thesis 
work; its in vitro characterisation is reported below. The theoretical design and 
development of assay designs 2 and 3 is presented in Chapter 4.  
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3.2.8 Optimisations of the MPA-Candida probes in two detection channels 
 
Initial testing of the two THOs were labelled with the same fluorophore, C. krusei-
specific (CK THO1:PCO1) and pan-Candida (PC THO1:PCO1) in a single reaction 
tube have demonstrated reproducible melting curves (Figure 3.20). Initial assay design 
for multiple set of probes were prepared in two tubes. In tube 1 it consists of three 
probes of C. krusei-specific, pan-Candida and C. glabrata-specific, whereas in tube 2 
it consists of the probes of C. auris-specific and IC (Figure 3.21). Multiple melting 
peaks from the mixture of THO and PCO sets are reproducible and specific to each 
probe. However, mixture of all five sets of THO and PCO in a single reaction for a 
single channel of detection resulted non-specific melting curves (Figure 3.22). 
Therefore, careful considerations of multiplexing the probes based on the melting 
characteristics is important for the specific melting peaks in one reaction detection 
channel. In the optimisation of the MPA-Candida, C. glabrata-specific (CG 
THO1:PCO1), C. auris-specific (CA THO1:PCO1) and IC probe (IC THO1:PCO1) 
were re-designed and the PCO sequences were modified. The IC THO was changed to 
pair with PCO2 to avoid an overlapping melting temperature with that of the C. auris-





Figure 3. 20 Assembly of two MPA probes in a single reaction with a unique 
melting curve analysis. Two specific melting peaks were reported from triplicate 
reaction for C. krusei-specific (CK THO:PCO1) at 30.89°C and pan-Candida (PC 
THO:PCO1) at 40.52°C in a reaction without amplification step. The melt peaks are 
plotted as the negative derivative plot of the fluorescence emission versus temperature.  
 
 
Figure 3. 21 Five target-specific melting peaks in the two reaction mixtures. In 
the Tube 1 is a mixture of the three probes generating melting peaks for C. krusei-
specific (CK THO:PCO1), pan-Candida (PC THO:PCO1) and C. glabrata-specific 
(CG THO1:PCO1) and Tube 2 for C. auris-specific (CA THO1:PCO1) and internal 
control (IC THO:PCO1) are representative of triplicate reactions. In both tubes, 
melting curve analysis was performed from the FAM detection channel and the 
reaction contained no target sequence for the negative control profile.  



























Figure 3. 22 Assembly of five MPA probes in a single reaction resulted in non-
specific melting curve. The pan-Candida probe (PC THO:PCO1) can be detected at 
41.40°C; the two other peaks approximately at 32°C and 50°C are not specific. Along 
with the pan-Candida probe, the reaction contains probes for C. krusei-specific (CK 
THO:PCO1), C. auris-specific (CA THO1:PCO1), internal control (IC THO:PCO1) 
and C. glabrata-specific (CG THO1:PCO1). The experiment was tested in triplicate.   
 
 
Figure 3. 23 Characterisation of the melting peaks from the mixtures C. auris-
specific THO and IC probe in a single reaction analysis. Internal Control probe (IC 
THO) was paired with PCO2 produced distinguishable melting peaks (34°C) against 
probe CA THO2:PCO1 (48°C) within the same reaction mixture. Both probe melting 
peaks were detected in the HEX channel (533 nm) and analysed in triplicate.   








The FAM labelled probes; C. krusei-specific (CK THO1:PCO1), pan-Candida 
(PC THO1:PCO1) and C. glabrata-specific (CG THO2:PCO1) were optimised the 
probes concentrations from the 0.4 µM for a sharp melting peaks in the FAM detection 
channel (Figures 3.24 and 3.25). The two HEX-labelled probes; C. auris-specific (CA 
THO2:PCO1) and IC (IC THO1:PCO2) probes were exclusively detected in the same 
tube without interfering the characteristics of melt curves of other probes. An 
optimised MPA-Candida assay with three FAM-labelled probes and two HEX-
labelled probes generates a novel melt curve profiles in a single reaction mixture 
(Figure 3.26).  For simplicity and flexibility, the MPA-Candida PCR assay was 
engineered to complement the Pan-Fungal reaction. A two-tube system that could be 
run simultaneously under the same experimental conditions is described in Material 
and Methods, Section 2.14.   
 
 
Figure 3. 24 Melt curves analysis of the FAM-labelled probes. Each probe was 
prepared in an equivalent final concentration, THO:PCO at 0.4:0.8 µM. MPA probes 
melting peaks for C. krusei-specific (THO1:PCO1), pan-Candida (PC THO:PCO1) 
and C. glabrata-specific (CG THO2:PCO1). Pan-Candida melting peak masked C. 










Figure 3. 25 Optimisations of the probe’s concentration for comparable height 
of melting peaks in the FAM detection channel. Panel A) Pan-Candida (PC) THO 
reduced from 0.4 µM to 0.2 µM, C. krusei (CK) and C. glabrata (CG) THOs at 0.4 
µM. Panel B) C. glabrata (CG) THO increased to 0.6 µM, C. krusei (CK) and pan-
Candida (PC) THOs at 0.4 µM.  Panel C) Pan-Candida (PC) THO reduced to 0.2 µM, 
C. glabrata (GC) THO increased to 0.6 and C. krusei (CK) THO maintained at 0.4 
µM. In all cases, concentrations of the THO and PCO were prepared in 1:2 ratio. All 
experiments were performed in triplicate.  
CK THO1:PCO1 











   
Figure 3. 26 A single tube, 2-channel MPA-Candida melt curve profiles. The 
negative fluorescence derivative (-dF/dT) melt peaks obtained from dissociation 
between the THO and PCO for the C. krusei-specific (CK THO1:PCO1), pan-Candida 
(PC THO1:PCO1) and C. glabrata-specific (CG THO2:PCO1) probes in the FAM 
channel (Panel A); internal control (IC THO1:PCO2) and C. auris-specific (CA 
THO2:PCO1) detection in the HEX channel (Panel B). All melting temperatures were 















C. krusei    Pan-Candida  C. glabrata






























3.2.9 Specificity of MPA-Candida melting curves analysis 
 
The specificity of each probe in the MPA-Candida assay was tested in vitro for DNA 
amplifications of C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. 
dubliniensis, C. auris, C. haemulonii and C. guilliermondii (Table 3.8). The assay 
specificity was evaluated from the detection by pan-Candida and species-specific 
probes. The MPA-Candida, specificity experiments were reported with the probe 
optimisations for detection of target species. Post-amplification melting curve 
generated from the detection of the target species was compared against the negative 
control temperature profile.  
Nine Candida species including C. albicans, C. dubliniensis, C. krusei, C. 
glabrata, C. auris, C. parapsilosis, C. tropicalis, C. haemulonii, C. guilliermondii 
inclusive of IC plasmid DNA in each reaction was amplified and analysed for its 
specificity of detection in the FAM and HEX channels.  The analysis of melt curves of 
all the Candida species showed peaks which disappeared at 40°C (pan-Candida) as 
compared to the NDC melt curve (Figure 3.27, panels A to D). The detection of 
resistant Candida-species can be distinguished by an additional peak reduction in the 
melt curve at 30°C (C. krusei), 46°C (C. glabrata) in the FAM channel and 48°C (C. 
auris) in the HEX channel (Figure 3.27, panels B, C and D, respectively). None of the 
other seven Candida species tested showed a decrease in melt peak at C. krusei- or C. 
glabrata-specific melt peaks. Furthermore, none of the eight Candida species tested 
showed a decrease in the C. auris-specific melt peak in the HEX channel. Collectively, 
there was no cross-reactivity issue between the tested Candida species and the species-
specific detections in the assay.  
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Table 3. 8 Nine Candida species DNA amplification Ct values in FAM and 
HEX channels. The Ct values were evaluated in parallel with the melting curve 
analysis for the probe(s) specificity analysis.  
 
Candida species FAM HEX 
Mean Ct ± SD  Mean Ct ± SD 
C. albicans 26.81± 0.16 31.85± 1.57 
C. dubliniensis 22.60± 0.98 30.14± 0.60 
C. tropicalis 25.75± 0.62 28.44± 1.44 
C. parapsilosis 25.02± 0.10 28.48± 0.50 
C. guilliermondii 26.67± 0.07 30.22± 0.57 
C. haemulonii 25.60± 0.44 30.90± 0.04 
C. krusei 25.08± 0.13 31.83± 0.39 
C. glabrata 25.83± 0.48 29.08± 2.67 
C. auris 24.23± 0.65 25.97± 0.04 
*The FAM channel detecting pan-Candida, C. krusei-specific, and C. glabrata-specific probes 
and the HEX channel detecting IC and C. auris-specific probes. The qPCR was performed in 





Figure 3. 27 Specific detection of Candida plasmid DNA in MPA-Candida post-
amplification melt curve profiles across the FAM and HEX detection channels. 
Panel A) Detection of Candida species (dotted lines) other than C. krusei, C. glabrata 
and C. auris with reduced levels of the melt peaks only at the corresponding pan-
Candida (PC) temperature in the FAM channel and at IC temperature for detections of 
IC plasmid in the HEX channel compared to NDC melting curves (solid lines) in the 
FAM and HEX channels. Panels B to D) Representative melting curves of resistant C. 
krusei and C. glabrata and C. auris, plot by the dotted lines showing lower intensity 
of the melt peaks at the corresponding temperature (CK: C. krusei, CG: C. glabrata or 
CA: C. auris) compared to NDC melting curves plot in solid lines in the FAM and 
HEX channels. In each panel, reduced level of the melt peak for pan-Candida 
temperature in the FAM channel indicates genus Candida biomarker detections and at 
IC temperature indicates IC plasmid detections in the HEX channel.  In all cases 
diagnosis is supported by the corresponding DNA amplification curves and associated 
Ct values. CK: C. krusei-specific; PC: pan-Candida; CG: C. glabrata-specific; IC: 





Comparison of the means peaks height at every melting temperature (Tm) 
between the detected Candida-species DNA and the control reaction was tested using 
Analysis of Variance (ANOVA) followed by Dunnett’s multiple comparison test 
(Figures 3.28 and 3.29). Melting peaks height for detection of C. krusei DNA specific 
at 30°C of C. krusei-specific showed significance difference (P<0.0001) against the 
NDC. C. dubliniensis DNA was detected with less significance (p<0.05) and not 
significant for the rest of Candida species compared against the NDC (Figure 3.28, 
panel A). The middle Tm peak detected in the FAM channel at 39.4°C of pan-Candida 
showed significance difference values (p<0.0001) for all the reactions with Candida 
species against NDC melting profile (Figure 3.28, panel B). Next, the melting peaks 
at 45.5°C of C. glabrata-specific showed highly significance values (p<0.0001) for 
detection of C. glabrata DNA and C. dubliniensis was detected with less significance 
(p<0.05) and not significant for the rest of all Candida species (Figure 3.28, panel C).  
Moreover, another set of melting curves in the HEX channel for the MPA IC probe Tm 
at 34°C and the C. auris-specific probe Tm at 48.9°C were also analysed. Amplification 
IC templates inclusive in every Candida reaction was detected and showed 
significance difference (p<0.0001) in the peaks heights as compared with NDC peak 
(Figure 3.29, panel A). The second peak in the HEX channel detected at 48.9°C of C. 
auris-specific showed expected significance values (p<0.0001) for the sample with C. 





Figure 3. 28 Comparison of the melting peaks heights of the three-specific 
temperature in the FAM channel between the NDC and Candida species DNA. 
Panel A) A comparison between peaks height at 30°C of C. krusei-specific NDC and 
a detection of C. krusei DNA with highly significance p<0.0001 compared to C. 
dubliniensis, p<0.05. Panel B) The Tm 39.4°C of pan-Candida NDC peak height 
significantly different against all Candida species (p<0.0001). Next, a comparison 
between peaks height at 45.5°C of C. glabrata-specific NDC and C. glabrata sample 
DNA with highly significance p<0.0001 compared to C. dubliniensis, p<0.05 (Panel 
C). Each sample comparison with the NDC using Dunnett’s test; ns: not significance. 



















































































































































































































Figure 3. 29 Comparison of the melting peaks heights of the two-specific 
temperature in the HEX channel between the NDC and Candida species DNA. 
Panel A) A comparison between peaks height at 34.4°C of internal control NDC and 
detection of the IC plasmid DNA presents in all Candida species DNA with highly 
significance p<0.0001 values. Panel B) The Tm 48.9°C of C. auris-specific NDC peak 
height was significantly different (p<0.0001) against the reaction with C. auris DNA 
and none of the other Candida species has reduced melting peak height at 48.9C except 
C. auris. Each sample comparison with the NDC using Dunnett’s test; ns, not 






















































































































































The assay’s specificity was further tested using heterologous fungal and 
bacterial DNA to rule out the possibility of cross-detection in clinical samples. None 
of these species were detected in the MPA-Candida assay (Figure 3.30). The 
functionality of the components in the assay with non-target fungal and bacterial DNA 
was monitored with the inclusion of 106 copies of the IC plasmid template in every 
sample. An amplification curve and a reduced melt peak for the detection of the 
amplified control template was consistently detected in the HEX detection channel. C. 
albicans genomic DNA was successfully detected with reduced melting peaks when 
analysed for Candida at 40.7°C (PC) and 34.7°C (IC) in FAM (Figure 3.31, panel A) 
and HEX channels (Figure 3.32, panel A), respectively. As expected, no significant 
reduction of peak height of reaction with C. albicans at 30°C (CK), 46°C (CG) and 
49°C (CA). However, less significance peak reduction against NDC profile at pan-
Candida (PC) temperature (40.7) was noted for Staphylococcus aureus (Figure 3.31, 
panel B). Meanwhile, the melting curves analysed in the HEX channel consistently 
with reduced height at 34.7°C (IC) for every reaction that contained IC plasmid DNA 
against the NDC peak (Figure 3.32, panel A). None of the species tested in this 




















Figure 3. 30 Amplification and melt curves analysis of assay’s specificity for 
fungal and bacterial genomic DNA detection. Panel A) Amplification curve clearly 
detected for C. albicans compared to other species with the corresponding melt curves 
analysis showing obvious reduction at PC peak compared to NDC in the FAM channel. 
Panel B) Amplification curves of the IC present in every fungal and bacteria samples 
and its melt curves analysis showing reduction at the IC temperature against NDC in 
the HEX channel. CK: C. krusei-specific; PC: pan-Candida; CG: C. glabrata-specific; 
IC: Internal Control; CA: C. auris-specific. Each sample was performed in triplicate.  
 
 












































































Figure 3. 31 Comparison of the melting peaks heights of the three-specific 
temperature in the FAM channel between the NDC and Candida species DNA. 
Panel A) A comparison between peaks height at 30°C of C. krusei-specific NDC and 
non-target fungal and bacterial species. Panel B) The Tm 40.7°C of pan-Candida NDC 
peak height significantly different against C. albicans (p<0.0001). Panel C) A 
comparison between peaks height at 45.5°C of C. glabrata-specific NDC and non-








































































































































































































































































Dunnett’s test; ns, not significance. CK: C. krusei-specific; PC: pan-Candida; CG: C. 




Figure 3. 32 Comparison of the melting peaks heights of the two-specific 
temperature in the HEX channel between the NDC and Candida species DNA. A 
comparison between peaks height at 34.7°C of internal control NDC and detection of 
the IC plasmid DNA presents in all Candida species DNA with highly significance 
from p = 0.0001 and p<0.0001 values (Panel A). The Tm 49.2°C of C. auris-specific 
NDC peak height not significantly different against non-target fungal and bacterial 
species (Panel B). Each sample comparison with the NDC using Dunnett’s test; ns, 



















































































































































































In a separate reaction tube, the Pan-Fungal assay is designed to detect a range 
of clinically relevant fungal pathogens that can be performed simultaneously with the 
MPA-Candida assay (Table 3.9). The TaqMan® pan-fungal reaction was designed to 
inherit the conditions of MPA-Candida PCR conditions with two channels of 
fluorescence detection. In this study, further to detection of Candida DNA in the MPA-
Candida reaction, the pan-fungal probe was able to detect yeast from nine Candida 
species including C. albicans, C. dubliniensis, C. krusei, C. glabrata, C. auris, C. 
parapsilosis, C. tropicalis, C. haemulonii, C. guilliermondii and pathogenic 
filamentous fungi species including A. fumigatus, A. flavus, F. solani, P. rubens and 
M. circinelloides (Table 3.10). A specificity check of the pan-fungal probe was 
performed against four species of bacteria that constitute part of the normal human 
flora including S. epidermidis, S. aureus, P. mirabilis and E. coli. All bacterial and 
fungal genomic DNAs were tested at 105 genome equivalent copies number per 
reaction. None of the bacterial DNA was detected in the Pan-Fungal assay (Table 
3.10). In every reaction tube, the IC plasmid DNA was included, and the amplification 
signal was detected in the HEX detection channel. In a separate experiment, early 
amplification (Ct =16) of the same E. coli genomic DNA samples was observed using 
the universal bacterial 16S primer set. The detection of the organisms’ genomic DNA 
in the assay was summarised in Table 3.10 which includes qualitative interpretations 







Table 3. 9 MPA-Candida Assay. For simplicity and flexibility, the MPA-
Candida assay was engineered as a two-tube system, run simultaneously under the 
same experimental conditions. Tube 1 contains the genus-specific and species-specific 
Candida probes; tube 2 harbours the pan-fungal probe. The two fluorescent detection 
channels used in the multiprobe melting curve analysis are indicated. 
 
Reaction name Probe target & symbol Probe label & 
channel wavelength  
Tube 1: MPA-
Candida 
C. krusei (CK) FAM  
(465 nm/510 nm) Pan-Candida (PC) 
C. glabrata (CG) 
C. auris (CA)  HEX  
(538 nm/580 nm) Internal Control (IC) 
Tube 2: TaqMan® 
Pan-Fungal 
Pan-fungal (PF) FAM  
IC  HEX 
















Table 3. 10 Application of the pentaplex MPA-Candida and the TaqMan® Pan-
Fungal assay for specific detection in only two channels of real-time PCR. Fungal 







MPA-Candida  Pan-Fungal 





FAM  HEX  FAM  HEX 
CK PC CG IC CA PF IC 
Candida                
C. albicans 23.40  26.00  ND + ND  + ND  22.00  21.00 
C. krusei 22.20  26.20  + + ND  + ND  22.90  25.60 
C. glabrata 24.40  26.50  ND + +  + ND  24.30  24.80 
C. auris 23.60  29.00  ND + ND  + +  23.00  26.20 
C. haemulonii 24.60  27.80  ND + ND  + ND  21.00  26.00 
C. dubliniensis 23.60  28.00  ND + ND  + ND  22.00  26.30 
C. parapsilosis 23.90  26.90  ND + ND  + ND  21.80  25.40 
C. tropicalis 23.50  26.00  ND + ND  + ND  21.00  26.00 
C. 
guilliermondii 
23.60  26.50  ND + ND  + ND  22.90  26.50 
Moulds               
A. fumigatus ND  28.10  ND ND ND  + ND  22.90  23.40 
A. flavus ND  28.50  ND ND ND  + ND  21.10  23.20 




ND  28.00  ND ND ND  + ND  17.00  24.10 
Bacteria               
S. aureus ND  29.70  ND ND ND  + ND  ND  22.80 
S. epidermidis ND  28.90  ND ND ND  + ND  ND  23.50 
P. mirabilis ND  28.40  ND ND ND  + ND  ND  23.00 
E. coli ND  28.00  ND ND ND  + ND  ND  23.20 
Ct: Threshold Cycle, the cycle intersection with the point where the curve first clearly rises off 
baseline value; FAM, detection channel (465 nm/510 nm); HEX,  detection channel (533 nm/580 
nm); CK, C. krusei-specific peak (30°C); PC, Pan-Candida peak (40°C); CG, C. glabrata-specific 
peak (46°C); CA, C. auris-specific peak (48°C); IC, Internal Control-specific peak (34°C); PF, Pan-




3.2.9.1 Optimisations of MPA-Candida specificity of detection 
 
The MPA-Candida real-time PCR assay was tested for quantitative and qualitative 
efficiencies through the amplification and detection of accurate target(s) DNA 
sequences in the reaction. In the PCR reaction with Candida species DNA 
endonuclease activity hydrolysed the dual-labelled THO probe(s) and left minimal 
intact probe(s) to bind PCO sequences in the post-amplification stage. In the melting 
curve analysis, the hydrolysed probe was unable to hybridise to its PCO and resulted 
in the reduction of the specific melting peak(s) compared to the NDC melting curve 
profile.  
An initial optimisation of the melting curve profiles was performed in the two 
separate reactions as described in Section 3.2.8; Figure 3.21. Amplification curves 
were seen for the amplification of C. albicans, C. krusei, C. glabrata and IC plasmid 
DNAs (Figure 3.33). Samples with C. albicans, C. krusei and C. glabrata correctly 
identified as Candida species from the melting curve analysis (Figure 3.33, panels A 
to C). Moreover, detection of intrinsic drug-resistant C. krusei can be informed from 
the melting curve profile with an additional reduction of melting peak at 30°C (Figure 
3.33, panel B). However, the assay did not accurately identify C. glabrata DNA as 
seen from the melt curve. High copies of C. glabrata plasmid DNA, 106 and 105 copies 
per reaction, demonstrated raised melting peaks with higher than NDC signal at the C. 
glabrata-specific melting peak temperature and no reduction of peak for identification 
of C. glabrata plasmid DNA from five other dilutions (Figure 3.33, panel C).  
Meanwhile, in a separate reaction for tube 2, amplification and detection of IC serially 
diluted plasmid DNA was also tested and showed amplification curves and responsive 







Figure 3. 33 Assessing four MPA probes arranged in two tubes for functionality 
in a multiplex amplification and melting curve detection reaction in the FAM 
channel.  Tube 1 amplification curves and their respective melting curves outcome for 































































































































































detection of C. albicans (Panel A), C. krusei (Panel B) and C. glabrata (Panel C) 
from the range of serially diluted plasmid DNA. Tube 2 amplification curves and the 
respective melting curves tested internal control plasmid DNA (Panel D) without C. 
auris DNA sample in the reaction. The melting peaks for each target was compared 
against NDC reaction for qualitative identification of target species. The real-time PCR 
was performed in triplicate and amplification and melting curves were analysed as 
mean values (n=3). The horizontal dotted line is fixed as the threshold value of 
fluorescence. CK: C. krusei-specific; PC: pan-Candida; CG: C. glabrata-specific; IC: 
Internal Control; CA: C. auris-specific. 
 
 
As a result of the malfunctioned C. glabrata-specific probe, CG THO1:PCO1 
probe, a second design of the probe, CG THO2:PCO1 was tested through amplification 
and melting curves probes analysis.  The MPA-Candida assay with CG THO2:PCO1 
along with C. krusei-specific probe (CK THO1:PCO1) and pan-Candida probe (PC 
THO1:PCO1) was performed for the detection of C. glabrata plasmid DNA for 
simultaneous output at the genus Candida and species-level. A PCR reaction of serially 
diluted C. glabrata plasmid DNA was detected from the amplification curves with the 




Figure 3. 34 Amplification of C. glabrata plasmid DNA and melting curves 
analysis of the samples along with NDC melt curves profile as a comparison. 












































Amplification curves from five ten-fold dilutions of C. glabrata plasmid DNA from 
106 to 102 copies per PCR reaction. Post-amplification melting curve analysis of MPA 
probes of C. krusei (CK), pan-Candida (PC) and C. glabrata (CG) in a single reaction 
demonstrated reduction of melt peaks at pan-Candida (PC) and C. glabrata (CG). The 
real-time PCR was performed in triplicate and amplification and melting curves were 
analysed as mean values (n=3). The horizontal dotted line is fixed as the threshold 
value of fluorescence.  
 
 
The MPA-Candida assay was established from the assembly of five MPA 
probes that generate control melting curves profile in two-channel of detection; three 
FAM-labelled probes and two HEX-labelled probes as depicted in Section 3.2.8; 
Figure 3.26.  The assay is sensitive for the detection of C. auris plasmid DNA from 
the range of 106 to 102 copies of target per reaction. Amplification curves resulting 
from probe hydrolysis and post-amplification analysis with reduced melting peaks of 
pan-Candida (PC) temperature in the FAM channel (Figure 3.35, panel A) and 
identified at the species-level for C. auris (CA) temperature in the HEX channel 
(Figure 3.35, panel B). The reaction was also contained the IC plasmid DNA that was 
amplified and detected by the IC HEX-labelled probe to ascertain reaction 








Figure 3. 35 Amplification of C. auris plasmid DNA and melting curves analysis 
of the samples along with NDC melt curves profile as a comparison in the FAM 
and HEX channels. Amplification curves from five ten-fold dilutions of C. auris 
plasmid DNA from 106 to 102 copies per PCR reaction. Post-amplification melting 
curve analysis of MPA probes of C. krusei (CK), pan-Candida (PC) and C. glabrata 
(CG) in a single reaction demonstrated reduction of melt peaks at pan-Candida (PC) 
in the FAM channel (Panel A) and C. auris (CA) in the HEX channel (Panel B). 
Internal control (IC) with reduced melting peaks ascertain assay functionality. The 
real-time PCR was performed in triplicate and amplification and melting curves were 
analysed as an average (n=3). The horizontal dotted line is fixed as the threshold value 
of fluorescence.  
  
























































































3.2.10 Determination of MPA-Candida sensitivity of detection 
The MPA-Candida assay’s limit of detection was determined using a genome 
equivalent range of 100 to 105 copies. DNA amplification profiles and the 
corresponding reduction of melting curve was evaluated against the NDC melt curve 
profiles. The amplification curve detected in both channels was used to monitor the 
accumulation of the pan-Candida and C. krusei, C. glabrata and C. auris DNA 
biomarkers. The Ct was read before 45 cycles to avoid inconclusive late amplification 
curve. Crucial interpretation of PCR outcomes from the MPA-Candida assay relied on 
melt curve analysis collected during post-amplification in the FAM and HEX detection 
channels.  
The lowest copy of genomic DNA that was detected in the assay at 10-copy for 
C. krusei and C. auris by the pan-Candida probe showed from the amplification curve 
and a significant reduction of the pan-Candida peak (40°C peak in FAM channel) 
compared to the NDC melt curve (Figure 3.36, panel B, panel D i). C. albicans, C. 
dubliniensis, C. glabrata, C. auris, C. parapsilosis, C. tropicalis, C. haemulonii and 
C. guilliermondii were detected from 100 copies by the pan-Candida probe (Figure 
3.36; Table 3.11). The C. glabrata-specific probe (46°C peak in the FAM channel) 
was able to detect C. glabrata genomic DNA at a 100-copy number (Figure 3.36, panel 
C). The C. krusei-specific (30°C peak in the FAM channel) and C. auris-specific 
probes and 48°C peak in HEX channel) were able to detect their respective DNA 
templates at a 10-fold superior in comparison to the C. glabrata probe.  Figure 3.36, 
panels A to D show five different amplification and melt curves profiles that were 










Figure 3. 36 Amplification of serially diluted Candida species genomic DNA and 
their respective melt curve analysis. Amplification reactions containing a range of 1 
to 105 copies of target DNA per reaction were carried out.  Panel A) Amplification 
plots of C. albicans and the corresponding melt curves analysis showing proportional 
to the different copies at pan Candida (PC) peak in the FAM channel. Panel B) 
Amplification plots of C. krusei and its melt curves analysis showing proportional to 
the different copies at pan Candida (PC) as well as C. krusei (CK) peaks in the FAM 
channel. Panel C) Amplification plots of C. glabrata and its melt curves analysis 
showing proportional to the different copies at pan Candida (PC) as well as C. glabrata 
(CG) peaks in the FAM channel. Panels D; i, ii) Amplification plots of C. auris and 
its melt curves analysis showing proportional to the different copies at pan Candida 
(PC) and C. auris (CA) peaks detected in the FAM and HEX channels 
respectively. The horizontal dotted line is fixed as the threshold value of fluorescence. 






Table 3. 11 MPA-Candida assay limit of detection as analysed from 
amplification curve.  
 
Candida species Detection 
channel (s) 
Ct < 45 cut-off 
value 
Limit of detection 
(genomic DNA 
copies per reaction) 
C. auris FAM, HEX 43.60, 32.40 10 
C. krusei FAM 41.00 10 
C. glabrata FAM 41.30 100 
C. albicans FAM 37.10 100 
C. dubliniensis FAM 35.60 100 
C. parapsilosis FAM 36.50 100 
C. tropicalis FAM 37.90 100 
C. guilliermondii FAM 36.50 100 









3.2.11 The complement Pan-Fungal assay standard curve  
 
The amplification efficiency of the Pan-Fungal quantitative assay was calculated from 
the gradient generated from eight Candida species standard curves, with three 
independent repeats in triplicate incorporating 360 data points. The efficiency range 
was 82.99 to 104.49% (Table 3.12), and the gradient between the standards were not 
significantly different (Analysis of Covariance, ANCOVA p value = 0.8561).  A 
representative standard curve with an overall efficiency of 92.56% and correlation 
coefficient, R2= 0.9992 (Figure 3.37).  The Pan-Fungal assay exhibited an excellent 
reproducibility throughout the dilutions in each Candida species plasmid DNA with 
intra-assay and inter-assay CV less than 5%. Dilutions covered five orders of 
magnitude ranging from 106 to 102 plasmid DNA copies number per reaction. 
 
Table 3. 12 Standard curves generated for each Candida species plasmid DNA 
in TaqMan® Pan-Fungal reaction from three independent experiments.  
 
Candida species Equation R2 
C. albicans Y = -3.365*X + 46.37 0.9994 
C. dubliniensis Y = -3.393*X + 44.42 1 
C. krusei Y = -3.227*X + 45.11 0.9772 
C. glabrata Y = -3.811*X + 48.53 0.9891 
C. auris Y = -3.348*X + 41.79 0.9996 
C. parapsilosis Y = -3.633*X + 43.99 0.9957 
C. guilliermondii Y = -3.726*X + 47.61 0.9938 




Figure 3. 37 TaqMan® Pan-Fungal assay standard curve. Standard curve 
generated by plotting the mean Ct values as a function of the known starting 
concentration of the standard dilutions. Ten-fold serial dilutions (106 to 102 copies) of 
the cloned Candida species plasmid DNA were analysed in three independent 
experiments with three replicate reactions per dilution step. Error bars represent SD of 
Ct values from replicated standards. Confidence intervals (CI) of the means of Ct 
















Log DNA copy number
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Y = -3.514*X + 45.44
R2= 0.9992
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The Pan-Fungal assay limit of detection of serially diluted fungal genomic 
DNA was determined from the amplification curve in the FAM channel. In general, 
Candida species can be detected from 10 genome copies except for C. glabrata, C. 
tropicalis and C. guilliermondii which 10-fold higher (Table 3.13).  
 
Table 3. 13 TaqMan® Pan-Fungal assay limit of detection as analysed from the 
amplification curve. 
 
Fungal species  Ct < 45 cut-off value in 
FAM detection channel 
Limit of detection 
(genomic DNA 
copies per reaction) 
Aspergillus flavus 40.00  10 
C. auris 42.00 10 
C. krusei 41.00 10 
C. albicans 40.00 10 
C. dubliniensis 41.30 10 
C. parapsilosis 41.50 10 
C. haemulonii 40.00 10 
C. glabrata 43.10 100 
C. tropicalis 35.00 100 
C. guilliermondii 37.30 100 
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3.2.12 External validation and evaluation tests 
All spiked serum samples (6/6) of Candida Evaluation Panel (Qnostics) were 
successfully detected in a TaqMan® Pan-Fungal assay and no detection for panel’s 
negative sample (S07). The panel was further tested for the qualitative detection of 
Candida species in the MPA-Candida assay. C. albicans “High” positive sample 
(S01), C. krusei “High” and “Medium” (S05 & S06) positive samples were detected 
from the reduction of pan-Candida melt peak (40°C) and concomitant C. krusei 
specific-detection at 30°C melt peak (Table 3.14). No amplification was detected for 
the Negative sample (S07) therefore, no reduction of melt curve compared to NDC 
melt curve. C. albicans “Medium” sample (S02), C. glabrata “High” and “Medium” 
samples (S03 & S04) were not detected in MPA-Candida assay. However, all samples 
were detected positive in the Pan-Fungal assay. C. glabrata samples 03 & 04 were 
detected positive with mean Ct values of 28.55, SD ± 0.53 and 32.48, SD ± 0.75 
respectively.  
Multiplex Candida species detection assay, MPA-Candida, showed the 
comparable magnitude of detection of C. auris genomic DNA with a single C. auris 
detection kit (Genesig® Standard Kit, Primerdesign™ Ltd) (Figure 3.38). Linear 
dynamic range of detection was demonstrated for Genesig kit (correlation coefficients, 
R2 = 0.997; PCR efficiency, E = 79.02%) and MPA-Candida in both level of 
detections; C. auris-specific (R2 = 0.9973; E = 125.09%) and genus-Candida (R2 = 
0.9935; E = 73.57%). Dilutions spanned from 105 to 101 genome copies of C. auris per 
reaction. In a separate experiment, Genesig kit showed cross-reactivity with C. auris-






Table 3. 14 Quantitative and qualitative analysis of Qnostics Candida 






Pan-fungal reaction MPA-Candida 
melting curve 
qualitative analysis Mean Ct ± SD Estimation of target 
copy number (1) 
S01: C. albicans 
(24.5) 
24.19 ± 0.68 1.11 × 106 Positive Pan-Candida 
S02: C. albicans 
(27.2) 
27.70 ± 0.26 1.11 × 105 Negative  
S03: C. glabrata 
(30.4) 
28.55 ± 0.53 6.40 × 104 Negative 
S04: C. glabrata 
(31.9) 
32.48 ± 0.75 4.88 × 103 Negative 
S05: C. krusei 
(29.0) 
30.04 ± 0.63 2.41 ×104 Positive Pan-Candida 
& C. krusei 
S06: C. krusei 
(31.3) 
34.04 ± 0.23 1.75 × 103 Positive Pan-Candida 
& C. krusei 
S07: Negative 
(Negative) 
ND ND Negative 
* Reference Ct value provided in the Qnostics Candida Evaluation Panel product information. 
1) Estimation of fungal target copy number present based on the calibration curve established for the 
Pan-Fungal qPCR assay, y= -3.514Log (x)+ 45.44; R2= 0.999. Ct, Threshold cycle; SD, Standard 




Figure 3. 38 Detection of C. auris genomic DNA in MPA-Candida and simplex 
C. auris qPCR diagnostic kit (Genesig® standard kit). C. auris genomic DNA was 
detected across five tenfold dilutions ranging from 105 to 101 genome copies per 
reaction. The reaction has small SD and error bar only can be seen in the latest Ct 


























Y = -3.954*X + 37.30
Y = -2.838*X + 36.69
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3.3 Discussion  
 
In this study, biomarkers for the detection of all fungal species (pan-fungal), all 
Candida species (pan-Candida) and species-specific sequences for each resistant 
species C. krusei, C. glabrata and C. auris were identified. Candida species 
biomarkers were identified and adapted as probes in the MPA-Candida assay from the 
variable domains (D1/D2) of the LSU rDNA gene. The first 381 bp from the 5’ end of 
the LSU region showed great intraspecies sequence diversity for Candida species. This 
region has been used to analyse and identify clinically relevant Candida species 
(Makene, 2014). Availability of the D1/D2 of the LSU sequences in the database 
increased the sequence utility to resolve individual yeast species (Page & Kurtzman, 
2005). However, a BLAST result for the pan-Candida probe sequence resulted in 
several other yeast species with 100% similarity, which could lead to cross-reactivity. 
Further analyses of sequence alignments of the D1/D2 of the LSU gene between S. 
cerevisiae and C. albicans revealed 85% sequence similarity.  S. cerevisiae is 
phylogenetically related and showed a high sequence identity to other Candida species 
(Pérez-Torrado & Querol, 2016). Nevertheless, this should not be a major concern, as 
standard antifungal therapy with fluconazole is effective to treat S. cerevisiae 
infections (Enache-Angoulvant & Hennequin, 2005). Moreover, invasive infections 
caused by S. cerevisiae is very low compared to Candida species that is the 
predominant cause of IFIs (Miceli, Díaz & Lee, 2011).  
The pan-fungal probe was selected from the ITS2 region, and the target region 
was amplified by the universal primer set (ITS3 and LR1). The target region was 
selected to ensure coverage of fungal species where most, if not all, potential pathogens 
can be detected in the Pan-Fungal assay. Although there is no single locus for fungal 
identification, consensus decided that the whole ITS region (ITS1-5.8S-ITS2) be 
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accepted as a universal fungal DNA barcode for fungi (Schoch et al., 2012; Irinyi et 
al., 2016). The ITS region has been long used in the fungal phylogenetic studies 
(Robert et al., 2011), and establishment of the curated fungal sequence database such 
as the ISHAM (International Society for Human and Animal Mycology) Barcoding 
Databases (http://its.mycologylab.org/) providing a reliable identification of 
biomarkers at the species-level. In the present study, a unique IC probe sequence was 
designed and incorporated into both MPA-Candida and Pan-Fungal reactions. The 
detection of the IC plasmid DNA in the assays was independent regardless of the 
presence or absence of a fungal target sequence in the reaction. Through the inclusion 
of the IC, the functionally of the PCR mixture was monitored from inhibitors in every 
sample to avoid false negative results. Although the universal primers M13 was 
utilised in the reaction may contribute to non-specific amplification, but a novel design 
of the IC target probe for detection of amplified region is specific. 
This novel MPA-Candida assay is capable of detecting nine medically 
important Candida species most frequently associated with candidiasis. The genus-
level biomarker for Candida (pan-Candida) probe detects C. albicans, C. dubliniensis, 
C. parapsilosis, C. tropicalis, C. guilliermondii, C. haemulonii, C. krusei, C. glabrata 
and C. auris. Species-level discrimination of the drug-resistant C. krusei, C. glabrata 
and C. auris could also be correctly identified simultaneously in the assay by their 
corresponding specific probes. Collectively, the MPA-Candida assay consisted of five 
different probes labelled with only two different fluorophores. MPA technology 
provides a great advantage over the standard hydrolysis probe real-time PCR 
diagnostic tests which is limited to one channel for one biomarker (Fu, Miles & 
Alphey, 2012). In the MPA-Candida, the pan-Candida, C. krusei-specific and C. 
glabrata-specific probes were labelled with the FAM reporter dye. Meanwhile, the C. 
auris-specific and IC probes were labelled with the HEX reporter dye. The probes 
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melting temperatures can be distinguished by providing the variability of the probe 
constituents and composition of the probe complementarity to the target sequence 
(Huang et al., 2011). In the MPA-Candida assay, the IC and C. auris-specific probes 
were labelled with HEX to avoid overlapping melting peaks from a single detection 
channel. The THO and PCO hybrid of the C. auris-specific had a melting temperature 
almost identical to that of the C. glabrata-specific probe, and the IC probe had a 
melting temperature less than 5°C to the C. krusei-specific probe. Ideally, the melting 
temperature between the probes labelled with the same fluorophore should differ by 5 
to 7°C. Characterisation of the MPA-Candida assay with an assembly of the pan-
Candida and C. glabrata-specific probes labelled with FAM at the equivalent 
concentration (0.4 µM) had masked the C. glabrata fluorescence signal in the melt 
curve. Therefore, the pan-Candida probe final concentration in the assay was reduced 
to 0.2 µM to regain the specific melting peak signal for C. glabrata-specific probe. 
The pan-fungal probe was engineered as a separate reaction to complement the 
MPA-Candida assay diagnostic to detect and quantify other fungal species that may 
be present in the clinical sample. The Pan-Fungal assay was based on standard 
hydrolysis probe real-time PCR therefore, amplification curve analysis for the Ct was 
used to monitor detection of the fungal biomarker. The ITS2 region has been utilised 
for detection of fungal pathogens in many PCR assays (Hasseine et al., 2015; Zeller et 
al., 2017). Detection channels and the reaction protocol of the Pan-Fungal assay were 
consistent with the MPA-Candida assay, which enabled simultaneous reaction and 
results analysis in a single run of PCR. A separate assay designed for the Pan-Fungal 
reaction could assist the clinicians ruling out non-fungal infections before proceeding 
the diagnosis for candidiasis in the MPA-Candida assay. High NPV in some of the 
molecular tests such as LightCycler SeptiFast (Roche) and T2 Candida (T2 
Biosystems) are useful to rule out the diseases in the population of the prevalence of 
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fungal infections is low (Chang et al., 2013; Pfaller & Castanheira, 2016). A test with 
a high NPV (88-100%) could give justification to stop unnecessary antifungal 
treatment to the patients and would reduce development of antifungal resistance and 
indirectly save the cost of patient care (Halliday et al., 2015). Positive and Negative 
Predictive Values measure the performance of diagnostic test and reflect the 
probability of a test result predicting whether a disease is present or absent in the 
specific population (Khot & Fredricks, 2009). It is also worth noting that the Pan-
Fungal assay is more straightforward to analyse and could save the precious DNA 
material and cut the cost for unnecessary diagnosis processes. However, future 
approach to combine this current Candida and Pan-Fungal reactions into a single tube 
and single detection channel reaction could be promising.  
The MPA-Candida assay demonstrated specific melt peaks for detections of 
Candida species and resistant species of C. krusei, C. glabrata and C. auris. The post-
amplification melting curve analysis provides a qualitative value of specificity. In the 
presence of the target(s), the corresponding melting peak(s) either reduced or 
disappeared when compared with the NDC melt curves. All nine Candida species were 
detected by the pan-Candida probe, and each resistant species was detected by the 
corresponding species-specific probe. However, a slight reduction of the C. krusei 
melting peak was noticed in the presence of non- krusei Candida species DNA in the 
assay throughout this study. This phenomenon has been described as “shrunk 
neighbouring peaks” in the original research article reporting the MPA technology and 
does not affect the diagnostic specificity and accuracy of the assay (Fu, Miles & 
Alphey, 2012). The melting peak for C. krusei detection could be differentiated with a 
significant reduction of signal compared to a small reduction as in the presence of non-
krusei Candida species.  The probes melting temperature are widely distributed across 
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the two channels. One could easily tell whether single or double target sequence was 
detected from the melting curve pattern as compared to the control melting curve.    
 It was demonstrated that the MPA-Candida and Pan-Fungal PCR reactions 
were able to detect 100 copies of genomic DNA and could confidently detect 10 copies 
of C. krusei and C. auris genomic DNA. This range of detection is approximately 
equivalent to the clinical range of candidaemia of 5 to 100 CFU/mL (Loeffler et al., 
2000).  Its detection sensitivity for fungal rDNA is comparable with other 
commercially available kits. For example, SeptiFast (Roche) could detect fungal DNA 
in a range of 30 to 100 CFU/mL blood (Chang et al., 2013), and MycoReal Candida 
kit (Ingenetix) could detect from 5 to 10 CFU/mL blood (Schabereiter-Gurtner et al., 
2007). The amplification curve from the MPA-Candida reaction was evaluated in 
parallel with the melt curve analysis. A threshold cycle was set based on the cycle at 
which fluorescence from amplification exceeded the background noise. Although the 
exponential amplification curve was detected at early cycle, it has no mean to discern 
the source of the probe detected for species-specific identification. Therefore, the melt 
curve analysis in the MPA-Candida reaction is essential for the qualitative 
identification of the Candida species with reduced susceptibility or resistant to 
antifungals. Interestingly, although the quantification cycle value could be detected (Ct 
= 45.25 ± 2.07) for samples with a single copy C. krusei genomic DNA, the 
corresponding melting peak was not reduced significantly compared to the NDC peak. 
Thus, the interpretation of results should be carried out with caution, especially when 
low concentrations of DNA sample are used.  
The external evaluation panel was employed in this study to assess the 
performance of the MPA-Candida and Pan-Fungal assays from the spiked serum 
samples. The Qnostics’ Candida spp. Evaluation Panel was processed according to the 
standard technique to release the DNA from the cell wall using a vigorous mechanical 
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lysis method (Preuner & Lion, 2013). The spiked samples were detected positive in 
the TaqMan® Pan-Fungal assay confirming the presence of fungal DNA in the 
extraction products. The panel’s negative sample was detected negative in both 
reactions, Pan-Fungal and MPA-Candida; thus, eliminating the possibility of samples 
cross-contamination throughout the processes. The MPA-Candida reaction 
successfully detected C. albicans “High” and C. krusei “High” and “Medium” samples 
from the genus-level of pan-Candida melt peak and with an additional reduction of 
melt peak to speciate C. krusei. Cross-reference of Ct value was comparable to the 
Qnostics’s reference assay (Table 3.14). However, the MPA-Candida assay was less 
sensitive for C. glabrata and C. albicans “Medium” samples hence, no qualitative 
analysis can be evaluated to confirm these samples. The in vitro limit of detection 
testing showed 100 copies of C. glabrata genomic DNA was detected late (Ct = 41.30 
± 0.45) relatively to the other Candida species by 3 to 6 cycles (Table 3.11). This 
variability of the Ct values suggests the assay is less sensitive towards detection of C. 
glabrata DNA, thus limiting the detection of the panel’s C. glabrata spiked samples.  
Finally, we tested the MPA-Candida assay performance specifically for 
detection of emerging C. auris.  The assay was sensitive up to 10 genome copies per 
reaction and efficient throughout the genus- and species-level of detections. 
Commercially available biochemically based yeast identification systems, such as 
Vitek 2 (bioMérieux) and BD Phoenix (BD Diagnostics) has misidentified C. auris as 
C. haemulonii (Centers for Disease Control and Prevention, 2018). Our multiplex 
Candida PCR assay consist of a highly specific DNA biomarker for C. auris and 
manifest an excellent specificity with no cross-reactivity with one of the closely related 
species, C. haemulonii.   
In summary, the MPA technology allows the development of a real-time PCR 
assay for the detection of five different targets including of the IC in just two channels 
 166 
of detection. The antifungal resistant C. krusei, C. glabrata and C. auris can be 
accurately discriminated from the other Candida species from a straightforward melt 
curve analysis. Robust and simple features of the MPA-Candida assay would allow 
practical adaptation in the less sophisticated qPCR instruments (Qiagen’s Rotor-Gene 
Q 2-Plex HRM, Applied Biosystems™ 7500), with seamless integration in the 
laboratories that operate in the conditions of limited resources. The MPA-Candida 
assay range of species detection as well as its high specificity and sensitivity could 
help clinicians for a prompt initiation of accurate therapeutic drugs to the patients and 
effective disease management. As the results of this in vitro study have been highly 





CHAPTER 4: Exploring Alternative Single-tube Designs for the MPA-Candida assay 
 
4.1 Introduction 
MPA technology has been used previously for the diagnosis of Human Papilloma virus 
(HPV) infection. Genefirst’s Papilloplex® High-Risk HPV kit can multiplex 14 probes 
using four channels for the detection of HPV in a single closed-tube PCR test (Bhatia 
et al., 2017). This chapter describes experiments aimed at re-designing the MPA-
Candida assay for use as a single closed-tube diagnostic test capable of fungal 
biomarker detection employing either two (assay design 2) or three (assay design 3) 
fluorescence detection channels. Assay design 2 incorporates the pan-fungal probe into 
the MPA-Candida assay and was optimised for its melting curve profiles. A slight 
modification to the original MPA-Candida, the assay design 2 without the pan-fungal 
probe, was initially tested for its diagnostic specificity and sensitivity. As an alternative 
strategy, the inclusion of the pan-fungal probe for three detection channels was 
pursued. Assay design 3 incorporates the pan-fungal probe and aimed to monitor the 
biomarkers amplification by 3-channel hexa-plexing. 
 
4.2 Experimental Results 
 
4.2.1 Assay design 2: testing of MPA-Candida melting curve profile to 
incorporate pan-fungal target 
Various MPA probes labelled with FAM and HEX were tested for their melting curves 
within the two channels of detection. The C. krusei-specific probe and IC probe were 
exchanged their fluorophore dye to avoid the overlapping melting temperatures with 
the pan-fungal HEX-labelled probe (PF THO2: PCO2). A modified MPA-Candida 
assay, the FAM-labelled probes; IC, pan-Candida and C. glabrata-specific and, the 
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HEX-labelled probes; C. krusei-specific probe and C. auris-specific were assembled 
in a single tube reaction for their melting curves prior to inclusion of the pan-fungal 
probe pair (Figure 4.1). The HEX-labelled C. krusei-specific probe (CK THO1:PCO1) 
unexpectedly showed a higher melting temperature at 34°C in multiple probes 
detection, than in single probe detection (Figure 4.2). As anticipated, the assembly of 
the HEX-labelled pan-fungal probe (PF THO2:PCO2) in a multiplex reaction had 
concealed the C. krusei-specific melting peak. Although three HEX-labelled probes 
were present in the reaction, only two melting peaks were appeared at 36°C and 48°C 
which latter was for C. auris-specific probe (Figure 4.3). Optimisation of probes 
concentration attempted to obtain three melting peaks from the HEX-labelled probes 
(Figures 4.4 and 4.5). Throughout the optimisations, a small and non-specific peak at 
low temperature can be observed in both channels of the melt curve analysis and is an 
unexpected melting temperature for any of the probes in the reaction. At this point, the 
inclusion of the pan-fungal probe for detection in the HEX channel was unsuccessful.  
A second attempt was performed to accommodate the pan-fungal probe in the 
MPA-Candida assay. The C. krusei-specific probe was re-designed and to have a 
higher melting temperature detected at 41°C. The HEX-labelled THO probes, C. 
krusei-specific (CK THO2:PCO1) was assembled with the pan-fungal and C. auris-
specific probes (Figure 4.6). However, the melting temperature profile was not 
reproducible in the post-amplification analysis. Three melting peaks of C. glabrata-
specific, pan-fungal as well as C. krusei-specific probes disappeared in the FAM and 








Figure 4. 1 An alternative combination of MPA probes pairs in a single 
reaction for five melting peaks of the control profile. Panel A shows melting peaks 
for IC, 34°C; pan-Candida (PC), 39°C; C. glabrata (CG), 46°C in the FAM channel 
and panel B shows melting peaks for C. krusei-specific (CK), 34°C and C. auris-










Figure 4. 2 The C. krusei-specific probe melting temperature was 
compromised in a multiplex reaction. The C. krusei-specific probe, CK 
THO1:PCO1 melting peak detected at 34°C as in 2-probe reaction (green lines) and 
shown at 30°C as in a single probe detection. Analysis was performed in triplicate in 
















Figure 4. 3 Optimisation of six MPA probes in a single reaction. Three melting 
peaks detected in the FAM channel (Panel A), but only two melting peaks appeared 
in the HEX channel (Panel B). The melting peak which appeared at 36°C in the HEX 
channel is not specific for either the C. krusei-specific probe (CK THO1:PCO1) or the 
pan-fungal (PF THO2:PCO2). The concentration of the probes was tested at 0.2 µM 
for the IC: Internal Control, 0.2 µM for the PC: pan-Candida; 0.4 µM for the CG: C. 
glabrata-specific; 0.4 µM for the CK: C. krusei-specific; 0.4 µM for the PF: pan-fungal 
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Figure 4. 4 Optimisation of C. krusei-specific probe (CK THO1:PCO1) 
concentration for a visible melt peak in the HEX channel. The reaction consists of 
six MPA probes in a single tube reaction. Panel A has three probes in the FAM channel 
for IC, THO:PCO2; pan-Candida, PC THO:PCO1; C. glabrata-specific,  CG 
THO2:PCO1; Panel B consists of three HEX-labelled probes, but only two melting 
peaks can be detected at 36±1°C (the peak is not specific either to C. krusei-specific 
(CK THO1:PCO1) or pan-fungal (PF THO2:PCO2) and at 48°C for C. auris-specific 
















Figure 4. 5 Optimisation of the HEX-labelled probes concentration. The upper 
signal in Panel B (HEX channel) is a reaction with the C. krusei-specific probe (CK 
THO1:PCO1) at 0.6 µM and the pan-fungal probe (PF THO2:PCO2) at 0.4 µM and; 
the lower signal is a reaction with the CK THO1:PCO1 probe at 0.4 µM and; PF 
THO2:PCO2 probe at 0.3 µM. The experiments were unable to produce specific melt 
peaks for both probes in the HEX channel. The upper and lower signals in Panel A 
(FAM channel) consist of the probes at constant concentrations; 0.2 µM for the IC: 
Internal Control, 0.2 µM for the PC: pan-Candida; 0.4 µM for the CG: C. glabrata-
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Figure 4. 6 Optimisation of six MPA probes in a single reaction for a specific 
melting temperature for each target probe in the FAM and HEX detection 
channels. Panel A consists of three probes of internal control (IC), 34°C; pan-Candida 
(PC), 39°C and C. glabrata-specific (CG), 45°C melting peaks detected in the FAM 
channel. Panel B consists of three probes of pan-fungal (PF), 36°C; new designed C. 
krusei-specific probe (CK), 41°C and C. auris-specific (CA), 48°C. The experiment 
was performed in triplicate.  
PC THO:PCO1 
CG THO2:PCO1 






4.2.2 Testing the specificity of the melting curve analysis   
The assay design 2 as described in Figure 4.1 was evaluated for its specificity of the 
detection in FAM and HEX channels. Amplification of the IC plasmid template 
without fungal DNA showed accurate downshift of melting peak against NDC at the 
IC temperature (Figure 4.7). The experiment was further tested with the inclusion of 
Candida genomic DNA in every reaction. Specificity of detection of C. albicans, C. 
glabrata, C. krusei and C. auris in the present of IC plasmid DNA was determined 
with two or three peaks change their height against the NDC (from Figures 4.8 to 4.11). 
The qualitative outcomes including of C. haemulonii, C. dubliniensis, C. parapsilosis, 
C. tropicalis, C. guilliermondii and the filamentous fungi species as well as bacterial 




Figure 4. 7 Post-amplification melting curve analysis of the IC. The reaction 
contained no Candida genomic DNA with a specific melting peak reduction (blue 
arrow) at 34°C compared to NDC reaction. Melting curves analysis in the FAM 
channel (Panel A); internal control (IC) probe hybrid of THO and PCO2, pan-Candida 
(PC) probe hybrid of THO and PCO1 and C. glabrata-specific (CG) probe hybrid of 
THO2 and PCO1. Melting curves analysis in the HEX channel (Panel B); C. krusei-
specific (CK) probe hybrid of THO1 and PCO1 and C. auris-specific (CA) probe 











Figure 4. 8 Amplification and melting curve analysis of the IC and C. albicans 
DNA. The reaction showed two melting peaks reduction (blue arrows) at 34°C and 
40°C compared to NDC profile. Melting curves analysis in the FAM channel (Panel 
A); internal control (IC) probe hybrid of THO and PCO2, pan-Candida (PC) probe 
hybrid of THO and PCO1 and C. glabrata-specific (CG) probe hybrid of THO2 and 
PCO1. Melting curves analysis in the HEX channel (Panel B); C. krusei-specific (CK) 
probe hybrid of THO1 and PCO1 and C. auris-specific (CA) probe hybrid of THO2 
and PCO1. The qPCR was performed in triplicate. 









Figure 4. 9 Amplification and melting curve analysis of the IC and C. glabrata 
DNA.  The reaction showed three melting peaks reduction (blue arrows) at 34°C, 40°C 
and 46°C compared to NDC profile. Panel A, melting curves analysis in the FAM 
channel; internal control (IC) probe hybrid of THO and PCO2, pan-Candida (PC) 
probe hybrid of THO and PCO1 and C. glabrata-specific (CG) probe hybrid of THO2 
and PCO1. Panel B, melting curves analysis in the HEX channel; C. krusei-specific 
(CK) probe hybrid of THO1 and PCO1 and C. auris-specific (CA) probe hybrid of 
THO2 and PCO1. The qPCR was performed in triplicate.   







        
        
Figure 4. 10 Amplification and melting curve analysis of the IC and C. krusei 
DNA. The reaction showed three melting peaks reduction (blue arrows) across two 
channels; at 34°C (IC) and 40°C (PC) in the FAM detection channel and 35°C (CA) in 
the HEX detection channel compared to their NDC profile. Panel A, melting curves 
analysis in the FAM channel; IC probe hybrid of THO and PCO2, pan-Candida (PC) 
probe hybrid of THO and PCO1 and C. glabrata-specific (CG) probe hybrid of THO2 
and PCO1. Panel B, melting curves analysis in the HEX channel; C. krusei-specific 
(CK) probe hybrid of THO1 and PCO1 and C. auris-specific (CA) probe hybrid of 
THO2 and PCO1. The qPCR was performed in triplicate. 
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Figure 4. 11 Amplification and melting curve analysis of the IC and C. auris 
DNA. The reaction showed three melting peaks reduction (blue arrows) across two 
channels; at 34°C (IC) and 40°C (PC) in the FAM detection channel and 48°C (CA) in 
the HEX detection channel compared to their NDC profile. Panel A, melting curves 
analysis in the FAM channel; IC probe hybrid of THO and PCO2, pan-Candida (PC) 
probe hybrid of THO and PCO1 and C. glabrata-specific (CG) probe hybrid of THO2 
and PCO1. Panel B, melting curves analysis in the HEX channel; C. krusei-specific 
(CK) probe hybrid of THO1 and PCO1 and C. auris-specific (CA) probe hybrid of 
THO2 and PCO1. The qPCR was performed in triplicate. 
C. auris in FAM  
IC THO:PCO2 PC THO:PCO1 CG THO2:PCO1 
CK THO1:PCO1 
CA THO2:PCO1 




Table 4. 1 Specificity evaluation of dual-channel MPA-Candida assay design 










 FAM  HEX 
IC PC CG CK CA 
Internal control  ND  ND  + ND ND  ND ND 
Candida            
C. albicans 19.30  ND  + + ND  ND ND 
C. glabrata 18.80  ND  + + +  ND ND 
C. krusei 20.60  19.0  + + ND  + ND 
C. auris 18.0   21.0  + + ND  ND + 
C. haemulonii 22.0  ND  + + ND  ND ND 
C. dubliniensis 20.5  ND  + + ND  ND ND 
C. parapsilosis 20.5  ND   + + ND  ND ND 
C. tropicalis 19.8  ND  + + ND  ND ND 
C. guilliermondii 19.8  ND  + + ND  ND ND 
Moulds           
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A. fumigatus 28±1  ND  + ND ND  ND ND 
A. flavus 28±1  ND   + ND ND  ND ND 
P. rubens 28±1  ND  + ND ND  ND ND 
M. circinelloides 28±1  ND  + ND ND  ND ND 
Bacteria           
S. aureus 28±1  ND  + ND ND  ND ND 
S. epidermidis 28±1  ND   + ND ND  ND ND 
P. mirabilis 28±1  ND  + ND ND  ND ND 
E. coli 28±1  ND  + ND ND  ND ND 
* Ct: Threshold cycle, the cycle intersection with the point where the curve first clearly rises off 
baseline value; FAM: Detection channel (465 nm/510 nm); HEX: Detection channel (533 nm/580 
nm); IC: Internal Control-specific peak (35°C); PC: Pan-Candida peak (40°C); CG: C. glabrata-
specific peak (46°C); CK: C. krusei-specific peak (30°C); CA: C. auris-specific peak (48°C); +: 





4.2.3 Testing the sensitivity of detection  
The melting curves analysis for the detection of five tenfold dilutions genomic DNA 
were tested for C. albicans and C. glabrata, C. krusei and C. auris. The signal with a 
significant reduction of melting peaks 40°C of pan-Candida (PC) generally limited up 
to 104 copies of genomic DNA per reaction in all four Candida species tested (Figures 
4.12 and 4.13; FAM channel). Furthermore, the melting peaks 45°C of C. glabrata-
specific (CG) shown reduced peak against the NDC only in the reaction with the 
highest concentration of C. glabrata genomic DNA (Figure 4.12, panel B).  
Meanwhile, the sensitivity of detections of C. krusei and C. auris were analysed across 
two channels of detection, FAM and HEX. C. krusei-specific melting peaks (CK) 
(Figure 4.13, panel A) showed proportionate reduction of the peaks in the HEX channel 
against the NDC from 105 to 101 copies genomic DNA. C. auris-specific melting peak 
(CA) (Figure 4.13, panel B) showed the assay sensitivity limited to 104 copies of C. 
auris genomic DNA.  
In addition, the IC melting peak was also showed a significant reduction of the 
peak compared to its NDC at 34°C in every reaction. Nevertheless, the IC melting 
peaks in reaction with 105 or 104 copies of Candida species DNA has a greater reduced 
height compared to the melting peaks for the reaction with lower concentrations of 
Candida genomic DNA (from 103 to 101 copies) (Figures 4.12 and 4.13), despite of 
every reaction containing the same number of copies (105 copies) of the IC plasmid 
DNA. As the assay demonstrated poor sensitivity, the objective to include the pan-




A) C. albicans melting curves analysis 
 
 
B) C. glabrata melting curves analysis 
 
Figure 4. 12 Post-amplification melting curves analysis of the assay’s sensitivity 
for detection of the C. albicans and C. glabrata. The reaction containing a range of 
serially diluted C. albicans (Panel A) and C. glabrata (Panel B) genomic DNAs in the 
present of IC plasmid DNA. The FAM channel melting curve consists of MPA probes 
of IC, pan-Candida (PC) and C. glabrata-specific (CG). The HEX channel melting 
curve consists of MPA probes for C. krusei-specific (CK) and C. auris-specific (CA). 
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A) C. krusei melting curves analysis 
 
 
B) C. auris melting curves analysis 
 
Figure 4. 13 Post-amplification melting curves analysis of the assay’s sensitivity 
for detection of the C. krusei and C. auris. The reaction containing a range of serially 
diluted C. krusei (Panel A) and C. auris (Panel B) genomic DNAs in the present of 
IC plasmid DNA. The FAM channel melting curve consists of MPA probes of internal 
control (IC), pan-Candida (PC) and C. glabrata-specific (CG). The HEX channel 
melting curve consists of MPA probes for C. krusei-specific (CK) and C. auris-specific 























































































4.2.4 Assay design 3: optimisation of the MPA-Candida melting curve and 
TaqMan internal control probe in a single reaction  
Initial optimisations of the assay design 3 involved probes targeting Candida species 
with an inclusion of pan-fungal probe in a single reaction mixture. Initial experiments 
were performed with no IC probe in the reaction to avoid unspecific melting curves 
between the pan-fungal and IC probes. The pan-fungal target probe (PF THO2:PCO2) 
has a melt peak at 37°C (Figure 4.14, panel B). Therefore, the pan-fungal and IC probes 
melting temperatures differ by 3°C to 4°C. 
The assay design 3 was tested for post-amplification analysis; however, the 
melting curves profile were unable to be reproduced (Figure 4.15). No melting peak of 
the pan-fungal probe from the PF THO:PCO hybrid and only C. auris-specific melting 
peak at 48°C in the HEX channel was detected (Figure 4.15; panel B, i). The reaction 
mixtures contained two sets of primers for the pan-fungal (ITS3-F & LR1-R) and pan-
Candida (LR0-F & GSCand-R) which contributed to the non-specific hydrolysis of 
the pan-fungal THO during the PCR steps. Furthermore, the reaction was analysed for 
its amplification curves and recorded continuous increased of fluorescence signal over 
the PCR cycles that was unexpected in the negative control reaction (Figure 4.15; panel 
B, ii).  
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Figure 4. 14 The melt curve analysis of five MPA probes in a single reaction with 
dual-channel fluorescence detection. Melt curve analysis was performed 
independently without the amplification steps and PCR primer in the reaction. Melting 
peaks in the FAM channel read at 29.85°C for C. krusei-specific (CK), 39.29°C for 
pan-Candida (PC), 46.02°C for C. glabrata-specific (CG) (Panel A); in the HEX 
channel melting peaks read at 37.24°C for pan-fungal (PF) and 48.87°C for C. auris-









         
           
                
Figure 4. 15 The post-amplification melting curve analysis of the assay design 3. 
Panel A) Melting peaks for C. krusei-specific (CK), pan-Candida (PC); C. glabrata-
specific (CG) in FAM channel. Panel B, i) Only one melting peak was detected for the 
C. auris-specific probe (CA) in the HEX channel, and the missing of a pan-fungal 









PCR primer sets. Panel B, ii) An increased fluorescence signal was detected in the 




Consequently, the reaction was performed only with a single set of primer, 
ITS3-F forward primer and GSCand-R reverse primer.  The expected melting curves 
profile was generated from the negative control reaction (Figure 4.16). An optimised 
assay was tested for amplification and detection of DNA biomarkers for its specificity 
and sensitivity of detections. The filamentous fungi and Candida species genomic 
DNA were targeted from ITS3 to the GSCand primers binding sites eliminating the 
need for primer LR0 and primer LR1 in the reaction. The results of the amplification 











   
 
Figure 4. 16 The post-amplification melting profiles for assay design 3 in a 
reaction contained a single primer set. CK: C. krusei-specific; PC: pan-Candida; 
CG: C. glabrata-specific; PF: pan-fungal; CA: C. auris-specific. The test was 
performed in triplicate.  
 
 
The MPA-Candida assay design 3 was also engineered to accommodate up to 
four probes per detection channel. The real-time PCR LightCycler 480 instrument 
principally can detect six melting peaks in a single channel of detection. The assembly 
of four THO:PCO probes of C. krusei-specific (CK THO1:PCO1), IC (IC 
THO:PCO2), pan-Candida (PC THO:PCO1) and C. glabrata-specific (CG 
THO2:PCO1) in a single reaction has successfully demonstrated four melting peaks in 
the FAM detection channel (Figure 4.17). The melting temperature of each probe has 
consistently demonstrated in the multiplex reaction as in simplex reaction. C. krusei-
specific probe concentration was increased by 0.1 µM to the final concentration 0.5 
µM of THO probe for a sharp melt peak in the reaction (Figure 4.18). An optimised 
CA THO2:PCO1 PF THO2:PCO2 
B 
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concentration for the FAM-labelled probes for the characterised melt curve profile was 
not reproducible with an inclusion of the HEX-labelled probes. The pan-fungal (PF 
THO2:PCO2) and C. auris-specific (CA THO2:PCO1) probes detected in the HEX 
channel had ablated the C. krusei-specific peak of 30°C in the FAM channel (Figure 
4.19). Optimisation steps were performed with C. krusei-specific probe final 
concentration tested at 0.5 µM (Figure 4.20), and in a range of 0.4 to 0.8 µM (Figure 
4.21) while maintaining the others concentration. The IC probe concentration was also 
reduced from 0.1 µM (figure 4.22) to 0.08 µM (figure 4.23) maintaining the 
concentration of the C. krusei-specific probe at 0.4 µM.   
 
 
Figure 4. 17 Detection of four probes melting peaks of the negative control 
reaction. The probes melting peaks detected in the FAM channel for C. krusei-specific 
IC THO:PCO2 
CK THO1:PCO1 PC THO:PCO1 
CG THO2:PCO1 
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(CK), 31°C; internal control-specific (IC), 35°C; pan-Candida (PC), 41°C and C. 





Figure 4. 18 Optimisation of C. krusei-specific probe concentration. The 
concentration was changed from 0.4 to 0.5 µM for an apparent melt peak. C. krusei-
specific (CK), 31°C; internal control (IC), 35°C; pan-Candida (PC), 41°C and; C. 










Figure 4. 19 Disappearance of C. krusei-specific melting peak in FAM channel. 
Melting curve analysis of six probes in the negative control reaction in the FAM (Panel 
A) and HEX (Panel B) detection channels. Upper and lower sets of peaks in the FAM 
channel differed by the concentration of the probes used in the reaction. The Tm of the 
THO and PCO hybrid in the FAM channel is specified in the boxes and in the label for 
the probes in the HEX detection channel. CK: C. krusei-specific; IC: Internal Control; 
PC: pan-Candida CG: C. glabrata-specific; PF: pan-fungal; CA: C. auris-specific. 
Each analysis was performed in triplicate. 
 
Tm 1= CK THO1:PCO1 
Tm 2= IC THO:PCO2 
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Figure 4. 20 The signal generated with an increased concentration of C. krusei-
specific probe. No clear C. krusei- specific (CK) melting peak can be seen in the FAM 
channel (Panel A). The CK probe concentration was tested at 0.5 µM while other 
probes were kept at constant concentrations. Internal Control probe (IC), pan-Candida 
probe (PC) and C. glabrata-specific probe (CG), pan-fungal probe (PF) and C. auris-
specific probe (CA). The experiment was performed with six replicates.  
A 
B 
Tm 1= PF THO2:PCO2 

















Figure 4. 21 Testing of C. krusei-specific probe (CK THO1:PCO1) at different 
concentrations in a multiplex reaction. Panel A) The reactions contained the CK 
probe at 0.4 µM, 0.6 µM and 0.8 µM while maintaining the other probes at constant 
concentration. The Internal Control probe (IC), 0.2 µM; pan-Candida probe (PC), 0.2 
µM and C. glabrata-specific probe (CG), 0.4 µM. Panel B) The pan-fungal probe (PF), 
















Figure 4. 22 Optimisation of the IC probe concentration for a 4-melting peak in 
FAM detection channel. IC probe concentration was reduced from 0.2 to 0.1 µM for 
a visible C. krusei-specific (CK) probe melting peak in the FAM channel (Panel A).  
The melting peaks in the FAM channel are the C. krusei-specific probe, 0.4 µM; pan-
Candida (PC), 0.2 µM and C. glabrata-specific (CG), 0.4 µM. Melting peaks detected 
in the HEX channel (Panel B) are the pan-fungal probe (PF), 0.4 µM and C. auris-
specific probe (CA), 0.4 µM. The experiment was performed in triplicate.  
B 
IC THO:PCO2 
CK THO1:PCO1 PC THO:PCO1 
CG THO2:PCO1 






Figure 4. 23 Optimisation of the IC probe concentration. Reduction of an IC 
probe concentration from 0.2 µM to 0.08 µM for a visible C. krusei-specific (CK) 
probe melting peak in FAM channel (Panel A).  Melting peaks in the FAM channel 
are the C. krusei-specific probe, 0.4 µM; pan-Candida (PC), 0.2 µM and C. glabrata-
specific (CG), 0.4 µM. Melting peaks detected in the HEX channel (Panel B) are for 
the pan-fungal probe (PF), 0.4 µM and C. auris-specific probe (CA), 0.4 µM. The 
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4.2.5 Testing the specificity of the melting curve analysis   
The specificity of the assay design 3 with the pan-fungal probe was determined by the 
amplification and detection of fungal and Candida genomic DNA. The melting curve 
analysis for C. albicans, C. krusei, C. glabrata and C. auris were specifically detected 
at the three levels of detections from the kingdom, genus and resistant species (Figures 
4.24 to 4.27). Within a single target sequence, the different probes were detected and 
hydrolysed as reflected in the melting curves analysis. The amplification of non-
Candida species was also tested with A. fumigatus and dramatic changes were detected 
in the pan-fungal melting peak only (Figure 4.28). However, late amplification curves 
and less significant changes of melting peaks compared to the NDC were observed in 
the reaction that may erroneously mislead the outcomes. No amplification and 
detection of the E. coli DNA in the reaction exhibits assay specificity (Figure 4.29). 
Multiplexing the internal control in every reaction was included with the IC 
MPA probe THO labelled with Cyanine (Cy5) dye. The IC probe was present to 
ascertain the functionality of the PCR components in the reaction. The probe amplified 
the target plasmid DNA included in every tube and detected by the dual-labelled 
hydrolysis probe in the same manner of TaqMan probe reaction. The detection of C. 
krusei and C. albicans genomic DNA at 105 copies per reaction with simultaneous 
detection of IC in the three different detection channels were demonstrated in Figures 
4.30 and 4.31. The amplification curve with the Ct value at 29 was determined in FAM 
and HEX channels of detection. The detection of C. krusei genomic DNA was detected 
by the pan-Candida and the C. krusei-specific probe. However, the melting peak was 






Figure 4. 24 Amplification and melt curves analysis for detection of C. albicans 
genomic DNA in dual-channel assay multiplexed with pan-fungal probe. Two melt 
peaks reduction (denoted by blue arrows) compared to the control melting profile 
across FAM and HEX detection channels. Panel A) C. krusei-specific (CK), pan-
Candida (PC) C. glabrata-specific (CG) probes in the FAM channel. Panel B) The 
pan-fungal (PF) and C. auris-specific (CA) probes in the HEX channel. Amplification 
was performed with primers ITS3 and GSCand. The qPCR was performed in three 
replicates. The reaction contained no IC.  
CK THO1:PCO1 PC THO:PCO1 
CG THO2:PCO1 







Figure 4. 25 Amplification and melt curves analysis for detection of C. krusei 
genomic DNA in dual-channel assay multiplexed with pan-fungal probe. Three 
melt peaks reduction (denoted by blue arrows) compared to the control melting profile 
across FAM and HEX detection channels. Panel A) C. krusei-specific (CK), pan-
Candida (PC) C. glabrata-specific (CG) probes in the FAM channel. Panel B) pan-
fungal (PF) and C. auris-specific (CA) probes in the HEX channel. Amplification was 
performed with primers ITS3 and GSCand. The qPCR was performed in three 












Figure 4. 26 Amplification and melt curves analysis for detection of C. glabrata 
genomic DNA in dual-channel assay multiplexed with pan-fungal probe. Three 
melt peaks reduction (denoted by blue arrows) compared to the control melting profile 
across FAM and HEX detection channels. Panel A) C. krusei-specific (CK), pan-
Candida (PC) C. glabrata-specific (CG) probes in the FAM channel. Panel B) pan-
fungal (PF) and C. auris-specific (CA) probes in the HEX channel. Amplification was 
performed with primers ITS3 and GSCand. The qPCR was performed in three 
replicates. The reaction contained no IC. 










Figure 4. 27 Amplification and melt curves analysis for detection of C. auris 
genomic DNA in dual-channel assay multiplexed with pan-fungal probe. Three 
melt peaks reduction (denoted by blue arrows) compared to the control melting profile 
across FAM and HEX detection channels. Panel A) C. krusei-specific (CK), pan-
Candida (PC) C. glabrata-specific (CG) probes in the FAM channel. Panel B) pan-
fungal (PF) and C. auris-specific (CA) probes in the HEX channel. Amplification was 
performed with primers ITS3 and GSCand. The qPCR was performed in three 
replicates. The reaction contained no IC. 
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Figure 4. 28 Amplification and melt curves analysis for detection of A. 
fumigatus genomic DNA in dual-channel assay multiplexed with pan-fungal 
probe.  One melt peak reduction (denote by blue arrow) for pan-fungal probe 
detection. Panel A) C. krusei-specific (CK), pan-Candida (PC) C. glabrata-specific 
(CG) probes in the FAM channel. Panel B) pan-fungal (PF) and C. auris-specific (CA) 
probes in the HEX channel. The qPCR was performed in three replicates.  The reaction 
contained no IC. 
 
 
CK THO1:PCO1 PC THO:PCO1 
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Figure 4. 29 Amplification and melt curves analysis tested for E. coli genomic 
DNA. No amplification curve can be detected in FAM (Panel A) and HEX (Panel B) 
channels. CK: C. krusei-specific; PC: pan-Candida; CG: C. glabrata-specific; PF: pan-
fungal; CA: C. auris-specific. The qPCR was performed in three replicates. 
 
CK THO1:PCO1 PC THO:PCO1 
CG THO2:PCO1 







Figure 4. 30 Amplification and melt curves analysis for detection of C. krusei 
genomic DNA in three-channel assay. Panel A) IC amplification signal detected in 
Cy5 channel. Panel B) C. krusei-specific (CK), pan-Candida (PC), C. glabrata-
specific (CG) in FAM channel. Panel C) PF: pan-fungal; CA: C. auris-specific in 
HEX. The qPCR was performed in three replicates.  
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Figure 4. 31 Amplification and melt curves analysis for detection of C. albicans 
genomic DNA in three-channel assay. Panel A) IC amplification signal detected in 
Cy5 channel. Three melt peaks reduction (denoted by blue arrows) across FAM and 
HEX detection channels. Panel B) C. krusei-specific (CK), pan-Candida (PC), C. 
glabrata-specific (CG) in FAM channel. Panel C) PF: pan-fungal; CA: C. auris-
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4.3 Discussion  
 
The inclusion of the pan-fungal probe into the MPA-Candida PCR assay offers a 
comprehensive diagnostic tool for the evaluation of possible fungal infections. An 
individual characterisation of the pan-fungal THO:PCO hybrid melting temperature 
was determined at 38°C as summarised in Chapter 3; Table 3.6. Ideally, the probes 
labelled with the same fluorophores should have the melting temperature differ by 5°C 
to 7°C. Therefore, addition of the pan-fungal probe into the MPA-Candida assay was 
optimised for detection in the HEX channel. However, the melting temperature of the 
C. krusei-specific probe changed from 30°C to 34°C in the HEX detection channel. 
The change of the probe melt peak between the channels was unexpected and has led 
to the ambiguity of the melting curves in the HEX channel. An alternative C. krusei-
specific probe pair (CK THO2:PCO1) with a higher melting temperature was also 
tested; however, the profiles are not reproducible (Figure 4.6).  
The assay design 2 without the pan-fungal probe was tested for the specificity 
and sensitivity of the detection. The amplification of all nine Candida species was 
detected by the pan-Candida probe with the reduced melting peak at 40°C compared 
to the no-template control. The identification of the drug-resistant C. glabrata, C. 
krusei and C. auris by their corresponding species-specific probes were detected 
simultaneously with the pan-Candida probe. In all cases, the IC was consistently 
recognised and ruled out the possibility of the amplification or probe failure in the 
reaction. The assay’s limits of detection were determined using a range of 10 to 105 
equivalent genome copies. The sensitivity of the test was poor and only can detect up 
to 104 copies of genomic DNA; however, the result showed tenfold sensitive for C. 
krusei-specific probe detection.  
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An attractive assay design such as incorporating the pan-fungal target probe in 
a single reaction with three detection channels was also attempted. Activation of three 
fluorescence channels in the LightCycler 480 instrument (Roche, Germany) with 
colour compensation setting for FAM, HEX and Cy5 can detect probes targeting for 
the fungal kingdom, pan-Candida and species-specific as well as IC plasmid DNA. 
Although the melting curve analysis showed the specificity for the C. krusei and C. 
albicans detections, the Ct values were relatively late compared to the detection of the 
same copy of DNA in other assay designs. For this reason, assay design 3 did not 
proceed with the serially diluted DNA samples for determination of the assay’s limit 
of detection. In summary, the exploration was unable to achieve another ideal 
alternative for the MPA-Candida assay. The MPA technology allows for up to four 
probes detection a single detection channel (Fu, Miles & Alphey, 2012; Bhatia et al., 
2017). However, in this study, the detection of the three probes in one channel is more 
feasible to accomplish. Further improvement of the assay designs can be performed 











CHAPTER 5: Assessing the Effectiveness of Independent DNA Isolation Protocols 




Genomic DNA isolation from the fungal cell is an essential step for molecular 
detection techniques such as PCR to detect a specific DNA biomarker. A fungal cell 
including as in Candida species is encapsulated by a rigid cell wall that protects the 
cell. The structures of the cell wall are formed between the outer and inner layers of 
crystalline arrangements of chitin, a linear polysaccharide made of N-
acetylglucosamine, forming an insoluble structure that difficult to break (Ruiz-Herrera 
et al., 2006). Mechanical lysis process is recommended to break the fungal cell wall 
for optimum DNA extraction (Halliday et al., 2015; White et al., 2010). There are few 
mechanical cell lysis techniques available including a conventional method such as 
bead beating procedures (Lõoke, Kristjuhan & Kristjuhan, 2011), that operates in the 
mechanical homogeniser instrument. Meanwhile, a less conventional instrument, for 
example, hand-held mini-pestle that can be applied to fungal cells in a specialised 
extraction tube (Zhang, Chen & Lu, 2012). In this chapter, several commercial DNA 
isolation kits were integrated with both of the mechanical cell lysis techniques 
mentioned and evaluate the DNA yields. The DNA isolation protocol was also 
optimised to extract the DNA from the spiked samples in saline, whole blood and 
serum; to achieve a sensitive fungal genomic DNA extraction method from three 
different samples.  
A range of microbial DNA isolation kits included in this study was from the 
RTP® Pathogen Kit (Stratec Molecular), Wizard Genomic DNA Purification Kit 
(Promega) and the ZymoBiomicsÔ DNA Miniprep Kit (Zymo Research). The kits are 
 210 
intended for bacterial, yeast and viral (RTP® Pathogen Kit) DNA isolation from whole 
blood or blood-based samples but also can be applied to the cell cultures media or 
suspension. According to the manufacturer’s protocol, the maximum yeast input from 
the overnight culture has to be in a range of 108 yeast cells. Therefore, a standardised 
starting material with the number of yeast cells from the stock culture was counted on 
the haemocytometer and determined the cells viability in the CFU/mL. The kit’s 
protocol was adapted for yeast cell wall lysis technique using a standardised bead-
beating instrument either in an ultra-speed beater, FastPrep-24™ (MP Biomedicals) or 
Disruptor Genie (Scientific Industries) cell homogeniser. Importantly, as two of the 
kits (RTP® Pathogen Kit and ZymoBiomicsÔ DNA Miniprep Kit) are using spin 
column, the starting amount of the sample was strictly followed as outlined in the 
instruction to avoid suboptimal performance of the process. 
The final step of DNA dilution was standardised with 50 µL of nuclease-free 
water throughout the investigations. Importantly, an inhibitor-free DNA product is 
needed for PCR to perform efficiently. Each DNA extraction products was measured 
in a spectrophotometer NanoDrop™ instrument to determine the DNA concentration 
and purity scale.  
Ultimately, C. albicans DNA extracted from the range of spiked and diluted 
samples were tested in the Pan-Fungal real-time PCR reaction. The fungal DNA 
biomarker targeting the detected DNA from the ITS2 region of the fungal rDNA used 
was quantified to evaluate the isolation methods. Quantification of DNA copy number 
present in the sample was also attainable through an established calibration curve to 
correlate the DNA extraction products. Not less important, the optimum method 
achieved in this study was used to process spiked serum samples of the Candida 
Evaluation Panel (Qnostic, UK) for the detection in the MPA-Candida assay. The 
detailed of the evaluation results and associated discussion are presented in Chapter 3.  
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5.2 Experimental Results 
 
5.2.1 Microscopic yeast cell counting and CFU.  
The yeast DNA extraction experiment was started by determining the number of cells 
present in the sample. For each protocol in this experiment, all the samples had almost 
the same concentration of cells. A stock yeast culture with a known number of cells 
was also serially diluted for a range of dilutions, and cell dilutions from 105 to 102 cells 
were plated on the SDA media for cell counting. The number of live cells in the sample 
suspension confirmed its viability and was expressed in terms of CFU. The C. albicans 
cells were counted using a microscope and haemocytometer, an improved Neubauer 
ruling and its coverslip, as described in Materials and Methods. The number of C. 
albicans cells from haemocytometer and the calculation of CFU/mL over a range of 
dilutions is depicted in Figure 5.1. The procedures were performed on three 
independent occasions on overnight cell culture. 
 
Figure 5. 1 The colony growths from the serial dilutions of the conidia. The 
dilutions were set up across four magnitudes of dilutions from three independent 
preparations.  
 












5.2.2 DNA isolation using the RTP® Pathogen Kit (Stratec Molecular GmbH)  
The isolation of C. albicans’s nucleic acid from a known number of cells, 1.1 ´ 108 
cells /mL, was performed along with a control sample with the no cell spiked in the 
saline. A slight modification of the early steps for the cell lysis is summarised in Figure 
5.2. The mechanical cell lysis steps were performed in the conditions of lysing the cells 
in the supplied Extraction buffer to enhance the releasing of DNA from the cells 
(Method 1).  As a methodological comparison, a duplicate preparation of cell 
suspension was also processed in the absence of the Extraction buffer, which was only 
added in the later steps (Method 2). An experiment without the mechanical cell lysis 
step was tested at a high incubation temperature (95°C) to break the cell wall (Method 
3). Each method was processed in duplicate along with the negative controls of no cell 
samples. In the case of mechanical lysis method was utilised, Method 1 and Method 2 










Figure 5. 2 A flow diagram of the optimisation experiments of the RTP Pathogen kit protocol for the isolation of C. albicans DNA/RNA. 
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The results of the optimisations steps in this series of experiments are 
summarised in Table 5.1 from the spectrophotometer readings. The measurements of 
nucleic acid concentration for each sample was read in triplicate and reported as a mean 
value. The spectrophotometer readings showed that Method 1 produced the highest 
nucleic acid yield, at an average of 190 ng/µL followed by method 2 in an average of 
175.97 ng/µL. Method 3 produces the lowest nucleic acid yield and, one of the 
duplicate tubes (tube 2) has lower reading than the negative control. All methods 
showed the purity for RNA with an absorbance 260:280 ratios of more than 2.0. The 
negative controls were found with a significant detection of the background DNA 
concentration (~64 ng/µL). According to the instruction manual, the co-purified 
Carrier-RNA accounted for 5 μg per 200 μL sample for most of the present DNA/RNA 
in the sample. This suggests for DNA concentration detected in the negative controls 
were from the Carrier-RNA that pre-formulated in the solid lysis reagent in the 
Extraction tube. The total nucleic acid concentrations measured in methods 1, 2 and 3 
did not exclusively represent the DNA yields from the spiked yeast cells, therefore; 
spectrophotometer analysis was not helpful to gauge the concentrations of C. albicans 
DNA recovered. Ideally, the DNA extraction products from the RTP® Pathogen kit is 










Table 5. 1 The values of the C. albicans nucleic acid concentrations and 
purities using three methods of RTP Pathogen kit. Each method was performed in 
duplicate and the DNA readings were performed three times, and values represented 
as mean ± SD. 
 





Estimation of the DNA 
concentration* (ng/µL) 
Method 1, tube 1 185.00 ± 1.52 2.40 ± 0.01 121.98 
Method 1, tube 2 196.10 ± 1.12 2.41 ± 0.02 133.08 
Method 2, tube 1 193.23 ± 2.60 2.45 ± 0.01 131.23 
Method 2, tube 2 158.72 ± 0.85 2.45 ± 0.02  96.72 
Method 3, tube 1 71.06 ± 0.34 2.74 ± 0.57 5.19 
Method 3, tube 2 62.71 ± 0.43 2.71 ± 0.04 -3.16  
Method 1, NC 63.02 ± 0.37 3.24 ± 0.10 n/a 
Method 2, NC 62.00 ± 0.86 3.20 ± 0.10 n/a 
Method 3, NC 65.87 ± 0.67 3.32 ± 0.03 n/a 
* The estimation was calculated by subtracting the background (NC, Negative Control) 
value from the sample mean concentration obtained for each method. n/a, not applicable  
 
 
5.2.2.1  Quantification of the extracted genomic DNA using a pan-fungal 
PCR amplification assay. 
A known number of C. albicans cell, 1.0 ´ 108 cells/mL, was spiked into 0.9% NaCl 
solution and was serially diluted for seven tenfold dilutions. Method 1 was followed 
for DNA isolation, and the final step for the DNA pellet was eluted in 50 µL elution 
buffer and 1 µL DNA samples subjected to the Pan-Fungal qPCR assay. The IC 
plasmid DNA was included in each PCR mixture to avoid false negative results. The 
controls reaction, which either contained the IC plasmid DNA only or no cell sample 
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(Negative Control), demonstrated early Ct value for IC plasmid DNA (Ct = 25.75) and 
no detection of the amplification curve for the negative control (Table 5.2). Moreover, 
each Pan-Fungal PCR reaction was considered inhibitor-free and valid with the 
detection of the IC plasmid DNA that present along with the extracted C. albicans 
DNA in the reaction. A consistent reading of the IC in all the reactions with a mean Ct 
value of 26.03 ± 0.60 detected in the HEX qPCR channel. The Pan-Fungal qPCR can 
detect fungal DNA from the diluted spiked sample of up to 1: 10 000 dilution ratio or 
equivalent to 100 cells of C. albicans present in the sample.  However, the sample was 
detected at a late Ct value; therefore, under-represents the amount of extracted DNA 
compared to the detection of 100-copy of genomic DNA. No amplification was 
detected from the samples of 1: 100 000 and 1: 1 000 000 cells dilutions ratio, however, 
in each reaction with Pan-Fungal negative results were consistent with the detection of 














Table 5. 2 The Pan-Fungal PCR amplification and quantification of the 
extracted fungal genomic DNA from a serial dilution of saline cell suspension. The 
Ct values are mean (n=3) ± SD. 
 
Number of cell 
(Dilution ratio of cell 
suspension in saline) 
Pan-Fungal PCR  Estimation of 
fungal target copy 
number,  
y= -3.514Log (x)+ 
45.44(1) 
IC 
(mean Ct ± SD) 
Fungal 
(mean Ct ± SD) 
Negative Control  Negative (ND) Negative (ND) ND 
IC DNA only Positive  
(25.75 ± 0.41) 




(25.66 ± 0.97) 
Positive  






(26.07 ± 0.47) 
Positive  





(25.50 ± 0.45) 
Positive  





(25.58 ± 0.60) 
Positive  





(26.83 ± 0.68) 
Positive  





(25.37 ± 0.76) 
Positive  





(26.60 ± 0.23) 
Negative (ND) ND 
1 cell 
(1:1 000 000) 
Positive  
(26.89 ± 0.60) 
Negative (ND) ND 
1Estimation of fungal target copy number present based on the calibration curve established for Pan-
Fungal qPCR assay, R2= 0.999. IC, Internal Control; Ct, Threshold cycle; SD, Standard deviation; 




5.2.2.2  Extraction and quantification of DNA from spiked blood and 
serum samples 
To further evaluate the extraction protocol, the same number of cells were spiked into 
1 mL aliquots of blood and serum. In both sample types, C. albicans conidia 
suspension was serially diluted for seven tenfold dilutions followed by DNA 
extraction. DNA was eluted with a standardised volume of 50 µL of elution buffer. 
One µL of DNA sample was subjected to PCR in triplicate, and each reaction contained 
the IC plasmid DNA that was monitored in the HEX channel. The multiplex qPCR 
assay contained pan-fungal and IC probes that are detectable in the FAM channel and 
HEX channel respectively.  
The detection of the amplified products from the extracted whole blood spiked 
samples was validated by the detection of the IC in all reactions and mean of the Ct 
values at 26.07 ± 0.52 (Table 5.3). Briefly, the Pan-Fungal qPCR can detect fungal 
DNA throughout the samples from 107 to 103 cells. The limit of detection was 
determined at Ct value 41.76 ± 0.76 for the detection of DNA in the sample with 103 
cells. No amplification curve was detected at the higher dilution ratio of cells, from 1: 
10 000 to 1: 1 000 000 samples. All the pan-fungal negative samples were validated 
inhibitor-free as the IC DNA was consistently detected in the same reaction. 
Furthermore, the limit of detection of C. albicans DNA extraction performed on the 
spiked serum samples was also determined (Table 5.4). All samples were detected with 
positive for IC detection with a mean Ct value at 25.53 ± 0.46. Along with the detection 
of the IC, the pan-fungal Ct values spanned from 17.79 to 37.47 for detection of DNA 
from the extracted serum samples from 107 to 103 cells. Detection of the fungal DNA 
biomarkers from the extracted 107 cells of spiked serum was recorded early by one 
cycle compared to the same number of cells from the whole blood. The limit of 
detection of fungal DNA in the serum was demonstrated in the same magnitude as in 
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the whole blood sample. Each spiked sample was processed in the same way as whole 
blood except for the starting volume (200 µL) for the serum to load into the RTA spin 
column.  The detection of fungal biomarkers and the magnitude of detection across the 
three different spiked samples (saline solution, whole blood and serum) are 
summarised in Figure 5.3.  
 
Table 5. 3 The Pan-Fungal PCR amplification and quantification of the 
extracted fungal genomic DNA from a serial dilution of spiked whole blood 
samples. The Ct values are mean (n=3) ± SD. 
 
Number of cell 
(Dilution ratio of cell 
suspension in whole 
blood) 
Pan-Fungal PCR Estimation of 
fungal target copy 
number,  
y= -3.514Log (x)+ 
45.44(1) 
IC 
(mean Ct ± SD) 
Fungal 
(mean Ct ± SD) 
Negative Control  Negative (ND) Negative (ND) ND 
IC DNA only Positive  
(25.77 ± 0.55) 




(25.38 ± 0.64) 
Positive  






(26.37 ± 0.18) 
Positive  






(26.27 ± 0.50) 
Positive  





(25.26 ± 1.21) 
Positive  





(26.64 ± 0.05) 
Positive  






Negative (ND) ND 
10 cells Positive  Negative (ND) ND 
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(1:100 000) (26.18 ± 0.36) 
1 cell 
(1:1 000 000) 
Positive  
(25.78 ± 0.47) 
Negative (ND) ND 
1Estimation of fungal target copy number present based on the calibration curve established for Pan-




Table 5. 4 The Pan-Fungal PCR amplification and quantification of the 
extracted fungal genomic DNA from a serial dilution of spiked serum samples. 
The Ct values are mean (n=3) ± SD. 
 
Number of cell 
(Dilution ratio of cell 
suspension in serum) 
Pan-Fungal PCR Estimation of fungal 
target copy number,  
y= -3.514Log (x)+ 
45.44(1) 
IC 
(mean Ct ± SD) 
Fungal 
(mean Ct ± SD) 
Negative Control  Negative (ND) Negative (ND) ND 
IC DNA only Positive  
(25.57 ± 0.46) 




(24.89 ± 0.97) 
Positive  





(25.74 ± 0.27) 
Positive  





(24.62 ± 0.43) 
Positive  





(25.74 ± 0.36) 
Positive  





(26.00 ± 0.30) 
Positive  





(25.52 ± 0.54) 




(25.76 ± 0.62) 
Negative (ND) ND 
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1 cell 
(1:1 000 000) 
Positive  
(25.81 ± 0.56) 
Negative (ND) ND 
1Estimation of fungal target copy number present based on the calibration curve established for Pan-





Figure 5. 3 The detection of C. albicans DNA in Pan-Fungal PCR assay. 
Variation of the Ct values and magnitude of detections of the spiked cells into three 
different samples. The triplicate Ct values were plotted with error bars, which 

























5.2.3 DNA extraction using the WizardÒ Genomic DNA Isolation kit (Promega) 
The isolation of C. albicans genomic DNA was performed using the Wizard Genomic 
DNA Purification kit (Promega) with a slight modification of the protocol for the cell 
lysis steps. The standard kit protocol was tested with two techniques of mechanical 
cell lysis; using a hand-held homogeniser mini-pestle (BioMasherÒ) and an automated 
bead beating instrument (FastPrep-24™). A known number of C. albicans cells was 
spiked in two different samples – saline solution and whole blood. Then, the samples 
were serially diluted for seven tenfold dilutions and subjected to the DNA extraction 
process. 
The trial of instruments was performed using the mini-pestle homogeniser 
(BioMasherÒ) and bead beating (FastPrep-24™) for mechanical cell lysis. All 
extraction samples were processed in parallel following the modified kit’s protocol 
(Figure 5.4). In the final step, the DNA pellet was rehydrated in 50 µL of nuclease-
free water and was kept constant throughout all experiments. The average DNA 
concentration for each sample is summarised in Table 5.5.  In the result, the highest 
DNA concentration measured at 48.49 ng/µL for a method using the handheld cell 
homogeniser but, the variation between the duplicate was noticeably high. Contrary to 
the bead-beating technique, although the DNA recovered was lower, it showed a 
consistent reading of DNA yields between the duplicates. The next experiments were 
followed with the mechanical cell lysis method using the bead beating technique and 









Figure 5. 4 A flow diagram of the optimisation process of the Promega Wizard 
Genomic DNA isolation kit protocol for C. albicans DNA. BB, Bead-beating tube; 
NLS, Nuclei Lysis Solution; PPS, Protein Precipitation Solution; RPM, Revolutions 
Per Minute; secs, seconds; mins, minutes.   
WizardÒ Genomic DNA 
Isolation Kit
C. albicans 108 cells/mL 
in NaCl suspension
Bead-beating 
Add 200 µL cell 
suspension to NLS
Add sample to BB; max 
speed 5 mins
Add 100 µL PPS to 
sample, vortex
Recover the supernatant 
from the beads
Keep sample on ice; 
centrifuge 13,000 RPM for 3 
mins & follow the standard 
protocol 
Mini-pestle
Obtain cell pellet from 
200 µL cell suspension 
Homogenise the pellet 
with mini-pestle for 3 
mins
Add NLS and mix
Add 100 µL PPS to 
sample, vortex
Keep sample on ice; 
centrifuge 13,000 RPM for 3 
mins & follow the standard 
protocol 
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Table 5. 5 The values of DNA concentrations and purities extracted from the 
107 C. albicans cells in saline solution. The DNA extraction was performed by the 
Wizard Genomic DNA isolation kit tested with two different mechanical cell lysis 
techniques.  
 
Mechanical cell lysis technique 
& Promega isolation kit 
Mean Concentration 
(ng/µL) 
Mean A260/280 ratio 
Mini-pestle + kit, tube1 48.49 ± 0.37 2.09 ± 0.015 
Mini-pestle + kit, tube 2 27.57 ± 0.30 2.10 ± 0.093 
Negative Control, tube 1 ND ND 
Negative Control, tube 2 ND ND 
Bead beating + kit, tube 1 36.59 ± 0.79 2.01 ± 0.093 
Bead beating + kit, tube 2 35.83 ± 0.75 2.06 ± 0.11 
Negative Control, tube 1 ND ND 
Negative Control, tube 2 ND ND 
* Each technique was performed in duplicate and the DNA readings were performed three times. 










5.2.3.1  Extraction and quantification of DNA from spiked blood and saline 
samples 
The experiment was continued using the spiked whole blood sample using the method 
established from the previous experiment. Initially, the whole blood sample containing 
1.0 ´ 107 cells was diluted 1:10 in blood sample to contain one log lower amount of C. 
albicans cells (106) and subjected to the extraction procedures. The same cell 
preparation was made in the saline solution as a control reaction. Both sample types 
were prepared in duplicate and were processed in parallel using the same established 
protocol. The total DNA concentrations reduced significantly from the cell dilution 
step in the whole blood sample compared to the saline solution (Table 5.6).  An 
absorbance ratio in a range of 1.8 and 2.0 taken at 260 nm and 280 nm as an indicator 
of reasonable DNA purity of the samples of 107 cells in whole blood; however, a lower 
than 1.8 indicator for protein contamination measured for other samples. The DNA 
concentrations detected from the spiked saline samples were considerably lower than 
the whole blood; however, it demonstrates way far less decreased over the dilution 
step.  
A wider dilution range of the spiked whole blood sample was prepared and 
processed according to the DNA isolation protocol. The results were reproducible for 
the whole blood samples with the reading of DNA concentration loss considerably 
over the first 1:10 dilution step (Table 5.7). For all samples, including a negative 
control, the DNA yield was read in triplicate using a spectrophotometry instrument. 
Next, all samples were amplified in the real-time PCR assay for detection of biomarker 
targeting ITS2 region of fungal rDNA (Table 5.8).  Three-fold dilution samples, from 
107 to 106 cells, were detected positive for detection of the pan-fungal biomarkers in 
the sample. The pan-fungal biomarker copy quantified in those samples did not 
correlate with the number of cells spiked in the samples.  
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Table 5. 6 The values concentrations and purities of nucleic acids isolated 
from the spiked whole blood and saline solution. All samples were processed in 
parallel using a bead-beating cell lysis technique followed by the Wizard Genomic 
DNA Isolation kit (Promega).  
 




Mean A260/280 ratio 
Whole blood   
107 cells tube 1 80.57 ± 0.98 2.03 ± 0.03 
107 cells tube 2 76.53 ± 3.44 2.08 ± 0.04 
106 cells tube 1 8.54 ± 0.28 1.47 ± 0.26 
106 cells tube 2 8.30 ± 0.58 1.44 ± 0.01 
0 cell (Negative Control 1) ND ND 
0 cell (Negative Control 2) ND ND 
NaCl saline solution   
107 cells tube 1 38.91 1.36 
107 cells tube 2 37.51 1.29 
106 cells tube 1 25.12 0.75 
106 cells tube 2 25.20 0.68 
0 cell (Negative Control 1) ND ND 
0 cell (Negative Control 2) ND ND 
* Each dilution was performed in duplicate, and the DNA readings were performed three times. 






Table 5. 7 The values of the nucleic acid concentration and purity from a 
range of spiked whole blood samples.  
 
Number of cells spiked in 
whole blood 
Mean Concentration (ng/µL) Mean A260/280 ratio 
107 cells tube 1 101.10 ± 2.20 1.99 ± 0.08 
107 cells tube 2 120.18 ± 1.24 2.04 ± 0.03 
106 cells tube 1 11.65 ± 1.50 1.61 ± 0.05 
106 cells tube 2 11.51 ± 1.61 1.53 ± 0.09 
105 cells tube 1 6.64 ± 0.32 1.42 ± 0.10 
105 cells tube 2 6.20 ± 0.05 1.25 ± 0.05 
104 cells tube 1 6.00 ± 1.20 1.13 ± 0.05 
104 cells tube 2 6.35 ± 0.27 1.45 ± 0.18 
103 cells tube 1 6.55 ± 0.90 1.04 ± 0.24 
103 cells tube 2 7.12 ± 0.21 1.34 ± 0.04 
102 cells tube 1 6.44 ± 0.56 1.36 ± 0.20 
102 cells tube 2 5.18 ± 0.54 1.58 ± 0.13 
10 cells tube 1 6.40 ± 0.90 1.34 ± 0.03 
10 cells tube 2 5.26 ± 0.84 1.22 ± 0.04 
1 cell tube 1 6.23 ± 0.21 1.21 ± 0.10 
1 cell tube 2 5.64 ± 0.40 1.41 ± 0.15 
 0 cell (Negative Control 1) 6.07 ± 0.30 1.18 ± 0.10 
 0 cell (Negative Control 2) 6.39 ± 0.05 1.28 ± 0.05 
*Each dilution was performed in duplicate, and the DNA readings were performed three times, and 




Table 5. 8 The Pan-Fungal PCR amplification and quantification of extracted 
DNA products from a serial dilution of spiked whole blood samples. Extraction of 
C. albicans genomic DNA using the bead-beating cell lysis technique and the Wizard 
Genomic DNA Isolation kit (Promega). The Ct values are mean (n=3) ± SD. 
 
Number of cell 
(Dilution ratio of 
the whole blood) 
Pan-Fungal reaction Estimation of fungal 
target copy number,  
y= -3.514Log (x)+ 
45.44(1) 
IC 
(mean Ct ± SD) 
Fungal 
(mean Ct ± SD) 
Negative Control  Negative (ND) Negative (ND) ND 
IC DNA only Positive  
(30.40 ± 0.89) 




(36.55 ± 1.96) 
Positive  





(28.72 ± 0.99) 
Positive  





(29.21 ± 1.43) 
Positive  





(30.30 ± 0.95) 




(29.45 ± 1.40) 




(26.43 ± 2.67) 




(30.16 ± 0.76) 
Negative (ND) ND 
1 cell 
(1:1 000 000) 
Positive  
(29.26 ± 0.16) 
Negative (ND) ND 
1Estimation of fungal target copy number present based on the calibration curve established for Pan-





5.2.4 DNA extraction using the ZymoBIOMICSÔ DNA Miniprep Kit (Zymo 
Research)  
The DNA isolation of the yeast cell was performed in ZymoBIOMICS DNA kit. C. 
albicans cell suspension (1.1 ´ 108 cells/mL) was prepared in 0.9% NaCl solution. The 
cell suspension was processed for DNA isolation using the kit’s standard instruction 
manual. The manufacturer’s recommendation was followed using a homogeniser 
instrument, FastPrep-24™ bead-beating steps (Figure 5.5). The final step of DNA 
elution of 50 µL with nuclease-free water was kept constant for all samples. In all 
samples, including a negative control, the DNA yield was measured three times using 
a spectrophotometer NanoDrop™ instrument. The DNA concentration recovered from 
the 107 cells was very low and inconsistent amongst replicates, compared to the other 


















Figure 5. 5 The recommended flow of extraction steps for yeast DNA isolation using the bead beating technique and ZymoBIOMICSÔ  




cells/mL in NaCl 
suspension
Add sample into ZR BB 
tube
Add 750 µL ZB Lysis 
solution
Add 2% (v/v) 
Proteinase K
Incubate at 55°C; 30 
mins
Secure BB tube, 
homogenise at max 
speed for 5 mins
Centrifuge BB tube 
13,000 RPM for 1 min
Transfer 400 µL
supernatant into 
ZymoSpin III Filter 
fitted in Collection tube
Centrifuge 8,000 RPM 
for 1 min; discard 
ZymoSpin III Filter  
Add 1,200 µL of DNA 
Binding buffer, mix 
well in Collection tube
Continue with washing 
steps
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Table 5. 9 The mean values of the concentrations and purities of genomic 
DNA isolated using ZymoBIOMICSÔ  DNA Miniprep Kit. C. albicans cells were 
spiked in saline solution and processed in duplicate using the bead-beating cell lysis 
technique.  
 
Number of cells spiked in saline Mean Concentration 
(ng/µL) 
Mean A260/280 ratio 
107 cells tube 1 9.96 ± 0.33 1.60 ± 0.07 
107 cells tube 2 5.04 ± 0.21 1.96 ± 0.09 
0 cell (Negative Control 1) ND ND 
0 cell (Negative Control 2) ND ND 
*Each dilution was performed in duplicate, and the DNA readings were performed three times, and 





This investigation was driven by the need to develop an optimum C. albicans DNA 
isolation protocol using a bead-beating technique incorporated with several 
commercial DNA isolation kits. Generally, the RTP® Pathogen kit, Wizard Genomic 
DNA Purification kit and the ZymoBiomicsÔ  DNA Miniprep kit are suitable for high 
protein content samples such as whole blood, serum, plasma and tissues biopsies. The 
RTP® Pathogen and ZymoBiomicsÔ  DNA Miniprep kits are the specialised kits for 
viral and bacterial DNA extractions whereas, the Wizard Genomic DNA Purification 
is optimum for bacterial and yeast DNA. Ultimately, the DNA product was quantified 
in the Pan-Fungal PCR assay to evaluate the effectiveness of each isolation protocol. 
The quantification of genomic DNA is most accurately determined by the real-time 
PCR assay (Clements et al., 2008). The reagent in the RTP Pathogen kit is prefilled 
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with poly A carrier RNA fragments of 100-1000 bases. This RNA accounts for 5 µg 
per 200 µL sample (equivalent to 25 ng/µL) and likely exceeds the amount of isolated 
nucleic acid from samples. The RTP Extraction tube contained preformulated solid 
lysis reagent, lytic enzyme, Proteinase K to mix with the buffer at a particular pH. 
According to the extraction kit manual, the carrier RNA helps to stabilise the nucleic 
acids and enhance DNA adsorption to the membrane in the RTA Spin Filter. An 
analytical study shows that the presented method could improve the extraction 
efficiency of the small amount of DNA by five times compared to the extraction 
without the carrier RNA (Thain et al., 2009). Furthermore, the DNA extracted from 
spiked whole blood or serum samples may also contain a significant nucleic acid 
originated from the biological samples; thus, it is not a pure form of fungal genomic 
DNA. In these conditions, the measurement of nucleic acid concentration using a 
spectrophotometer does not reflect the functional quantity of genomic DNA isolation 
using the RTP Pathogen Kit method. Therefore, in this investigation, it was not suitable 
to analyse the DNA products from the optimisation experiments from the 
spectrophotometer results. 
Real-time PCR detection of fungal DNA was evaluated for the three different 
types of spiked samples spanned from 107 cells to 1 cell (approximately from 109 
CFU/mL to 102 CFU/mL equivalent). A consistent sensitivity of extraction was noted 
between the spiked cells in serum and whole blood samples. However, the detection 
limit of fungal DNA was increased by tenfold for the spiked saline sample. Although 
all the spiked samples used contained the recommended amount of starting material 
(107 cells), the yeast cells in the saline were the most efficient to be processed in every 
step. A small part of the filter membrane was noticed to clog the RTA spin column 
which may have led to the reduction of nucleic acid binding to the filter membrane. 
This suggestion for a significant accidental loss of nucleic acid particularly at the low 
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quantity of spiked yeast cells in the high protein containing samples. All 
recommendations were followed including increasing the cell lysis time and 
centrifugations speed and time during washing steps to remove the cellular 
contaminants. The necessary step was also adhered with a vigorous mixing of the cells 
in the buffer to ensure no cell clumps before subject the sample to the RTA spin 
column. The estimation of target DNA copy number from the Pan-Fungal assay 
calibration curve showed more than a one hundred-fold loss of genomic DNA 
(assuming 100% extraction efficiency) compared to the theoretical cell number, 
through the process of the DNA isolation by the RTP Pathogen Kit method. The target 
region presents in the tandem repetitive (50-100 copies per haploid genome) of the 
fungal rDNA gene cluster (Halliday et al., 2015; White et al., 2010).  
The use of other commercial DNA extraction kits with differently available cell 
lysis instrument was advocated in this investigation in order to achieve standardised 
methods and reagents. However, the different DNA extraction methods demonstrated 
large discrepancies of the fungal DNA detection by the Pan-Fungal real-time PCR, 
highlighting the importance of the extraction step in nucleic acid-based fungal 
diagnostics. There was almost a hundred-fold difference in DNA recovery levels from 
the spiked whole blood between the RTP pathogen and Wizard Genomics methods. 
Reproducibly low sensitivity of detection for the DNA products from the Wizard 
Genomics suggested the protocol is not flexible to integrate the process with the 
mechanical cell lysis steps in this study. Mini-pestle cell homogeniser using the hand-
held instrument (BioMasher) was not able to demonstrate reproducible DNA yield by 
almost 50% difference measured between the duplicate samples although one of the 
samples (Mini-pestle + kit, tube 1) produced 70% more DNA yields than another lysis 
method (Table 5.5). Inconsistency pressure or force from the human handling the 
instrument between the samples contribute to this error. The poor DNA yields were 
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noticed from the spiked sample with consistent loss of DNA concentration over the 
first sample dilution. The DNA yields from the amount of yeast (107 cells) spiked in 
whole blood and saline were not reproducible and significantly different (Table 5.6). 
A far less efficient method of extraction was demonstrated using ZymoBIOMICSÔ  kit 
with a minimal amount of DNA recovered from C. albicans 107 cells in saline samples. 
These methods are not practical for use in a clinical microbiology laboratory, where 
many samples must be processed for fungal DNA and where cross-contamination of 
samples must be avoided.  
In summary, the yeast DNA isolation method using RTP pathogen kit in 
combination with the bead-beating cell lysis step was used as an optimum method of 
DNA isolation. An effective method should produce maximal fungal DNA yield and 
purity in the absence of carryover contaminants that can significantly inhibit PCR 
amplification (Ali et al., 2017). Although the method is not exceptional from the 
inhibitor issues, it outperformed the other methods in extracting DNA of C. albicans 











The aim of this research is to develop an isothermal fungal biomarker detection 
technique based on MNAzymes for detection of fungi frequently associated with 
human fungal infection. MNAzymes that were successfully engineered from natural 
DNA enzymes further increase the practically of this non-protein class of enzyme 
(Mokany et al., 2010). Naturally, DNAzymes are capable to cleave a RNA sequence 
(RNA substrate) after it specifically binds to the enzymes (Santoro & Joyce, 1997). 
Taking advantage of deoxyribonucleic acid enzymes, Mokany et al., 2010 had 
elegantly engineered two types of optimised MNAzyme, originally derived from 10 – 
23 and 8 – 17 DNAzymes. The component of the MNAzyme is presented in the 
Introduction; Figure 1.7. MNAzymes are naturally inactive until they hybridize to both 
a specific target sequence (known as the Assembly Facilitator) and a hydrolysable 
oligonucleotide probe (the substrate). As illustrated in Figure 1.7 the substrate is 
doubly labelled with a fluorophore and a quencher molecule and, upon hydrolysis, it 
provides a measurable output signal that can be used to quantify the amount of target 
DNA present in a sample. The use of differently labelled substrates allows the 
development of multiplex MNAzyme-based assays. Furthermore, MNAzymes can be 
coupled with a qPCR approach that has proven to be useful strategy for multiplex 
detections and quantifications of multiples targets (Mokany et al., 2013).   
 Current epidemiological trends suggest that IFIs claim the lives of around 1.5 
million people every year and Candida species are recognised among the common 
fungal pathogens and a significant cause of nosocomial infections (Wisplinghoff et al., 
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2014; Brown et al., 2012).  As a pilot study, an MNAzyme system was designed to 
identify a pan-fungal DNA biomarker sequence present in all pathogenic fungal 
species tested. The pan-fungal DNA biomarker is part of the D1/D2 domain within the 
rDNA locus.  As yet, this technique is still laboratory based, but the aim in the future 
is to develop multiplex assay-based detection kits that can be taken into the field to 
assess IFIs.  
 
6.2 Experimental Results  
 
6.2.1 Selection of DNA biomarker target sequences 
Loci of primers ITS4 and LR1 were assessed and found to be conserved in all the 
pathogenic fungi species (Figure 6.1). Primer ITS4 is a reverse primer that universally 
amplifies the ITS2 region in combination with a forward primer, either with ITS3 or 
ITS1. The conserved sequences around the 5’end and 3’end of the whole ITS4 and 
LR1 provide a suitable length of the target sequence up to 43 bp. The query sequence 
was searched in BLAST nucleotide database and resulted in 100% homology hits for 
the fungal species in the top 100 subject sequences. 
Analysis of the pan-fungal DNA biomarker LS266 was found with sequence 
variation in Fusarium solani strains and hindered the sequence to be used as a target 
sequence for fungal detection in MNAzyme assay. Moreover, two points of single 
nucleotide changes were observed at the 5’ and 3’ end of LS266 sequences of the F. 
solani strains and in several Candida species strains. This limits the possibility of the 
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Aspergillus candidus      GCATCGATGA A-GAACGCAG CGAAATGCGA T--AACTAAT GTGAATTGCA GAATTCAGTG AA--TCATCG AGTCTTTGAA CGCAC-AT-T GCGCCCCCTG GT--ATTCCG  
A. terreus                GCATCGATGA A-GAACGCAG CGAAATGCGA T--AACTAAT GTGAATTGCA GAATTCAGTG AA--TCATCG AGTCTTTGAA CGCAC-AT-T GCGCCCCCTG GT--ATTCCG  
A. niger                  GCATCGATGA A-GAACGCAG CGAAATGCGA T--AACTAAT GTGAATTGCA GAATTCAGTG AA--TCATCG AGTCTTTGAA CGCAC-AT-T GCGCCCCCTG GT--ATTCCG  
A. fumigatus              GCATCGATGA A-GAACGCAG CGAAATGCGA T--AAGTAAT GTGAATTGCA GAATTCAGTG AA--TCATCG AGTCTTTGAA CGCAC-AT-T GCGCCCCCTG GT--ATTCCG  
A. flavus                 GCATCGATGA A-GAACGCAG CGAAATGCGA T--AACTAGT GTGAATTGCA GAATTCCGTG AA--TCATCG AGTCTTTGAA CGCAC-AT-T GCGCCCCCTG GT--ATTCCG  
A. nidulans               GCATCGATGA A-GAACGCAG CGAACTGCGA T--AAGTAAT GTGAATTGCA GAATTCAGTG AA--TCATCG AGTCTTTGAA CGCAC-AT-T GCGCCCCCTG GC--ATTCCG  
Fusarium oxysporum        GCATCGATGA A-GAACGCAG CAAAATGCGA T--AAGTAAT GTGAATTGCA GAATTCAGTG AA--TCATCG AATCTTTGAA CGCAC-AT-T GCGCCCGCCA GT--ATTCTG  
Rhizopus oryzae           GCATCGATGA A-GAACGTAG CAAAGTGCGA T--AACTAGT GTGAATTGCA TA-TTCAGTG AA--TCATCG AGTCTTTGAA CGCAG-CT-T GCACTCTATG GTT-TTTCTA  
Cryptococcus neoformans   GCATCGATGA A-GAACGCAG CGAAATGCGA T--AAGTAAT GTGAATTGCA GAATTCAGTG AA--TCATCG AATCTTTGAA CGCAA-CT-T GCGCCCTTTG GT--ATTCCG  
Absidia corymbifera       GCATCGATGA A-GAACGCAG CAAAGTGCGA T--AATTATT GCGACTTGCA TT-CATAGTG AA--TCATCG AGTTCTTGAA CGCAT-CT-T GCGCCTAGTA GTC-AATCTA --//-- 
C. glabrata               GCATCGATGA A-GAACGCAG CGAAATGCGA T--ACGTAAT GTGAATTGCA GAATTCCGTG AA--TCATCG AATCTTTGAA CGCAC-AT-T GCGCCCTCTG GT--ATTCCG  
C. parapsilosis           GCATCGATGA A-GAACGCAG CGAAATGCGA T--AAGTAAT ATGAATTGCA GATATTCGTG AA--TCATCG AATCTTTGAA CGCAC-AT-T GCGCCCTTTG GT--ATTCCA  
C. albicans               GCATCGATGA A-GAACGCAG CGAAATGCGA T--ACGTAAT ATGAATTGCA GATATTCGTG AA--TCATCG AATCTTTGAA CGCAC-AT-T GCGCCCTCTG GT--ATTCCG  
C. dubliniensis           GCATCGATGA A-GAACGCAG CGAAATGCGA T--ACGTAAT ATGAATTGCA GATATTCGTG AA--TCATCG AATCTTTGAA CGCAC-AT-T GCGCCCTCTG GT--ATTCCG  
C. tropicalis             GCATCGATGA A-GAGCGCAG CGAAATGCGA T--ACCTAGT GTGAATTGCA GCCATC-GTC AA--TCATCG AGTTCTTGTT CGCAC-AT-T GCGCC--TCG GCCCATTCCG  
C. krusei                 GCATCGATGA A-GAACGCAG CGAAATGCGA T--ACCTAGT GTGAATTGCA GCCATC-GTG AA--TCATCG AGTTCTTGAA CGCAC-AT-T GCGCCCCTCG GC--ATTCCG  
C. guilliermondii         GCATCGATGA A-GAACGCAG CGAAATGCGA T--AAGTAAT ATGAATTGCA GATTTTCGTG AA--TCATCG AATCTTTGAA CGCAC-AT-T GCGCCCTCTG GT--ATTCCA  
C. auris                  GCATCGATGA A-GAACGCAG CGAAATGCGA T--ACGTAGT ATGACTTGCA GA----CGTG AA--TCATCG AATCTTTGAA CGCAC-AT-T --GCGCCTTG G---------  
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Aspergillus candidus      ---------- -A---CCTCG G---ATCAGG TAGGGATACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACCGGGA TTGCCTC--- 
A. terreus                ---------- -A---CCTCG G---ATCAGG TAGGGATACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACCGGGA TTGCCTC---  
A. niger                  ---------- -A---CCTCG G---ATCAGG TAGGGATACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACCGGGA TTGCCTC---  
A. fumigatus              ---------- -A---CCTCG G---ATCAGG TAGGGATACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACAGGGA TTGCCTC---  
A. flavus                 ---------- -A---CCTCG G---ATCAGG TAGGGATACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACCGGGA TTGCCTC---  
A. nidulans               ---------- -A---CCTCG G---ATCAGG TAGGGATACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACCGGGA TTGCCTC---  
Fusarium oxysporum        ---------- -A---CCTCG G---ATCAGG TAGGAATACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACAGGGA TTGCCCT--- 
Rhizopus oryzae           ---------- ---------- ---------- ------TACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA ATAACAATGA TTTCCCT---  
Cryptococcus neoformans   ---------- -A---CCTCA A---ATCAGG TAGGGCTACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAAC----- ---------- 
Absidia corymbifera       CATTT----- --AGATCTGA A---ATCAAC TGAGACCACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAAC----- ---------- 
C. glabrata               ---------- ---GACCTCA A---ATCAGG TAGGGTTACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACTGGGA TTGCCTT---  
C. parapsilosis           ---------- --------CA A---ATCAGG TAGGACTACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACAGGGA TTGCCTT---  
C. albicans               ---------- -----CCTCA A---ATCAGG TAGGACTACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACAGGGA TTGCCTT---  
C. dubliniensis           ---------- -----CCTCA A---ATCAGG TAGGACTACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACAGGGA TTGCCTT--- 
C. tropicalis             ---------- -A---CCTCA A----TCAGG TAGGACTACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACAGGGA TTGCCTT--- 
C. krusei                 ---------- -A---CCTCA A---ATCAGG TAGGAATACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACAGGGA TTGCCTC---  
C. guilliermondii         ---------- -A---CCTCA A---ATCAGG TAGGAATACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACAGGGA TTGCCTT---  
C. auris                  ---------- -----CCTCA A---ATCAGG TAGGACTACC CGCTGAACT- TAAGCATATC AATAAGCGGA GGAAAAGAAA CCAACAGGGA TTGCCTT--- 
 
Figure 6. 1 Multiple-sequence alignment of the partial ITS and LSU regions of the fungal rDNA sequence. The conserved region around 
primers ITS4 and LR1 sequences (in red) for 43 nucleotides pan-fungal AF (AF-ITS4LR1).  
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6.2.2 Basic components of MNAzyme for fungal detection 
The MNAzyme Pan-Fungal assay was designed based on the universal partial enzymes 
and nucleic acid substrate (probe) that were developed by Mokany, Bone, Young, et 
al., (2010) (Figure 6.2). The Partzymes were derived from the 10 – 23 DNAzyme, 
which are single strands of deoxyribozymes comprising of a catalytic core of 15 
deoxynucleotides, flanked by two specific substrate binding arms of seven to eight 
deoxynucleotides each (Santoro & Joyce, 1997). The substrate is bound through 
Watson-Crick base pairing against substrate binding arms and is cleaved at a specific 
site with RNA bases on the substrate. The substrate is a dual-labelled probe that 
generates a fluorescent signal upon the cleavage and can be detected and monitored in 
real-time.  
In this study, the MNAzyme Pan-Fungal assay developed to detect fungal DNA 
biomarker as an AF or input sequence. The sequences of Partzymes were altered at the 
sensor arms to match the target sequence of interest and each constituent arrangement 
on the sequences has been detailed in Table 6.1. Although, the current assay would 
need further developing to incorporate with amplification steps, it may provide a 
concrete platform for the detection of fungal species in isothermal reaction. In the 
technical aspect, the 3’end of each Partzyme was phosphorylated to prevent it from 
being consumed by some 3’ exonucleases and to block extension by DNA polymerases 




Figure 6. 2  Structural components of the MNAzyme Pan-Fungal assay. The 
nucleotide sequence of Partzyme A (in blue) is present in a 5’ to 3’ direction, composed 
of a sensor binding domain (sensor arm), partial catalytic core and substrate binding 
domain (substrate arm) to hybridise towards 5’end of substrate (in yellow). 
Meanwhile, the nucleotide sequence of Partzyme B (in green) is present in a 5’ to 3’ 
direction composed of a substrate binding domain (substrate arm), partial catalytic core 
and sensor binding domain (sensor arm) portion capable of binding to the same AF (in 
grey) adjacent to the Partzyme A sensor arm. The Partzymes A and B were 
phosphorylated (P) at 3’end. The nucleic acid substrate was labelled with fluorophore 









Table 6. 1 List of sequences used in MNAzyme assay for fungal detection.  
 




ITS4LR1A/3-P  GCTGAACTTAAGCATATCAAT 




ITS4LR1B/3-P CGGTTGGTGA GGCTAGCT 
AAGCGGAGGAAAAGAAACCAAC-P 
 







*Nucleotides underlined are partial catalytic core sequences and those in italics form part of the 
substrate-binding arm. The “-P” at the end of the partzyme sequence indicates that the 
oligonucleotide was 3’ phosphorylated. RNA nucleotides (-g and -u) represents Guanine and Uracil 
present in the substrate sequence; JOE, 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluoresceine; 
BHQ1, Black Hole Quencher 1 
 
 
6.2.3 Optimisations of MNAzyme assay 
Several paramount parameters such as temperature, concentration of Partzymes and 
concentration of metal ion cofactor in the reactions were optimised to produce signals 
for the highest enzymatic activity.  
 
6.2.3.1  Optimisation of isothermal temperature 
Catalytic activity of the MNAzyme Pan-Fungal assay was assessed at various 
temperatures to determine the turnover (Figure 6.3). A series of experiments tested the 
temperatures at 30°C, 35°C, 40°C, 45°C, 50°C, 52°C, 55°C, 57°C, 59°C and 64°C, 
using isothermal direct detection method. The Kobs values were obtained by performing 
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a fit a hyperbolic equation to the fluorescence versus time data using Prism Version 
7.0 statistical package (GraphPad Software) The enzymatic activity measured shown 
increased the substrate catalytic rate dramatically by almost 10 times from 40°C to 
45°C and further increased to the highest point at 50°C. The data shown the activity 




Figure 6. 3 Enzymatic activity against different isothermal temperature. The 
MNAzyme Pan-Fungal assay was tested at various temperature to determine the 
catalytic rate. The optimal temperature for cleavage of the 19 nucleotides substrate in 
this assay is 50°C with the cleavage rate at 3.2 x 10-1 min-1. The reactions containing 






























6.2.3.2  Optimisation of Partzyme concentration 
The purpose of this optimisation was to achieve measurable fluorescence signal from 
the starting time against the negative control (reaction without AF). Initially, enzyme 
activity was observed too high from the starting point as the concentration of 
Partzymes (0.2 µM) was adapted from Mokany, Bone, Young, et al., (2010) into our 
MNAzyme assay. It could be thought that different set of nucleic acid substrate, design 
and constituents of Partzyme used in the MNAzyme, as well as level of sensitivity of 
the real-time PCR machine may contributes to this factor. In the experiment conducted, 
high signals readout, at approximately two fluorescence a.u., appeared at the first cycle 
of reaction although, both Partzyme A and B final concentrations were reduced to 0.1 
µM (Figure 6.4, panel A).  
The result testifies that, the reaction Partzymes concentration of 0.05 µM 
started the substrate hydrolysis at the same point as the negative control despite of 
abundance of AF (Figure 6.4, panel B). There was no increased signal over the time 
for the reactions with 0.01 µM and 0.005 µM. The Partzyme concentration in the Pan-












Optimisation of Partzyme Concentrations in MNAzyme Pan-Fungal Assay 





Figure 6. 4 The effect of the Partzyme concentrations towards enzyme activity 
determined at the first signal point. Panel A) Higher rate of substrate hydrolysis in 
the reaction with 0.1 µM partzyme compared to 0.05 µM partzyme in the first 2.5 
minutes. No activity in the reaction with 0.01 µM and 0.005 µM Partzymes (No AF). 
Panel B) Fluorescence changes against the negative control (No AF) at the starting 
data collection point (0.6 minute) for the reactions with 0.05 µM and 0.1 µM Partzyme 














































6.2.3.3  Optimisation of MgCl2 concentration 
The concentration of MgCl2 was optimised for the highest and stable enzymatic 
activity possible in the MNAzyme Pan-Fungal assay. The concentration of MgCl2 is 
generally higher than in other qPCR protocols since the metal ion cofactor is vital for 
the MNAzyme’s catalytic activity. In this experiment, 8 mM and 12 mM of MgCl2 
shows lower catalytic activities compared to reactions with 6 mM and 10 mM MgCl2 
before the signals reached plateau (Figure 6.5, i). The reaction with 10 mM MgCl2 
exhibited the highest fluorescence signal output achieved by catalytic activity and the 
signal surpassing the highest concentration (12 mM MgCl2) used in this experiment. It 
is reported that 8 mM is suitable for a single target reactions and may be increased to 
10 mM for multiplex reactions detecting three or more targets (Mokany et al., 2013). 
In any condition with absence of magnesium, there was no evidence of exponential 
accumulation of cleaved substrate (Figure 6.5, ii). Interestingly, constant high intensity 
of the fluorescence signals from the substrate (with no activity) were noted although 














Figure 6. 5 Effect of MgCl2 and different concentrations of MgCl2 on 
MNAzyme cleavage activity. The isothermal detection of the pan-fungal AF in 
various concentrations of magnesium in the MNAzyme assay. The detection was 
performed; i) in different concentrations of MgCl2 (6 mM, 8 mM, 10 mM and 12 mM) 
and negative control (no AF) represented as solid lines; ii) in the absence of MgCl2 
either in the reaction with complete parts of MNAzyme or incomplete part of 
MNAzyme (No Partzyme A, No Partzyme B) represented as dotted lines. In all cases, 
the MNAzyme reactions contained 0.2 µM of the pan-fungal AF (AF ITS4LR) except 
of the negative control (No AF ITS4LR1) and the background reaction which only 
contained dual-labelled probe in the PCR buffer.  
 
 
In a separate experiment, higher concentrations of MgCl2 in the reaction were 
tested to observe their effect towards the MNAzyme activity. In the original 
MNAzyme studies, various MgCl2 concentrations were used and can be categorised 
according to the experiments performed. The concentration of MgCl2 at 8 mM was 
used for detection in real-time PCR amplification; 25 mM for isothermal direct 
detection protocol and; 50 mM in the kinetics of MNAzymes catalysis experiments 
(Mokany et al., 2013, 2010). In the isothermal direct detection method of the 
























No MgCl & No Partzyme A
No MgCl & No Partzyme B
No MgCl: Complete
components
Substrate & Buffer only
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output was in the reaction with 10 mM MgCl2 but, it has wider error bar between its 
replicates (Figure 6.6). The reactions with MgCl2 tested at 25 mM and 50 mM yield 





Figure 6. 6 The MNAzyme Pan-Fungal activity at high MgCl2 concentrations. 
The mean of the fluorescence signals until the reaction plateaus with error bars depict 
SD between the triplicates in the MNAzyme Pan-Fungal assay with 10 mM, 25 mM 
and, 50 mM of MgCl2. All reactions were tested in 50°C with constant concentrations 
of enzyme, 0.05 µM; substrate, 0.2 µM and pan-fungal AF, 0.2 µM.  
 
 
6.2.4 Specificity testing of MNAzyme assay for detection of the synthetic AF 
sequence  
The purpose of this experiment was to assess the specificity of the MNAzyme Pan-
Fungal assay towards any possible detection of inaccurate target nucleic acids. The 
experiment was conducted in the various reaction controls. The direct detection of the 
pan-fungal AF as the positive control was compared against six different control 




















ITS4LR1mut) and Control 2 with a totally different AF sequence (AF-RO5). The pan-
fungal AF was also tested for detection in the reaction with the mutated partial catalytic 
core sequence of the Partzyme A (ITS4LR1A/3mut) represented as a Control 3 and 
mutated partial catalytic core sequence of the Partzyme B (ITS4LR1B/3mut) 
represented as a Control 4. The Pan-Fungal assay was also tested with incomplete 
components such as without one of the Partzymes; no Partzyme A for Control 5 and, 
no Partzyme B for Control 6. As a negative control, the reaction with no AF sequence 
(No AF) was included in the reaction. All controls were tested in an optimum 
MNAzyme reactions conditions described in the Materials and Methods chapter.  
The results of which are shown in Figure 6.7, the assay performance is not 
compromised, even with one nucleotide change in the sequence of the AF. The assay 
results in an increase intensity of fluorescence signal (up to six fluorescence a.u.), 
demonstrating cleavage activity, when only all correct components are present in the 
system. In the absence of any component that prevents the formation of complete 
MNAzyme systems, there is no catalytic activity to cleave the substrates, and therefore 
no fluorescence signals can be observed. This is consistent with experiments 
performed by Mokany, Bone, Young, et al., (2010), reported no cleavage activity by 
MNAzyme Mz2 in the reactions conditions without one of the Partzymes, or a different 
sequence of an AF or with a point mutation in one of the partial catalytic domains. This 
characteristic is important for specific detection of the fungal DNA biomarkers and 













Figure 6. 7 Specificity test of MNAzyme Pan-Fungal assay in six reaction 
controls. The positive control contained complete and correct components of 
MNAzyme, Partzyme A (ITS4LR1A/3-P), Partzyme B (ITS4LR1B/3-P) and AF (AF-
ITS4LR1), and a negative control contained Partzyme A (ITS4LR1A/3-P) and B 
(ITS4LR1B/3-P) without AF. Control 1: Partzyme A (ITS4LR1A/3-P), Partzyme B 
(ITS4LR1B/3-P) with mutated AF (AF-ITS4LR1mut); Control 2: A (ITS4LR1A/3-
P) and Partzyme B (ITS4LR1B/3-P) with totally noncomplementary sequence of AF 
(AF-RO5); Control 3: Partzyme B (ITS4LR1B/3) and AF (AF-ITS4LR1) with 
mutated Partzyme A (ITS4LR1A/3mut-P); Control 4: Partzyme A (ITS4LR1A/3-P) 
and AF (AF-ITS4LR1) with mutated Partzyme B (ITS4LR1B/3mut); Control 5: 
Partzyme A (ITS4LR1A/3-P) only with AF (AF-ITS4LR1); Control 6: Partzyme B 

























Positive Control Negative Control
Control 1: Mutated AF Control 2: Different AF
Control 3: Mutated Partzyme A Control 4: Mutated Partzyme B
Control 5: No Partzyme B Control 6: No Partzyme A
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6.2.5 Limit of Detection of an Assembly Facilitator 
  
A limit of detection experiment was performed to determine the lowest concentration 
of AF detectable by the MNAzyme Pan-Fungal assay. Three independent experiments 
were performed, and each reaction was carried out in triplicate and monitored in real 
time at 36-second intervals for an hour at 52°C. Isothermal direct detection method 
was prepared in 25 µL total reaction under optimum conditions. Reactions contained 
a range of pan-fungal AF (AF-ITS4LR1) concentrations (0.2 µM, 0.1 µM, 0.75 µM, 
0.025 µM, 0.01 µM, 0.0075 µM, 0.0025 µM, 0.001 µM and 0.0005 µM) and no AF 
(negative control). Reactions contained the optimal concentrations that were 
determined previously, with Partzyme A and B concentrations at 0.05 µM and MgCl2 
at 10 mM. The assay limit of detection was determined by reducing the concentration 
of the AF until no accumulation of fluorescence signal was detected. Consistent 
outcomes were obtained throughout the experiments, with the lowest concentration of 
AF detectable at 0.0025 µM (Figure 6.8). This equals to approximately 62.5 fmol or 
3.76 ´ 1010 copies of the AF nucleic acid sequence in a reaction. Further lower 
concentrations from 0.001 µM and 0.0005 µM lead to the MNAzyme becoming 
catalytically inactive due to lack of target sequence in the assay. An increase in 
fluorescence, demonstrated cleavage activity, which observed and compared with the 
signal of the negative control reaction. Consistently in the experiments performed, 0.75 











Figure 6. 8 Limit of detection of the MNAzyme Pan-Fungal assay. Test 
reactions contained Partzyme A (ITS4LR1/A-3), Partzyme B (ITS4LR1/B-3) and, 
substrate (Sub3-JB), with different concentrations of target sequence AF-ITS4LR1 
(0.2 µM, 0.1 µM, 0.75 µM, 0.025 µM, 0.01 µM, 0.0075 µM, 0.0025 µM, 0.001 µM 
and 0.0005 µM) and the negative control with no AF (No AF-ITS4LR1).   
 
 
6.2.6 In vitro detection of the C. albicans DNA in an isothermal MNAzyme Pan-
Fungal assay 
This experiment was performed to prove the concept that MNAzymes could produce 
significant catalytic activity by detection of C. albicans genomic DNA. In this 
experiment, the input was an amplified C. albicans double-stranded DNA containing 
the pan-fungal biomarker sequence. Prior to the detection in the MNAzyme reaction, 
the amplicon was allowed to denature to provide an access to the sensor binding 
domain towards the complementary target sequence. The total length of the amplicon 
from the primer sites was 84 bp, compared to the synthetic AF sequence which is only 
43 bp that fits perfectly against the sensor binding arms. From the results obtained, an 
increase in fluorescence signal can be seen in the reactions with the C. albicans 































was achieved as the enzymes catalysed all substrates completely (Figure 6.9). As 
expected, the fluorescence signal in the positive control reaction, containing a synthetic 
AF sequence, rapidly levelled off within the first 10 minutes, demonstrating a quick 
cleavage activity.  
The experimental demonstration for detection of C. albicans double-stranded 
DNA in the isothermal MNAzyme direct detection method was used the same molar 
concentration (0.2 µM) as to the concentration of synthetic sequence of an AF (Positive 
Control) in a 25 µL reaction. The C. albicans target DNA used was a thousand-fold 
higher copy number (3.43 ´ 1012 copies) than the AF sequence; however, the reaction 
rate was observed to be slower compared to the AF reaction. The assay catalytic rate, 
Kobs obtained in the reaction with the target amplicon was 3.6 x 10-2 min-1 meanwhile, 
the positive control reaction had a higher rate of 2.1 x 10-1 min-1. This result suggests 
that the double-stranded DNA renatured conforming to the base pairing arrangement 
after the high temperature disrupts the hydrogen bonds between the bases. The 
complexity of the double-stranded DNA and the complementary of the target sequence 
to the Partzymes’ sensor arms to hybridise could influence the enzymes catalytic 
activity. Further investigations could be performed to improve the experimental results 
by incorporating the amplification step into the MNAzyme assay for real-time 










Figure 6. 9 MNAzyme isothermal detection of C. albicans genomic DNA. 
Signals of cleavage activity for detection of an amplified C. albicans DNA in the 
MNAzyme Pan-Fungal assay. The experiment contained the synthetic target AF 
sequence (AF-ITS4LR1) at 0.2 µM as a positive control (PC) and the reaction with no 






































 PC (AF: ITS4LR1)
 NC (No AF)
 DNA amplicon
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6.2.7 Assessing the MNAzyme Pan-Fungal assay Kinetic Activity 
 
Kinetic analysis of the MNAzyme Pan-Fungal assay was initiated by converting the 
fluorescence data, in arbitrary units, into reaction velocities. To do so, a standard curve 
graph was plotted for a range of concentrations of the processed substrate (1, 0.5, 0.25, 
0.125, 0.0625 and 0.00311 µM of Sub3-JB ½). The processed substrate in this study 
was a half probe sequence from the 5’ end labelled with the JOE reporter dye (the 
sequence in Materials and Methods chapter). An initial fluorescence signal detected in 
various substrate concentrations, was subjected to linear formula generated, y = 
51.067(x) – 3.0966; correlation coefficient, R2= 0.9926 to assess the concentration of 
the substrate that was successfully cleaved at the first 18 seconds by the enzymes 
(Figure 6.10). The values obtained were used to calculate the gradient to gather enzyme 
activity values for different substrate concentrations used in the assay (Table 6.2).   
 
 
Figure 6. 10 Standard curve: total cleaved substrate. Standard curve generated 
from different concentrations of the cleaved substrate (Subs3-JB ½) that emitted 



















y = 51.067x - 3.0966
R² = 0.9926
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 Test 1 Test 2 Test 3 Average ± SD 
1.00 43.17 43.81 43.90 43.63 ± 0.40 
0.75  41.56 41.73 41.75 41.68 ± 0.10 
0.50  38.30 38.69 37.75 38.25 ± 0.48 
0.25  30.75 30.61 31.19 30.85 ± 0.30 
0.20  28.18 27.08 27.73 27.66 ± 0.55 
0.15  23.97 24.32 24.07 24.12 ± 0.18 
0.10  20.25 20.37 18.88 19.83 ± 0.83 
 
 
Enzyme kinetic analysis was performed to determine the enzyme's Km and Vmax 
for the MNAzyme Pan-Fungal assay (Table 6.3 and Figure 6.11). In definition, Km is 
the substrate concentration needed to achieve a half-maximum enzyme velocity. 
Whereas Vmax is the maximum enzyme velocity, it is the velocity of the enzyme 
extrapolated to very high concentrations of substrate, so its value is almost always 
higher than any velocity measured in the experiment. In fact, Vmax is only approached 
but never attained. The Vmax is determined by the total enzyme concentration (Et) in a 
reaction and the rate at which the enzyme can convert substrate to product (Kcat). 




Table 6. 3 Michaelis-Menten analysis of Vmax and Km for the MNAzyme Pan-
Fungal assay. It is also noted that the P value from the variation among triplicates is 
larger than 0.05 and suggests that the data was suitable to fit the model (values in bold). 
Table result obtained from Prism statistical pack version 7, GraphPad Software Inc.   
 
 Enzyme Activity 
Michaelis-Menten 
Best-fit values  
Vmax 50.62 
Km 0.1615 
Std. Error  
Vmax 0.3388 
Km 0.003411 
95% CI (profile likelihood)  
Vmax 49.91 to 51.33 
Km 0.1545 to 0.1688 
Goodness of Fit  
Degrees of Freedom 19 
R squared 0.9971 
Sum of Squares 4.274 
Sy.x 0.4743 
Replicates test for lack of fit  
SD replicates 0.4636 
SD lack of fit 0.5030 
Discrepancy (F) 1.177 
P value 0.3686 
Evidence of inadequate model? No 
Constraints  
Km Km > 0 
Number of points  
# of X values 21 







Figure 6. 11 Michaelis-Menten analysis for the MNAzyme Pan-Fungal assay. 
Values of the maximum enzyme velocity, Vmax = 50.62 µM per second and the affinity 
of the enzyme for the substrate assessed by the Michaelis-Menten constant, Km= 
0.1615 µM. The error bars represent the SD of the data from three independent 
experiments. 
 
The turnover was compared by measuring the kcat. The value for the Pan-Fungal 
assay was determined (kcat = 16.87 min-1) by constraining the enzyme site present to a 
constant value (Et = 0.05), and graph generated was identical to the curve defined by 
the Michaelis-Menten model (Figure 6.11). Kcat and km values for the MNAzyme Pan-
Fungal were 16.87 min-1 and 0.1615 µM, respectively. Therefore, the catalytic efficacy 
























-1 Vmax = 50.62
Km = 0.1615
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Table 6. 4 Turnover number, Kcat value by specifying the concentration of 
total enzyme (Et) of the MNAzyme Pan-Fungal assay. Table result obtained from 
Prism GraphPad statistical pack.  
 
 Enzyme Activity 
kcat  
Best-fit values  
Et = 0.05000 
kcat 1012 
Km 0.1615 
Vmax = 50.62 
Std. Error  
kcat 6.776 
Km 0.003411 
95% CI (profile likelihood)  
kcat 998.2 to 1027 
Km 0.1545 to 0.1688 
Goodness of Fit  
Degrees of Freedom 19 
R squared 0.9971 
Sum of Squares 4.274 
Sy.x 0.4743 
Replicates test for lack of fit  
SD replicates 0.4636 
SD lack of fit 0.5030 
Discrepancy (F) 1.177 
P value 0.3686 
Evidence of inadequate model? No 
Constraints  
Et Et = 0.05 
Number of points  
# of X values 21 










The screening for the target sequence in the MNAzymes assay was based on 
comparative sequence analysis. The engineering of the MNAzymes input AF sequence 
is challenging with the requirement of a long target sequence. The MNAzyme fungal 
DNA biomarkers were screened for the length of ~40 bp and examined for their 
specificity before it could be adapted as an AF. The practical analysis strategy applied 
for searching of a target sequence examined from the closely positioned universal 
fungal primers and, found the combined primers ITS4 and LR1 as a pan-fungal AF in 
the assay. Among other loci within the regions that were examined are PCR primer 
sites LS266 and NL4b, however these were not ideal to be used as an AF. In contrast, 
the standard PCR primers and specific probe-based detection sequence are 20-25 bp 
with either two or three levels of the specificity determinants derived from the 
recognition of two PCR primers and/or one target-specific probe hybridisation site. 
Meanwhile, a novel MNAzyme qPCR assay relies on the synergistic actions of 
amplification and detection with four levels of specificity originated from two primer 
sites and two Partzymes target-binding site on the AF or amplified products (Mokany 
et al., 2013). The pan-fungal AF sequence is a specific target for fungal detection, 
while other components involved in the MNAzyme system contribute to its function 
as a probe for the specific key. 
The nucleic acid sensing machineries of the MNAzymes are composed of 
multiple, nucleic acid oligonucleotides which are catalytically active in the presence 
of the target sequences. This class of enzyme has been modified from a single 
molecular DNAzymes to increase enzyme functionality and versatility (Mokany et al., 
2010). The DNAzymes split at the catalytic core (domains required for enzyme 
activity) into two parts and form a partial catalytic core (inactive state of enzyme). 
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Briefly, the MNAzymes are composed of oligonucleotide partzymes, each of which 
contain a partial catalytic core flanked by a substrate-binding domain (substrate arm) 
and sensor-binding domain (sensor arm) which can be designed to complement the 
specific target AF. In the events of the target detection, the sensor-arms bind to the AF 
sequence and align adjacently which re-unite the catalytic core.  Once assembled, the 
catalytic core becomes active and capable of cleaving a nucleic acid substrate in 
between of the fluorophore and quencher labels to produce a fluorescent signal 
detected in the real-time PCR instrument. The difference in nucleotide positions 
splitting the whole core has shown a substantial impact on the enzyme activity 
(Mokany et al., 2010). In this study, the MNAzyme Pan-Fungal assay was employed 
the optimum design of partial catalytic core which was divided between T8 and A9 of 
the DNAzyme 10–23 enzymatic core. MNAzyme features increase the functionality 
of nucleic acid enzymes enabling it to be incorporated with any specific input, which 
in turn simplifies the development of biosensors. The catalytic active MNAzyme 
modifies the hybridised substrate, thus generating an enzymatically amplified output 
signal. 
Numerous different substrates available could be used to design multiple or 
different target sequences, and this has tremendously increased the practicality of 
MNAzyme technology. The qPCR assay that use TaqMan® hydrolysis probe and PCR 
primers must be designed and optimised the target probe for detection of the amplified 
products in each of the new assay. The development of the multiplex TaqMan-based 
PCR assay for the detection of two or more targets are complex and involve further 
optimisations which can be time-consuming. In contrast, exemplified by at least one 
universal substrate reporter probe for detection of a target sequence, the same probe 
can be engineered for the detection of different targets in the qPCR assay (Mokany et 
al., 2013). The detection of the new target sequence requires minimal optimisation of 
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the sensor-binding domain and the rest are based on the universal characteristics of the 
MNAzyme oligonucleotides which simplifies assay design and development (Bone et 
al., 2014). Although the substrate probe is the most expensive to manufacture with the 
integration of ribonucleotides and deoxyribonucleotides labelled with the fluorophore 
and quencher moieties, this component is completely universal and can be used for 
different MNAzyme assays.  
Moreover, each substrate could be labelled with a different compatible 
fluorophore and quencher. Nevertheless, properties of each fluorophore, such as 
excitation and emission wavelength values and the analyser compatibility, must be 
carefully considered in designing a multiplex assay. Each real-time PCR instrument 
has a fixed spectrum to detect the fluorescence signals especially involving multiple 
(more than two) wavelength fluorescence readouts at the same time. Real-time PCR 
machines such as Roche Light Cycler® 480 have recommended combinations of dyes 
to use in the multiplex assay detection for up to four detections simultaneously. Issues 
dealing with the multiple detections in real-time PCR machines, such as “crosstalk” 
could result in one filter combination that may pick up signals from a dye measured by 
another channel due an overlap of the emission spectra of the dyes. This problem may 
cause result misinterpretations and a loss of sensitivity. Therefore, optimisation steps 
such as Colour Compensation analysis should be performed before running the real 
experiment (Molenkamp et al., 2007).  
In this study, sequences of the substrates and substrate binding arms in the 
MNAzyme Pan-Fungal assay were designed to be a total 19 nucleotides in length.  
Substrate binding arms were designed to be complementary towards the substrate 
sequence. The nucleic acids substrate sequence used in the MNAzyme Pan-Fungal 
assay is Sub 3-JB (Table 6.1) which was optimised by Mokany, Tan, Bone, et al., 
(2013). The optimal temperature achieved in our study for the Pan-Fungal assay was 
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consistent with the isothermal temperature used in other studies, which is 50°C (Gao, 
Shimada & Maruyama, 2015; Bone, Hasick, Lima, et al., 2014). Recently, re-
engineering of the MNAzyme’s substrate and substrate binding domains with a shorter 
sequence length has been demonstrated its potential to function at room temperature 
(Ven et al., 2019). It also has been proven that the optimum isothermal temperature for 
MNAzyme is directly influenced by the length of the substrate binding arms (Ven et 
al., 2019; Gao, Shimada & Maruyama, 2015). The needs for cycled and higher 
temperatures have limited the application of PCR-based assays in deprived resources 
area. Therefore, modification of MNAzyme assays with this enhancer will increase the 
adaptation of this technology to produce simple point-of-care diagnostic devices. 
The MNAzyme Pan-Fungal assay has shown 100-fold higher catalytic activity 
compared to the MNAzyme assay developed by Gao, Shimada & Maruyama, (2015). 
Although their assay was developed using the same set of the partial catalytic core that 
was previously engineered by Mokany, Bone, Young, et al., (2010), it shows the 
substrate cleavage rate, Kobs to be approximately 10-3 min-1. In the same study, the 
reaction was optimised using an enhancer which had proved to increase the catalytic 
rate tremendously to the value around 10-1 min-1. A cationic comb-type copolymer 
(PLL-g-Dex) facilitates hybridisation of the MNAzyme with the substrate. This 
cationic copolymer may improve the efficiency of less stable enzyme-substrate 
complexes, resulting in truncated substrate binding arms, which work at 37°C. 
Incorporation of this cationic copolymer into MNAzyme assay may increase the 
temperature window in which an MNAzyme is at maximum activity at a relatively 
lower temperature.  
The Partzyme concentration in the MNAzyme Pan-Fungal assay was optimised 
to achieve measurable signal over time. The pan-fungal Partzyme concentration that 
gives closer signal starting point with the negative control was determined. Measuring 
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initial velocity of this enzyme activity is not possible since the initial signals were not 
comparable starting point either with negative control (contains no AF) or the lowest 
concentrations of Partzyme used in the reaction. In the study conducted by Bone et al., 
0.04 µM concentrations of Partzyme A and Partzyme B were utilised in the MNAzyme 
developed to detect CAMP gene Streptococcus agalactiae (meningitis-causing 
bacterium) (Bone et al., 2014). Multiple substrates were cleaved from the assembled 
MNAzyme over time and the detection signal amplified throughout the process until 
the substrate exhausted (plateau).  
The concentration of magnesium in MNAzyme assays is generally higher (8 to 
10 mM) than for the standard PCR or probe-based protocols (1 mM to 4 mM) since 
the magnesium is required for the catalytic activity (Mokany et al., 2013). The low 
concentrations of magnesium ions may cause weak binding of the DNAzyme to the 
reporter substrate, causing no catalytic activity to occur (Yuan et al., 2007). Another 
role of magnesium includes neutralisation of the negative charges of the DNA 
phosphate backbone, thus facilitating interactions between DNAzyme and the 
substrate (Cieslak et al., 2003). The high concentrations of magnesium ions induce 
proper folding of the catalytic core allowing the enzyme to hydrolyse its substrate 
efficiently (Cieslak et al., 2003). Therefore, it could be suggested that the magnesium 
is also responsible for maintaining the proximity of the fluorophore and quencher on 
the substrate. In the absence of magnesium, the fluorophore and quencher on the probe 
are widely separated that may cause by the disrupted random coil structure of the 
substrate itself (Juskowiak, 2011). Interestingly, the absence of magnesium in our 
experiments showed high fluorescence levels (Figure 6.5); this result was unexpected, 
but it could be suggested that substrate molecules disintegrated or cleaved 
instantaneously in the absence of magnesium, leading to an increase in the intensity of 
the fluorescence signal. Future investigations to test these arguments through 
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incubation of the substrate with and without magnesium and perform polyacrylamide 
gel electrophoresis (PAGE) to observe the cleaved or un-cleaved substrate bands could 
be performed. Overall, it seems that high concentration of the magnesium ions in a 
reaction is necessary to ensure active conformational of the substrate-enzyme complex 
and favour hydrolysis or cleavage of substrates.  
The MNAzyme Pan-Fungal assay components – a substrate (Sub3-JB), 
Partzyme A (ITS4LR1A/3-P) and Partzyme B (ITS4LR1B/3-P), are associated with a 
specific target sequence designed from the fungal biomarker (AF-ITS4LR1) which 
then form a nucleic acid enzyme, capable to cleave the substrates and emits 
fluorescence which is subsequently detected and measured. It is reported that 
misidentification of fungal species frequently occurs in a clinical setting (Kwiatkowski 
et al., 2012). This problem is due to many factors such as low specificity of the 
diagnostic assay used and the characteristic of the species itself, which may have a 
similar morphology to other species (Osei Sekyere, 2018). Therefore, MNAzymes, 
through the development of a species-specific assay could promise a more accurate 
identification of closely related species and rule out uncertainties.  
The MNAzyme Pan-Fungal assay showed sensitivity (3.7 ´ 1010 molecules) 
one order of magnitude lower than MNAzyme assay demonstrated by Gao, Shimada 
& Maruyama 2015, of which the limit of detection was determined at 2.4 ´ 109 
molecules of an input sequence. An improved limit of an AF detection was 
demonstrated in the Mz1d assay at 5.0 ´ 10-6 µM, corresponds to 7.5 ´ 107 molecules 
or 0.125 fmol in a 25 µL reaction (Mokany et al., 2010). Several factors may affect the 
signal sensitivity including the difference in length of the sensor arms that significantly 
influenced the stability of MNAzyme complex (Gao, Shimada & Maruyama, 2015). 
Furthermore, it could be suggested that different substrates used in reactions may 
contribute to catalytic efficiency in the MNAzyme. From the higher range of AF 
 264 
concentrations tested, 0.75 µM has a higher binding efficiency compared to 0.1 µM, 
and therefore has greater catalytic activity and cleaving more substrates.  
The target sequence of C. albicans was amplified in a standard PCR 
amplification method before it was subjected for detection in the MNAzyme Pan-
Fungal assay. The PCR product was purified to ensure it was not in contact with any 
PCR primers that could mislead the detection, as the forward primer (pITS4LR1-F) 
was designed in overlapping position with 5’end of the sensor arm.  Ideally, the 
detection of the target sequence by MNAzymes is performed with  amplification of the 
target region in a qPCR-MNAzyme assay (Mokany et al., 2013). However, in this 
study, the reaction was included with the target sequence from C. albicans double-
stranded genomic DNA for the direct-detection method of the MNAzyme assay. The 
amplicon was detected at 50°C isothermal conditions and showed consistent outcomes 
at the end of the reaction with the synthetic target sequence reactions (Figure 6.9). The 
Kobs values obtained (2.1 ´ 10-1 min-1)  are comparable with the values obtained from 
two designs of Partzymes Mz1c and Mz1e, which are 7.1 ´ 10-1 min-1 and 1.1 ´ 10-1 
min-1, respectively (Mokany et al., 2010). Although the catalytic rate is lower in the 
reaction with the C. albicans DNA template, it could be improved by incorporating an 
amplification step into the MNAzyme direct detection method, a method established 
by Mokany, Tan, Bone, et al., (2013).  
An enzyme-catalysed reaction has a hyperbolic relationship between the rate 
of reaction and the concentration of substrate, as shown in Figure 6.11. At low 
concentrations of substrate, there is a steep increase in the rate of reaction with 
increasing substrate concentration. The catalytic site of the enzyme is empty, as it is 
not bound to a substrate, for much of the time, and the rate at which product can be 
formed is limited by the concentration of substrate which is available. Meanwhile, as 
the concentration of substrate increases (from 0.25 µM and above), the enzyme 
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becomes saturated with substrate. As soon as the catalytic site is empty, more substrate 
is available to bind and undergo reaction. The rate of formation of product now 
depends on the activity of the enzyme itself and adding more substrate will not affect 
the rate of the reaction to any significant effect. 
The value of Kcat/ Km was calculated for the MNAzyme Pan-Fungal assay to 
provide a direct comparison of the effectiveness of an enzyme toward different 
substrates that have been previously reported in separate assays. The parent enzyme, 
DNAzyme 10–23 is the most catalytically active DNA enzyme with Kcat/ Km of ~ 109 
M-1 min-1 approaching the efficiency of the most “catalytically perfect” enzymes 
(Gerasimova & Kolpashchikov, 2010). In this study, the catalytic efficacy of the 
MNAzyme Pan-Fungal was determined at 1.0 ´ 108 min-1 M-1. It is comparable with 
the catalytic efficiency of the Mz1d assay (2.9 ´ 108 min-1 M-1) and with DNAzyme 
10-23 (5.6 ´ 108 min-1M-1) (Mokany et al., 2010). It is clear, therefore, that the 
enzymatic activity demonstrated for the Pan-Fungal MNAzyme assay developed here 
would be capable of functioning efficiently in detecting pathogenic fungi DNA 
biomarkers.  
In summary, the purpose of this study was to design and characterise a pan-
fungal MNAzyme assay for the rapid and isothermal direct detection of pathogens 
associated with the invasive fungal diseases and may enable the diagnosis of 
uncommon and rare fungal infections. Although the investigation can be advanced 
with the incorporation of the PCR method for the amplification and quantification of 
the targets, current results laid the foundation for development of the multiplex qPCR-
MNAzyme assay. The robust and expandable features of the MNAzyme technology 
as a strategy for multiplexing assay can be developed for the multiple target detection 
in a single tube reaction (Zhou, Ding & Liu, 2017). Development of the qPCR-
MNAzyme Candida assay, for instance, could detect the pathogenic species from the 
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kingdom-level (pan-fungal), genus-level (pan-Candida) and further discrimination to 
the species-level for multi-drug sensitive species such as C. krusei, C. glabrata, C. 
auris and could facilitate diagnosis of invasive candidiasis (Casadevall, 2018; 
Schelenz et al., 2016). Nonetheless, these ideas and techniques are still at the 
laboratory stage, and the future aim is to develop a multiplex assay-based detection kit 









CHAPTER 7: Discussion 
 
7.1 Overview of the main findings 
Clinical diagnosis of IFIs is challenging as there is a lack of early signs of infection 
and non-specific symptoms undistinguishable from those of bacterial sepsis (Pfaller & 
Castanheira, 2016; Brown et al., 2012). Fever is the most common manifestation of 
disseminated fungal infection and may occur with or without localising clinical 
features (Martino & Girmenia, 2000). In most cases, diagnosis is complicated by the 
host’s underlying conditions (Patterson & Donnelly, 2019). Thus, laboratory 
procedures are primary to investigate and confirm the diagnosis of invasive fungal and 
establish disease aetiology. It has been suggested that reliable and rapid diagnostic 
tools are important to tackle most of the problems with regards to IFIs (Brown, 
Denning & Levitz, 2012).  
 An ideal fungal detection test should exclusively differentiate organisms at the 
species level, as some species may respond differently to antimicrobials. The specific 
information is useful for the clinicians to prescribe an accurate antifungal drug to the 
infected patients and avoid broad-spectrum antifungals. The implications of long term 
broad-spectrum or wrong antifungal treatments to the patients could lead to the 
emergence of resistant species and no cure for such diseases (Shor & Perlin, 2015). 
Multidrug resistant Candida species are reported all over the world, and their 
development is of particular concern (Ben-Ami et al., 2017; Jeffery-Smith et al., 2018; 
Alexander et al., 2013). Moreover, overuse of fluconazole as a prophylactic agent has 
been associated with the emergence of non-albicans Candida which selects those 
species that are intrinsically resistant or less susceptible to azole drugs. In this study, 
the detection assay can discriminate the drug-resistant C. krusei, C. glabrata and C. 
auris from other pathogenic Candida species. To date, there are over 5,100 cases of 
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life-threatening Candida infections in the UK (Pegorie, Denning & Welfare, 2017) 
associated with 40% to 50% mortality rates (Dhillon & Clark, 2011). Accurate 
diagnosis and therapies are important to reduce the mortality rates and reflect correct 
epidemiological data related to IFIs as well as successful delivery of the antimicrobial 
resistance (AMR) agenda (Ahmadi et al., 2014; Brown et al., 2012; O’Neill, 2016). 
However, early and accurate diagnosis and the subsequent usage of appropriate 
antifungal therapy are difficult to achieve (Casadevall, 2018).  
 The traditional microbiological methods such as organism cultivation, 
microscopic and histopathological evaluations are ‘gold standard’ and used widely in 
the hospital to diagnose IFIs. However, fungal cultures, for example, lack sensitivity 
and are time-consuming, leading to delayed treatments (Ostrosky-Zeichner, 2012; 
Hammond et al., 2011). Conventional microbiological techniques such as blood 
cultures lack sensitivity, as they were shown to be positive in less than 50% of patients 
with chronic candidiasis and it is rare to recover fungi from patients with invasive 
aspergillosis (Pemán et al., 2011; Bašková & Buchta, 2012). Methods of direct 
microscopy and histopathology require high laboratory skills to identify the species 
which are laborious and time-consuming. Immunological detection of the fungal cell 
wall polysaccharides is a routine test for screening of fungal infections and has shown 
limited specificity and low sensitivity to meet early-stage treatment needs (Badiee & 
Hashemizadeh, 2014).  Therefore, it is impossible to deliver accurate treatment to the 
patients as these methods are not specific, and only appear positive in the late stage of 
IFI.  
On the other hand, recent advances in the development of molecular methods 
have led to the significant improvement of IFI management by facilitating earlier 
detection of fungal pathogens (Al-Jalbout et al., 2019). These methods include nucleic 
acid probe chemistries and PCR technology. They are rapid, highly specific and can 
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be used to detect low quantities of fungal nucleic acids from patient samples before the 
symptoms are prominent; therefore, allowing appropriate therapy. There are various 
probe chemistries available (hydrolysis probes – TaqManÒ; dual hybridisation probes) 
that rely on the fluorescent signal emission during target sequence amplification. A 
multiplex assay can be designed for multiple target detection and discrimination in a 
single tube reaction. The multiple target probes in a single assay allowed the diagnostic 
testing for more comprehensive, rather than testing for individual pathogens in 
multiple tests. Furthermore, patients may be infected with more than one fungal 
pathogen and can be used to monitor the emergence of new fungal pathogens.  
However, probe-based assays often limit its potential due to the instrument’s 
incompatibility to some fluorogenic probes. The MPA technology enhance the full 
benefits of the dual-labelled hydrolysis probe with multiplexing capacity in a single 
fluorescence channel (Fu, Miles & Alphey, 2012). This offers interesting possibilities 
in the development of novel molecular diagnostic tools for fungal infections. For 
example, the Light Cycler SeptiFastÒ (Roche Diagnostics) and MycoReal Candida 
(Ingenetix GmbH) qPCR kits require four fluorescence channels in detecting five to 
seven Candida target species. In this thesis, an MPA-Candida diagnostic assay was 
developed that allows the identification of up to nine of the yeast species most 
frequently associated with invasive candidiasis. Crucially, this enhanced range of 
pathogen detection is achieved using only two fluorescence detection channels. It has 
been further demonstrated that the dual channel penta-plexing MPA assay reported 
here allows the species-specific identification of three of the most problematic 
antifungal drug resistant Candida species, including C. auris, an emerging pathogen 
responsible for severe hospital outbreaks worldwide (Forsberg et al., 2019; Benedict 
et al., 2017).  This assay has therefore the potential to allow clinicians to prescribe the 
correct chemotherapy for patients infected with drug-resistant strains, thus saving lives 
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and contributing to antifungal stewardship efforts worldwide (Rautemaa-Richardson 
et al., 2018; Pfaller & Castanheira, 2016). 
 Limitations of PCR-based diagnostic methods, including the requirement for 
expensive laboratory equipment and a clean environment to prevent sample cross-
contamination have driven the development of alternative molecular detection 
platforms based on isothermal DNA amplification methods. Isothermal amplification 
offers simplicity and eliminates the need for sophisticated thermal cycler machines and 
hence, are suitable to be developed as hand-held diagnostic devices that could be used 
at the patient’s bedside. One such method, loop-mediated isothermal amplification 
(LAMP), provides real-time monitoring of the reaction as reaction mixture turbidity 
correlates with the amount of DNA synthesised (Parida & Sannarangaiah, 2008). 
Numerous LAMP-based assays have been developed to detect fungal pathogens 
(Niessen, 2015). However, although LAMP has high sensitivity and specificity, the 
method requires a complicated design of primers and is limited to the detection of a 
single target per reaction (Eboigbodin & Hoser, 2016). An alternative robust and cost-
effective detection platform based on hydrolytic MNAzymes has simplified the 
development of the isothermal nucleic acid assay. The MNAzyme assay has excellent 
sensitivity of up to picomolar target concentration  and requires no previous DNA 
amplification steps (Mokany et al., 2010); this suggests its potential use in a limited 
resources area and during outbreaks controls. In this thesis a highly specific MNAzyme 
Pan-Fungal assay was developed. In vitro characterisation demonstrated its capacity to 
discern between two putative target sequences with a single nucleotide base pair 
difference. Such high level of specificity would allow differentiation between two 
closely related species such as multidrug-resistant C. auris and drug-sensitive C. 
haemulonii. In  recent years, the former has sparked outbreaks in hospital settings 
around the world (Chowdhary, Sharma & Meis, 2017; Schelenz et al., 2016). 
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The use of multiplex, qPCR test such as Roche SeptiFastÒ has enabled 
simultaneous and rapid detections of blood pathogens while maintaining excellent 
analytical sensitivity (Straub et al., 2017). Despite the vast potential of qPCR 
detections, the sensitivity associated with the use of fungal DNA from the clinical 
samples negatively impacted by the technical issues related to the fungal DNA 
isolation. In the SeptiFastÒ qPCR assay, the detection sensitivity of the fungaemia is 
significantly low (61%) compared to 80% in bacteraemia detection (Chang et al., 
2013). The SeptiFastÒ overall sensitivity (69%) and specificity (81%) for bacterial and 
fungal detection from blood samples (Lehmann et al., 2010). The discrepancies of the 
sensitivity could be suggested from the cumbersome and complex methods of the thick 
fungal cell wall digestion that possibly impede the quantity of the nucleic acid 
biomarkers for amplification. In the study conducted by Gosiewski et al., (2014),  
comparing the detection of fungi and bacteria species from the patient’s blood in the 
qPCR assay, resulted in no detection of fungi due to the complicated process of fungal 
DNA isolation. Bacterial and viral detection assays are not facing the same issue as the 
process of the microbial nucleic acid isolation can be accomplished from 
straightforward nucleic acid isolation and purification steps (Kajiura et al., 2015). In 
this thesis, the nucleic acids isolated from spiked blood and serum samples showed a 
1-log difference in sensitivity compared to the control sample (spiked saline sample) 
for pan-fungal DNA biomarker detection. The preferred clinical specimen to obtain for 
molecular-based screening is serum over whole blood mainly for its superior 
sensitivity (Lau et al., 2010), simple nucleic acid purification process, and allows 
utilisation of the same sample for multiple tests (Nguyen et al., 2012; Alanio & 
Bretagne, 2014).  The complexities of the PCR assay’s requirements for inhibitor-free 
sample and a cumbersome fungal DNA preparation process may be the factors that 
hindered the methodological standardisation and limit its widespread clinical utility. A 
 272 
collaboration network within the Fungal PCR Initiative (FPCRI) – Candida group; a 
working group under International Society for Human and Animal Mycology 
(ISHAM) focusing on a concerted effort towards standardisation and clinical trials of 
the PCR methods may shed a brighter light on the clinical utility of this method.  
 
7.2 Implications of research and future work 
The major challenge for a diagnostic assay development is that it must be able to 
sensitively detect infections early, possibly before the manifestations of symptoms, for 
appropriate therapy to take place to stop disease progression. Simple and robust 
diagnostic tests that could lead to a shorter turnaround time are desirable. This is 
particularly important in disseminated fungal infections as the mortality rate increases 
due to delays in diagnosis and ultimately treatment (Farmakiotis et al., 2015). The 
detection of antifungal drug resistance and the corresponding specific gene mutations 
(FKS1 gene; ERG11 gene mutations) enable more rapid identification of resistant 
Candida species. The DNA biomarkers identified could be utilised in other isothermal 
DNA amplification techniques such as Strand Invasion Based Amplification (SIBAÒ) 
and Recombinase Polymerase Amplification (RPA) for sensitive detection or further 
in vitro characterisations of the MNAzymes assay with the PCR amplification steps. 
Accessibility to the instruments particularly to the hospitals which have limited 
resources conditions should benefit from the development of the rapid molecular 
diagnostic tools.  This research project opened up a range of potential applications of 
the MPA and MNAzymes platforms including to design a PCO sequence for the RNA 
substrate in the MNAzymes assay as a way of multiplexing the probes detection in a 
single fluorescence channel. However, it is also important to consider the cost of the 
assay relative to the economic impact it causes, including the difficult estimations of 
the cost of misdiagnosis, leading to over or under treatment. Finally, the prototype 
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assay should then pave the road towards clinical validity and clinical utility before 
entering extensive clinical practice.  
 
7.3 Conclusion 
The exploration of potential biomarkers detection platforms as simple nucleic acid 
biosensors for the diagnosis of invasive candidiasis has demonstrated a vast potential 
to further the prototype development and validations.  The in vitro characterisations of 
the MPA-Candida and MNAzyme Pan-Fungal assays suggest their potential value in 
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